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ABSTRACT
Bioreductive agents are a class of anticancer drug primarily designed to
exploit to their advantage the hypoxic areas and cellular enzymology
present within solid tumours, ultimately via their metabolic activation
leading to the generation of toxic species. Such a therapy provides an
encouraging approach to treat solid tumours, in particular hypoxic cells
which often remain resistant to conventional therapy such as irradiation.
The quinone-containing antitumour antibiotic mitomycin C, often
regarded as the prototype bioreductive, requires enzymatic metabolic
activation which is known to be enhanced under hypoxia. The enzymes
or quinone reductases involved in this process are numerous and their
exact individual roles, in particular that of the two-electron reductase DT-
diaphorase, remains controversial. Ultimately, the identification of a
single or predominant reductase responsible for this bioactivation may
lead to the realisation of enzyme-directed bioreductive drug therapy, a
treatment programme tailoring a specific drug to an individuals' tumour
enzyme profile.
The enzymology of mitomycin C bioactivation was studied in vitro in
two solid mouse adenocarcinomas of the colon MAC 16 (high DT-
diaphorase) and MAC 26 (low DT-diaphorase). Metabolism of mitomycin
C by tumour subcellular fractions revealed a novel mitochondrial
reductase active under hypoxia in both tumours. DT-diaphorase and
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NADPH:cytochrome P-450 reductase activity was confirmed in MAC 16
but not MAC 26. The role of DT-diaphorase was examined in a tumour
homogenate system and was found to play a protective role under
hypoxia in MAC 16, predominating over the other enzymes present.
MAC 26 showed enhanced hypoxic metabolism due to the presence of the
mitochondrial reductase. The studies were extended to a human
perspective, using the human colon xenografts HT-29 (high DT-
diaphorase) and BE (low DT-diaphorase). In vivo studies, again using the
MAC tumours, revealed comparable mitomycin C metabolism. Marked
antitumour activity was also evident in both MAC 16 and MAC 26. Such
a result supports the use of DT-diaphorase as a target for enzyme-directed
bioreductive drug therapy with mitomycin C.
The mitomycin C analogue indoloquinone E09 is a promising new
bioreductive drug, although little is known about its metabolism and
mechanism of action. The chemical properties of the reactive
intermediates of E09 were studied under controlled conditions via pulse
radiolysis with the aim of proposing a mechanism for its cytotoxicity.
Results indicated that whether E09 undergoes reduction via one- or two-
electron reduction the hydroquinone intermediate, product of two-
electron reduction via enzymes such as DT-diaphorase, will predominate
and dictate the pattern of cytotoxicity. In vitro metabolism of E09 by the
tumours described above produced a number of metabolites which were
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Cancer chemotherapy is one of three main approaches to cancer
treatment. Unlike surgery and radiation which provide local treatment of
the disease, systemic drug therapy is still the principle way of treating
metastatic tumour growth. The use of cytotoxic drugs ie: drugs that can
damage or kill growing cells, was first introduced in 1942 with the
treatment of Hodgkins disease with the alkylating agent nitrogen mustard
(Gilman, 1963). In the next decade, a wide variety of malignancies were
treated with the newly discovered alkylating agents and antimetabolites.
With this success it became apparent that tests were required to allow
successful introduction of new compounds into the clinic - clinical trials.
Essentially, phase I trials establish the dose, route of administration,
excretion pattern and prominent toxicities. Once this information is
available, phase II trials are carried out in patients with varying
malignancies so that the spectrum of tumours sensitive to the agent can
be defined. Finally, phase III trials allow for in depth evaluation of
patients usually being treated for one form of malignancy in which the
new agent is compared to the best established method of treatment
currently in use.
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Cancer chemotherapeutic agents can be classified in a number of ways.
Broadly, they can be divided into alkylating agents, antimetabolites,
antitumour antibiotics, plant alkaloids and miscellaneous agents. The
latter group would include agents such as enzymes for example L-
asparaginase, the platinum coordination complexes cis- and carboplatin
and steroid hormones. Alternatively, it is possible to divide agents into
groups depending on what stage of the cell cycle they show selective
lethal toxicity. Non-phase specific agents are effective throughout the cell
cycle, whilst those only effective in a particular phase are referred to as
phase specific. The primary mechanisms of action of the main groups of
anticancer agents are summarised in figure 1.1.
1.2 Limitations of Cancer Chemotherapy
Cancer chemotherapy is used in a number of ways: (1) as the major
curative modality for rare malignancies such as Hodgkins disease and
other lymphomas, childhood acute leukaemias and testicular cancer; (2)
adjuvant therapy before or after local treatment for primary disease with
the aim of treating micrometastases; (3) as palliative treatment for
advanced cancers; and (4) in combination with other modalities to
improve therapeutic effects. Despite these regimes, limitations to their




























Figure 1.1. Summary of the main categories of anticancer agents and their
cellular effects.
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1.2.1 Drug Toxicity and Therapeutic Index
Although cancer chemotherapy is targeted at dividing malignant cells,
normal tissues are exposed to such agents. Normal tissues with a high
rate of cellular proliferation are at risk from the effects of cytotoxic drugs.
The major tissues affected are the bone marrow, hair follicles and
intestinal mucosa and are the commonest dose-limiting toxicities
associated with most anticancer agents. Other less common toxicities are
linked to specific agents, for example, cardiotoxicity is the main toxicity
limiting the use of doxorubicin (Bristow, 1982).
Toxicity can be divided into 4 main categories depending on time of
onset:- immediate, early, delayed and late. Immediate toxicity usually
occurs within hours ranging from nausea/vomiting to phlebitis. Early
toxicity is associated with myelosuppression, more commonly leucopenia
and thrombocytopenia, alopecia and diarrhoea and usually presents
within days to weeks. Anaemia and liver damage are considered to be
delayed toxicities presenting weeks or months later. Finally sterility and
second malignancies arise years later and are classed as late toxicities.
The clinical evaluation of any potential anticancer agent is a long and
complex process. The key to evaluating any new agent is to compare the
benefits achieved by the therapy with treatment related toxicity. This is
known as the therapeutic index. Therapeutic index was originally defined
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in mice from the following formula.
Therapeutic Index = maximum non-toxic dose
minimum effective dose
However this formula does not take into account individual variability
therefore the following more widely-used definition has been introduced.
Therapeutic Index = LDso
ED50
where LD50 and ED50 are the lethal and effective dose for 50% of the
group respectively. This gives an indication of the safety of the drug by
drawing attention to the relative toxicity and effective dose of a drug.
A high therapeutic index is generally considered to be of benefit with toxic
side effects at a minimum for a given dose. However, a low therapeutic
index may be accepted for treatment in patients with advanced
malignancy who have a significant change of meaningful palliation or
survival prolongation as a result of that therapy. This would however be
considered inappropriate for use in surgical adjuvant therapy in a patient
population with a significant chance of cure.
One method of improving the therapeutic index is by combining one
anticancer agent and/or radiotherapy with another. Two agents may often
be combined with only a small reduction in doses compared to those used
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when the agents are given alone but achieve less additive toxicity towards
normal tissues and increased antitumour activity.
1.2.2 Drug Resistance
Resistance to chemotherapeutic agents has been observed for many years
with many solid tumours showing infrequent response to treatment. The
mechanisms underlying drug resistance are numerous, spanning from
morphological factors such as poorly organised tumour vasculature
leading to limited drug penetration, stage of cell proliferation to altered
biochemical pathways and genetic factors. Broadly, drug resistance can be
divided into two categories: (1) intrinsic resistance observed before the
cancer has been exposed to treatment and (2) acquired resistance which
manifests itself after prior exposure.
Many agents enter cells by facilitated membrane transport involving
binding to a receptor protein located on the cell membrane followed by
internalisation. Alteration or reduction of these receptor proteins may
subsequently lead to impaired membrane transport, lower intracellular
drug concentrations and reduced toxicity. Well documented examples
include methotrexate (MTX) (Goldman, 1971) and nitrogen mustard
(Goldenberg & Begleiter, 1980). A similar type of transport alteration is
seen in cells possessing the so-called multidrug resistance (MDR)
phenotype (Endicott & Ling, 1989). Characteristically, cells exhibiting this
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phenotype are selected for resistance to one single agent. However, with
further investigation it emerges that cross-resistance has developed to a
variety of unrelated cytotoxic agents. These drugs were often observed to
be of plant or fungal origin such as the vinca alkaloids and antitumour
antibiotics respectively. Juliano and Ling (1976) linked this phenomenon
to the presence of a 170 kD cell surface membrane glycoprotein, now
commonly known as P-glycoprotein. Tumours high in P-glycoprotein
tend to develop from normal tissue high in the protein such as kidney,
colon and liver. Various methods have been used in an attempt to
circumvent MDR and in particular the use of calcium channel blocking
agents such as verapamil have potential (Tsuro, 1983).
Other forms of drug resistance involve altered intracellular targets. A
good example is MTX resistance and its target dihydrofolate reductase
(DHFR). Cells resistant to MTX may show increased amounts of DHFR
due to amplified gene expression (Schimke, 1984) or alternatively produce
variant forms of the enzyme disrupting DHFR inhibition (Goldie et al.,
1980). Other examples include alterations in type II topoisomerase
expression (Morrow & Cowan, 1990) and glutathione metabolism.
1.2.3 Treatment of Solid Tumours
Despite the success of chemotherapy in treating blood borne diseases such
as the leukaemias, treatment of solid tumours remains a challenge. The
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highly disorganised vascular system, slow blood flow and high interstitial
pressure of solid tumours hinder efficient drug perfusion leaving some
areas unexposed (Jain, 1987a), whilst the presence of necrotic and hypoxic
areas consequently lead to resistance to radiotherapy and treatment by
conventional anticancer agents. The use of alternative routes of drug
administration known as locoregional chemotherapy have achieved
higher drug concentrations in the bulk of the tumour. Such methods
include regional vascular perfusion, intraperitoneal, intrapleural and
intrathecal chemotherapy (Kerr & Los, 1993). An alternative approach is
to attack the endothelial cells lining the tumour vasculature rather than
the tumour cells themselves. Such a treatment would result in an
occlusive thrombosis halting blood flow throughout the tumour. This
can be achieved using a variety of immunotoxins directed at such
endothelial cells (Burrows & Thorpe, 1994).
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1.3 Rationale for the Use of Bioreductive Drug Therapy
Solid tumours generally develop areas of reduced blood flow, decreasing
pH and ultimately regional hypoxia. It has long been recognised that such
hypoxia is a major obstacle in the successful treatment of solid tumours
with particular reference to radiotherapy (Bush et al., 1978; Moulder, 1984;
Overgaard, 1992). However, despite its negative impact on cancer
treatment, such a problem can be exploited as a potential difference
between malignant and normal tissues. One strategy is the development
of bioreductive therapy in which hypoxic cells are eliminated through the
use of cytotoxic drugs selectively toxic in the absence of oxygen. Such
hypoxia-activated prodrugs or so-called bioreductive drugs require
metabolic activation via a number of enzyme-dependent pathways
consequently resulting in highly cytotoxic species. Under aerobic
conditions cells are placed under oxidative stress due to a process known
as redox cycling. Essentially the free radical intermediate generated via a
reduction step is back oxidised to the parent molecule. Although
superoxide and the highly damaging hydroxyl radicals are produced via
this futile cycling, this pathway is often less damaging than the toxic
species predominating in hypoxic cells and aerobic toxicity is at a
minimum (Powis, 1987).
The quinone-containing antitumour antibiotic mitomycin C is
considered to be the prototype bioreductive alkylating agent and its
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bioreductive properties have led to the generation of a number of related
quinone analogues (Oostveen & Speckamp, 1987). Other agents toxic to
hypoxic cells include the nitroheterocycles such as the nitroimidazoles
(Adams & Stratford, 1994) and the benzotriazines, the lead compound
being SR 4233 (Brown, 1993). Bioreductive drugs and their mechanism of
action will be discussed in more detail throughout.
The ability of bioreductive drugs to eradicate hypoxic cells can be
expressed as the hypoxic cell cytotoxicity ratio or HCR. This is obtained by
dividing the dose required to kill a proportion of oxygenated cells with
that required to destroy an equal fraction of the same cells under hypoxia.
For example, the HCR for mitomycin C is approximately 2 (Stratford &
Stephens, 1989) although this may vary with the cell type used. In
comparison, an improved HCR is observed with the nitroimidazole RSU
1069 which exhibits a HCR of 69 (Horwich et al., 1986).
The next section briefly deals with the rationale behind the use of
bioreductive anticancer drugs in preference to exisiting treatments.
1.3.1 Tumour Hypoxia
Differences in tumour blood vessels and blood flow in comparison to
their normal tissue counterparts are predominately responsible for
tumour hypoxia (Jain, 1994). Lack of smooth muscle, abnormal vessel
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branching, lack of innervation and often no endothelial lining results in
an inadequate tumour blood vessel network depleting areas of essential
nutrients particularly oxygen (Jain, 1994). In addition, the absence of a
lymphatic drainage system often contributes to high interstitial pressures
and consequently sub-optimal blood flow within solid tumours (Jain,
1987b).
Essentially as the distance from a microcapillary increases, tissue
oxygenation decreases falling to a level insufficient to support cell
division. Ultimately oxygen-deprived or anoxic cells die resulting in
regional necrosis. However, areas of slowly proliferating cells do survive.
Hypoxic tissues can be divided into 2 groups. Firstly, Thomlinson-Gray or
irreversible 'chronic' hypoxia results as a consequence of oxygen diffusion
limitations leading to zones of chronically hypoxic cells (Thomlinson &
Gray, 1955). These are often observed between the interface of well-
oxygenated and necrotic regions at distances 150-200 pm from capillaries
(Gray et al., 1953). This is often described as the diffusion limited model.
Secondly, reversible 'acute' hypoxia arises through transient blood flow
changes ie: varying oxygen delivery, often due to perfusion defects such as
intermittent vascular occlusion (Brown, 1979; Chaplin et al., 1986;
Chaplin et al., 1987).
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It is possible to exploit tumour hypoxia in a number of ways using
bioreductive therapy. As single antitumour agents, the benefit of
bioreductive drugs could potentially be minimal as hypoxic cells may
only constitute a minor proportion of the cells within the tumour.
However, used in conjunction with other treatments active against well-
oxygenated cells, for example irradiation, they may prove beneficial. In
this proposal, the administration of bioreductive drugs after irradiation
will decrease the number of hypoxic cells. This in combination with
irradiation induced cell death will improve tumour response.
Alternatively, using bioreductive drugs specifically designed to kill
surrounding oxygenated as well as hypoxic cells is a promising option.
Such bioreductive 'prodrugs' would produce stable cytotoxins capable of
diffusing out of hypoxic regions eradicating oxygenated cells or
continuing to act after hypoxic areas have reoxygenated. One example of
such a prodrug is the cobalt (Ill)-nitrogen mustard complex, SN 24771
(Wilson et al., 1994).
A third option is to increase the already existing hypoxic fraction which in
turn increases tumour cell sensitivity to that bioreductive drug. This can
be achieved by a wide variety of agents capable of modulating tumour
blood flow. These range from vasoactive drugs eg: hydralazine,
anaesthetics, cytokines eg: tumour necrosis factor and interleukin-1 and
cytokine inducers such as flavone acetic acid. More recently the treatment
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of tumours with the nitric oxide synthase inhibitor, nitro-L-arginine has
proved successful in hypoxia induction (Adams & Stratford, 1994). Other
methods include photodynamic therapy (PDT) and hyperthermia, both of
which result in increased ischaemic cell death.
1.3.2 Tumour Enzymology and pH
Bioreductive drugs require metabolic activation to generate toxic species.
A number of enzymes are able to catalyse this process. This can occur via
a one- or two-electron reduction step. Such enzymes include the one-
electron reductases NADPH:cytochrome P-450 reductase, xanthine oxidase
and NADH: cytochrome bs reductase, and the two-electron reductases DT-
diaphorase [NAD(P)H:(quinone acceptor) oxidoreductase, EC 1.6.99.2] and
xanthine dehydrogenase. With the quinone bioreductive drug mitomycin
C, all of the above enzymes have been implicated in the drug's
mechanism of action (Pan et al., 1984; Siegel et al., 1990a; Gustafson &
Pritsos, 1993; Hodnick & Sartorelli, 1993). In comparison NADPH:
cytochrome P-450 reductase and cytochrome P-450 itself have been
demonstrated to be important in the catalysis of benzotriazine di-N-oxide
SR 4233 reduction (Walton & Workman, 1990). However, the exact role of
each of the above reductases remains complex and multiple enzymes may
be involved in one or more parts of a given activation pathway
(Workman & Walton, 1990).
13
The presence of bioreductive enzymes as well as hypoxia provides an
attractive target for potential cancer therapy as many human tumours are
known to have increased levels of these enzymes in comparison to
normal tissues (Schlager & Powis, 1990; Fitzsimmons et al., 1996).
However different enzymes participate to different extents in the
activation of the various bioreductive drugs. Therefore patients may
benefit from tumour enzyme profiling so that the activity of a given drug
may be enhanced by the presence of a particular enzyme. For example, a
tumour rich in the enzyme DT-diaphorase may be an excellent target for
mitomycin C and its analogue indoloquinone E09 but may prove
resistant to SR 4233.
Other exploitable areas of solid tumours include tumour pH. As hypoxic
cells undergo anaerobic metabolism, it follows that such cells will
produce greater than normal levels of acid creating a low pH
environment. Potentiating this low pH throughout the tumour can be of
advantage in making the tumour more sensitive to treatments such as
hyperthermia (Hiraoka & Hahn, 1989) or increasing pH gradients between
intra- and extracellular environments (Gerweck et al., 1991). Using such
strategies, low tumour pH can be exploited by aiding in the activation of
cytotoxic drugs (Tannock & Rotin, 1989). Low extracellular pH, in addition
to low oxygen levels have proved an ideal environment for increasing
mitomycin C cytotoxicity in vitro (Newell et al., 1992; Parkins et al., 1993)
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1.4 Mitomycin C - The Prototype Bioreductive Drug
Mitomycin C is a naturally occurring antitumour antibiotic originally
isolated from Streptomyces caespitosus in 1958 (Wakaki et al., 1958). As
previously mentioned mitomycin C is often described as the prototype
bioreductive drug. By studying its properties and behaviour at clinical,
chemical and biological levels, it provides a firm basis on which to design
novel highly specific bioreductive drugs. The following sections detail
those properties of mitomycin C.
1.4.1 Chemistry of Mitomycin C
The structure of mitomycin C was first defined by Webb et al. (1962a,
1962b) and has a molecular weight of 334.13. The structural features of
mitomycin C are illustrated in figure 1.2. Essentially, the unique features
involve a quinone group, fused aziridine ring and a carbamate function
arranged around a pyrrolo[l,2-a]indole nucleus and is commonly known
as a mitosane structure.
Mitomycin C is unstable in aqueous solution and decomposition is
strongly pH dependent. Mild acid hydrolysis of mitomycin C results in
the cleavage of the C-9a O-methyl group subsequently followed by the loss
of methanol, formation of a C-9-C-9a double bond and the opening of the
aziridine ring (Beijnen & Underberg, 1985) and it is the protonation of
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a = quinone group
b = aziridine ring
c = carbamate function
Figure 1.2. The molecular structure of mitomycin C showing its three
unique structural features (a, b, c).
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this methyl group that is thought to be the triggering factor in acid
hydrolysis (Underberg & Lingeman, 1983). The overall result is the
formation of 1,2-disubstituted indoloquinone or mitosene structure of
which 1,2-ci's- (cis-hydro) and l,2-trans-l-hydroxy-2,7-diaminomitosene
(trans-hydro) are the primary products, figure 1.3. Extended acid
hydrolysis also causes the replacement of the C-7-amino function by a
hydroxyl group and cleavage of the C-10-carbamate function. Destruction
of the quinone chromophore also occurs under alkaline hydrolysis whilst
the aziridine ring remains unaffected and hence no additional products
can be detected (Beijnen et al., 1985).
Mitomycin C and its mitosene metabolite/degradation products exhibit
different UV/Visible (UV/Vis) absorption spectra. Mitomycin C is
characterised by X maxima at 216, 360 and 555 nm. The mitosene
structures exhibit altered absorption spectra with X maxima ranging from
244-250, 308-313, 343 and 550-558 nm depending on the product formed.
The change in absorption spectra is accompanied by a visible colour
change from the mauve mitosane to the violet mitosene.
Figure 1.4 illustrates the difference in the absorption spectrum of
mitomycin C and the primary metabolite 2,7-diaminomitosene (2,7-DM).
Similar spectra apply to trans- and cis-hydro metabolites.
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2,7-diaminomitosene X = H
1,2-cis 1-hydroxy
2,7-diaminomitosene X = en
1,2-trans 1-hydroxy
2,7-diaminomitosene X=
Figure 1.3. The molecular structure of the three principle mitosene
metabolites.
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Figure 1.4. Difference in absorption spectrum of mitomycin C (MMC) and
the principle metabolite 2,7-diaminomitosene (2,7-DM).
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1.4.2 Clinical Properties of Mitomycin C
1.4.2.1 Antitumour Activity of Mitomycin C
Initially clinical studies employed daily low dose schedules which
unfortunately resulted in severe dose-limiting toxicities, namely
cumulative myelosuppression (Crooke, 1979). This was followed by the
introduction of an intermittent dosing schedule using bolus injections
every four to eight weeks (Baker & Vaitkevicius, 1979). The net result was
reduced and often more manageable haematologic toxicity. Using such a
schedule mitomycin C was found to be active against a wide variety of
solid tumours including breast, lung, gastrointestinal and superficial
bladder cancers (Carter & Crooke, 1979).
Mitomycin C is now predominantly used in combination and intravesical
therapy. It has proved curative in the treatment of squamous cell
carcinoma of the anus when administered intravenously in combination
with continuous infusion of 5-fluorouracil and radiation therapy (Nigro
et al., 1983). Its use prophylactically and therapeutically in the treatment of
superficial bladder carcinoma when administered intravesically has also
proved successful (Zincke et al., 1985). Palliatively mitomycin C as a single
agent has produced remission in a number of cancers including pleural
mesothelioma (Bajorin et al., 1987) and recurrent colorectal, bladder and
breast cancers (Doll et al., 1985). However, its use in combination
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regimens still remains an integral component for the treatment of
recurrent or metastatic stomach, pancreatic, oesophageal and lung cancers
(Doll et al, 1985).
In an attempt to increase local exposure to mitomycin C, incorporation
into a variety of drug delivery systems has been employed, for example
ethylcellulose microparticles (Kato et al., 1980), polylactic acid
microcapsules (Tsai et al., 1986) and biodegradable albumin protein
microspheres (Fujimoto et al., 1985). Infused via the hepatic artery the net
result is reduced systemic toxicity and maintenance of high, local drug
concentrations.
1.4.2.2 Pharmacokinetics and Metabolism of Mitomycin C
Early pharmacokinetic data were obtained by the use of insensitive
microbiologic assays possessing sensitivity in the range of 0.1 (ig/mL
(Fujita, 1971). However, with the introduction of high-performance liquid
chromatography (HPLC), the detection limit was improved to
approximately 1 ng/mL (Dorr, 1988). Using such methods the
pharmacokinetic disposition of mitomycin C in blood has been shown to
follow a first-order elimination process best described by a two-
compartment model (Dorr, 1988). After a rapid initial half-life of
distribution, ti/2 a, of 2-10 minutes, there is an elimination half-life, ti/2
P, of 25-90 minutes (mean 54 minutes). Very little mitomycin C is
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excreted intact in urine, approximately 1-20% (Verweij et al., 1990).
Despite overwhelming evidence for the major role of drug metabolism in
the mechanism of action of mitomycin C and its clearance from the body,
no preclinical or clinical pharmacokinetic study has reported detection of
mitomycin C metabolites. Recently an HPLC analytical method and
liquid-liquid extraction sample preparation have been reported and used
to determine the levels of mitomycin C and its three primary metabolites
2,7-DM, trans- and cis-hydro in transplantable rodent tissue after in vivo
drug administration by intratumoural (i.t.) injection (Cummings et al.,
1993). In vitro 2,7-DM has a half-life of 13 minutes when incubated with
either NADPH:cytochrome P-450 reductase or xanthine oxidase (Pan et al.,
1984). In a separate study, 2,7-DM was shown to have a half-life of 30
minutes after i.t. injection of mitomycin C (Chirrey et al., 1995). The
secondary metabolite 10-decarbamoyl 2,7-diaminomitosene was also
detected in this study exhibiting a half-life of 130 minutes.
The primary metabolites have been shown to be formed after intial
enzymatic metabolic activation of mitomycin C (Tomasz & Lipman, 1981;
Pan et al., 1984; Siegel et al., 1992). Subsequent secondary metabolites, 10-
decarbamoyl 2,7-diaminomitosene, are produced as a result of further
enzymatic metabolism of the primary metabolites (Pan et al., 1984; Siegel
et al., 1992).
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1.4.2.3 Toxicity of Mitomycin C
The toxicities of mitomycin C are substantial, unpredictable and always
considered to be life-threatening. The most significant and frequent side
effect is delayed myelosuppression and is directly related to schedule and
total dose (Crooke & Bradner, 1976). More common toxicities such as
anorexia, nausea, vomiting and diarrhoea also occur. Hair loss is rare and
infrequent and extravasation injury and necrosis result due to mitomycin
C's vesicant properties. Potentially lethal chronic side effects include
microangiopathic haemolytic anaemia and congestive cardiomyopathy
and the latter has been shown to occur with greater frequency in patients
receiving doxorubicin and mitomycin C in combination (Buzdar et ah,
1978).
Mitomycin C is highly clastogenic, particularly to bone marrow cells
resulting in a number of chromosomal abnormalities including sister
chromatid exchanges and micronuclei (Perry & Evans, 1975). More recent
studies have shown that mitomycin C is however only a weak inducer of
gene mutations (Hayashi et ah, 1992), despite being demonstrated to be
carcinogenic in rats (Crooke & Bradner, 1976).
1.4.2.4 Mechanisms of Mitomycin C Resistance
The mechanisms of mitomycin C resistance result from changes in drug
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accumulation, bioactivation, inactivation of alkylating species and DNA
excision repair. In some cell lines expression of the MDR phenotype
corresponded to mitomycin C resistance and cross-resistance with other
natural-product anticancer agents including the anthracycline antibiotics,
vinca alkaloids and MTX (Dorr et al., 1987). Increased intracellular
sulphydryl levels correlate with resistance to certain alkylating agents
leading to enhanced DNA repair in the form of cross-link removal
(Lindahl et al., 1982). In addition, as metabolic bioactivation is a
prerequisite for mitomycin C activity, reduced expression of the enzymes
involved such as DT-diaphorase and NADPH:cytochrome P-450 reductase
have frequently been reported as causing resistance (Hoban et al., 1990;
Marshall et al., 1991).
1.4.3 Mechanism of Action of Mitomycin C
1.4.3.1 Bioreductive Activation
Iyer & Szabalski (1964) intially postulated mitomycin C's dependence for
enzymatic metabolic activation. This was subsequently adapted by Moore
(1977). This led to the introduction of the term T>ioreductive alkylation' to
describe the proposed mechanism of drug action (Lin et al., 1972).
The first stage in the activation of mitomycin C is quinone reduction. For
experimental purposes, reduction can be achieved chemically, for
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example sodium dithionite (Schiltz & Kohn, 1993), catalytically using
hydrogenation over platinum oxide (Kohn et al., 1987) and finally
electrochemically by reduction on a platinum or mercury electrode
(Andrews et al., 1986). However, the more biologically relevant enzymatic
activation is usually employed since it may correspond to possible
mechanisms occurring in vivo. The enzymes involved in this activation
process are discussed in more detail in section 1.4.3.2.
Quinone reduction can occur through a one-electron pathway producing
the semiquinone free radical intermediate or a two-electron pathway
yielding the hydroquinone intermediate, figure 1.5. In the presence of
oxygen, the semiquinone will enter into a redox cycle generating reactive
oxygen species (section 1.4.3.4), pathway 2, figure 1.5. In contrast, the
generation of alkylating moieties by two-electron reduction is unimpeded
by molecular oxygen (Powis, 1987). Upon bioreduction, the C-9a O-methyl
group leaves the parent mitosane nucleus as methanol resulting in a C-9-
C-9a double bond producing the mitosene nucleus. This promotes proton
assisted aziridine ring opening exposing an electrophilic carbon centre at
C-l which subsequently alkylates DNA (Moore, 1977).
The critical intermediate produced in this metabolic cascade that leads to
DNA cross-linking is thought to be the quinone methide (Tomasz &
Lipman, 1981; Peterson & Fisher, 1986). It is the binding of the quinone
methide to DNA at C-l that promotes a second DNA attachment point
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producing DNA cross-linking via the production of a C-10 reactive centre
(Tomasz & Lipman, 1981), after the loss of the carbamate group. While
mitomycin C possesses no DNA binding activity, the quinone methide is
believed to bind non-covalently to DNA with high affinity by non-specific
intercalation through a mechanism which is dependent on the ionisation
of its 2-amino group and is enhanced under acidic conditions (Kumar et
al., 1995). Reversible non-covalent binding can possibly be viewed as a
precursor event to irreversible covalent bonding.
The quinone methide is believed to be ambivalent in nature ie: it has
both electrophilic and nucleophilic properties. However, it has been
demonstrated more recently by purely chemical means that rather than
acting as an electrophile (figure 1.5, pathway 3) at neutral pH resulting in
DNA binding and a nucleophile (figure 1.5, pathway 1) at acidic pH as
originally hypothesised (Peterson & Fisher, 1986), the quinone methide is
predominantly nucleophilic in character at all functional pHs between 5.5
and 8.5 (Schiltz & Kohn, 1993). This theory explains why 2,7-DM, the
product of the quinone methide acting as a nucleophile, is the major
metabolite of mitomycin C seen in vivo. The electrophilic metabolites of
mitomycin C, cis- and trans-hydro are believed to be derived from a 7-
aminoaziridinomitosene intermediate, the oxidised form of
leucoaziridinomitosene (LAZM), figure 1.5, pathway 4. The formation of
7-aminoaziridinomitosene predominantly under alkaline conditions
explains why these metabolites are observed at more alkaline pH (Hoey et
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ah, 1988; Schiltz & Kohn, 1993).
Using the two-electron reductase DT-diaphorase to activate mitomycin C,
two other key intermediates have been proposed to be precursors to DNA
covalent bonding (Ross et al., 1993), figure 1.5, pathway 5. These are the
quinone-reduced intact aziridino products leucomitomycin C
(leucoMMC) or fully reduced mitomycin C and LAZM, fully reduced
mitomycin C minus the C-9a O-methyl group. Their dependence on
proton-assisted aziridine ring opening to yield electrophilic intermediates










DNA MONOADDUCT DNA 8ISADDUCT
Figure 1.5. Proposed pathways of metabolic activation of mitomycin C
after one- and two-electron quinone reduction. Pathways 1-5 are described
within section 1.4.3.1.
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1.4.3.2 Enzymology of Mitomycin C Activation
The enzymology of mitomycin C metabolic activation has been studied in
a number of systems ranging from bacteria and liver to neoplastic cells
and purified enzymes. Several enzymes have been implicated in the
bioactivation of mitomycin C. These include one-electron reductases such
as NADPH: cytochrome P-450 reductase (Kennedy et al., 1982; Pan et al.,
1984), xanthine oxidase (Pan et al., 1984) and NADH: cytochrome bs
reductase (Hodnick & Sartorelli, 1993), and the two-electron reductases
DT-diaphorase [NAD(P)H:(quinone acceptor) oxidoreductase, EC 1.6.99.2]
(Siegel et al., 1992) and xanthine dehydrogenase (Gustafson & Pritsos,
1993). In addition, cytochromes P-450, although unable to transfer
electrons directly to mitomycin C, may in fact facilitate quinone reduction
through drug binding (Keyes et al., 1984).
The role of each of the reductases in the metabolic activation of
mitomycin C in vivo has yet to be clarified, but it is emerging that
different reductases may prevail under different physiological conditions
(Cummings et al., 1994). For example, NADPHxytochrome P-450
reductase is thought to predominate in artificially hypoxic cells (Kennedy
et al., 1980; Krishna et al., 1991). In contrast, numerous studies support a
major role for DT-diaphorase in mitomycin C metabolic activation in
normally oxygenated but not hypoxic cells (Siegel et al., 1990a; Dulhanty &
Whitmore, 1991).
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1.4.3.3 Modification of DNA byMitomycin C
Early studies on the mechanism of action of mitomycin C indicated that
the principle cellular target was DNA (Iyer & Szybalski, 1963, 1964).
Mitomycin C itself does not react with DNA. Only upon enzymatic or
chemical activation does mitomycin C have the capability to interact with
DNA. A variety of mitomycin C-DNA adducts have been reported. It was
initially claimed that the major sites of covalent bonding are at 0-6
guanine, followed by N-6 adenine and finally N-2 guanine (Hashimoto &
Shudo, 1984).
Tomasz and colleagues (1986) demonstrated that monofunctional
alkylation by the quinone methide led to the formation of a covalent
guanine N2-linked mitosene monoadduct, Figure 1.6, adduct 2. This
adduct accounted for 90 % of the mitomycin C bound to DNA after
reductive activation with NADPH cytochrome P-450 reductase, xanthine
oxidase and H2/platinum oxide. Two minor guanine-N2 adducts were
also characterised, one a secondary degradation product of the major
adduct and the second a 1-J3 stereoisomer arising from attack of the P side
of the guanine amino group. Both accounted for 2-5 % of the total adduct
pool. In the same study, model-building studies indicated that the
guanine-N2-linked drug molecule fitted excellently inside the minor
groove of the (3 DNA exhibiting no obvious distortion of the structure of
the double helix.
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In addition, a number of bisadducts have subsequently been formed,
characterised and identified. The major product isolated under reductive
activation with sodium dithionite was an interstrand cross-linked adduct
bonded to the position of N-2 guanine on complementary strands of
DNA (Tomasz et al., 1987), figure 1.6, adduct 4. The drug-DNA complex
produced minimal DNA distortion. The same bisadduct was also isolated
from DNA from the livers of rats that had been injected with mitomycin
C (Tomasz et al., 1987). This study provided the first direct chemical proof
for formation of covalent cross-links between mitomycin C and DNA and
also postulated that oxygen and its possible role as an inhibitor of
bifunctional activation, may explain the enhanced mitomycin C toxicity
seen under hypoxia. The latter hypothesis was later demonstrated under a
purely chemical system (Tomasz et al., 1988a).
A second less frequently observed bisadduct, a cross-link within one
strand of DNA or intrastrand cross-link, was isolated exhibiting a single
2,7-diaminomitosene residue linked bifunctionally to guanines at their
N2 atoms to the C-l and C-10 positions of the mitosene (Bizanek et al.,
1992), figure 1.6, adduct 5. In contrast to the monoadduct and interstrand
bisadduct, observed bending of DNA near the cross-link site was a notable
effect of the intrastrand cross-link (Rink et al., 1996).
Finally, nucleophilic attack by water at the C-10 position subsequently
resulted in the formation of the 10-decarbamoylated monoadduct, figure
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1.6, adduct 3, and is also a major product of bifunctional activation
(Tomasz et al., 1988b).
All four major adducts previously isolated and characterised as described
above have been detected in vivo (Bizanek et al., 1993). The major species
observed under aerobic conditions were the interstrand cross-linked
adduct, followed by the 10-decarbamoylated monoadduct, then the
intrastrand adduct and finally the monofunctional monoadduct. A fifth
adduct, adduct Y, was also seen but not identified chemically. This
product may represent the N7 guanine adduct that appears to account for
greater than 90 % of all mitomycin C covalently bonded to DNA after
metabolic activation with purified rat DT-diaphorase (Prakash et al., 1993).
The structures of all the adducts indicated that the reaction of mitomycin
C with DNA was base specific: both the C-l aziridine and C-10 carbamate
alkylating functions of the drug react exclusively with 2-amino groups of
guanines in the minor groove of DNA. In addition, the reaction with
DNA is sequence specific. Mitomycin C alkylates guanines in the
sequence CpG.CpG on average five to ten-fold faster than guanines in
other sequence contexts (Li & Kohn, 1991; Kumar et al., 1992). However,
only 5 % of all guanines in the mammalian genome are present in the
CpG context compared to 70 % for Micrococcus luteus DNA which is used
throughout a number of the described studies. Therefore overall,
mammalian DNA is cross-linked poorly by mitomycin C and may be seen
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Figure 1.6. Structures of the mitomycin C-DNA adducts formed via
mono- and bifunctional activation. 1, mitomycin C; 2, N2-linked
mitosene monoadduct; 3, 10-decarbamoylated monoadduct; 4, interstrand
cross-link adduct; 5, intrastrand cross-link adduct. Adapted from Rink et
al, 1996.
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as a disadvantage in the treatment of tumour cells. However, such a
problem may prove vital in designing cross-linking agents that are more
efficient in killing tumour cells by altering their sequence specificity.
The non-covalent binding of mitomycin C directly to DNA has proved
difficult to examine. Unreduced mitomycin C does not bind to DNA and
the reductively activated form is too short lived to perform direct studies.
Teng et al. (1989) however, detected binding of reduced species to
synthetic oligonucleotides observing competitive inhibition of cross-
linking of GC containing oligonucleotides by those containing AT base
pairs and therefore no covalent drug binding sites. Kumar et al. (1995)
have subsequently used a stable tautomeric form of the quinone methide,
namely the metabolite 2,7-DM, and found that the positively charged
molecule intercalated non-specifically into DNA. This intercalation has
been demonstrated to hold DNA together under denaturing conditions
(Peterson et al., 1995). All of the above studies may represent a new
mechanism of DNA damage induced by mitomycin C.
1.4.3.4 Redox Cycling and Oxygen Free Radical Formation
In the presence of oxygen a second mechanism occurs through which
mitomycin C may develop its cytotoxic effect. The semiquinone free
radical intermediate of mitomycin C is capable of transferring an electron
to molecular oxygen. This leads to the formation of the superoxide anion
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radical and regeneration of the parent molecule, mitomycin C. The
repetitive reduction and reoxidation of mitomycin C under aerobic
conditions is known as redox cycling. The superoxide radical is not a
particularly reactive species but can give rise to the hydroxyl radical. The
powerful oxidising capabilities of this radical can cause oxidation of lipids,
degradation of DNA and protein damage (Halliwell & Gutteridge, 1984).
The formation of the hydroxyl radical during redox cycling of mitomycin
C has been demonstrated (Doroshow, 1981; Pritsos et al., 1985) and
subsequent lipid peroxidation has been observed with the co-incubation
of mitomycin C, pulmonary microsomes and NADPH (Trush, 1982).
However, although reactive oxygen species are evolved from this process,
it is generally accepted as not being critical for mitomycin C antitumour
activity (Powis, 1987; Butler & Hoey, 1987).
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1.5 New Approaches to Bioreductive Therapy
The ultimate goal in the use of any anticancer agent is to exploit a
potential difference between normal and tumour tissue. Physiological
differences such as those described in section 1.3 combined with the
knowledge of exisiting bioreductive drugs can potentially lead to the
rational design of highly specific anticancer agents.
1.5.1 Indoloquinone E09
E09 or (E)-5-(l-azirinyl)-3-(hydroxymethyl)-2-(3-hydroxy-l-propenyl)-l-
methyl-lH-indole-4,7-dione, figure 1.7, is the lead compound of a series of
novel and fully synthetic indoloquinone cytotoxic agents structurally
related to mitomycin C (Oostveen & Speckamp, 1987). However, despite
its structural similarities to mitomycin C, in preclinical models E09
exhibits a different antitumour profile. It was found to be very active in
vitro exhibiting IC50 values ranging from 1-100 ng/mL when tested
against R-l rat rhabdomyosarcoma, the human tumour cell lines A204
carcinoma, IgR-37 melanoma, human small cell lung cancer cell lines Oc-
NyH/Oc-Tol (Roed et al., 1989) and the National Cancer Institute (NCI)
disease-orientated in vitro screen (Hendriks et al., 1993). In the majority of
cases E09 was more potent than mitomycin C. In addition, bone marrow
toxicity, a major dose limiting toxicity associated with mitomycin C was




Figure 1.7. Comparative molecular structures of analogue indoloquinone
E09 and the parent drug mitomycin C.
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E09 has since passed through Phase I and has now entered Phase II
clinical trials. Initially E09 was administered as a 5 minute intravenous
infusion once every 3 weeks at a starting dose of 2.7 mg/m2 (Schellens et
al., 1994). Results indicated that E09 could be administered according to
this schedule with tolerable and predictable toxicity. The dose-limiting
toxic effect was proteinuria in coincidence with oedema development.
The maximum tolerated dose was reached at 27 mg/m2. Bone marrow
toxicity was absent in all patients in agreement with the animal toxicity
studies.
With the partial response of a number of patients with lung and liver
metastases and its distinct preclinical antitumour profile, E09 entered
Phase II clinical trials (Wanders et al., 1995). Patients with breast,
colorectal, gastric and pancreatic cancer received a recommended weekly
dose of 12 mg/m2. Additional non-small cell lung cancer patients
received 22 mg/m2 once every three weeks. Once again proteinuria was
the main toxicity recorded in 39% of patients. This was more frequent in
the 3 weekly schedule (52%). Nausea and vomiting were also noted. As
yet no antitumour responses have been observed.
As with mitomycin C, E09 requires bioreductive activation via a one- or
two-electron reduction pathway (Smitskamp-Wilms et al., 1996). E09 can
undergo one- and two-electron reduction resulting in the formation of
the semiquinone and hydroquinone respectively. Redox cycling of the
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semiquinone radical under aerobic conditions yielding potential toxic
superoxide radicals also occurs (Smitskamp-Wilms et al., 1996). Unlike
mitomycin C, no data has been published on the structure of DNA
adducts, if any, formed by E09. However, there is an indication that E09 is
capable of interacting with DNA. Walton et al. (1991) demonstrated that
E09 was reduced to species capable of causing single strand breaks in
pBR322 plasmid DNA. This was later supported by the use of the alkaline
elution technique (Bailey et al., 1992a). Both techniques required DT-
diaphorase. Recently, the pH and hypoxic dependence of E09 interstrand
cross-link formation for both DT-diaphorase and xanthine oxidase has
been shown (Maliepaard et al., 1995).
The enzymology of E09 bioreduction is much clearer than mitomycin C
with respect to the role of DT-diaphorase. Initially based on the use of DT-
diaphorase preparations from rodent and human tumour cell lines
(Walton et al., 1991), a good correlation between DT-diaphorase
expression and in vitro E09 sensitivity in the presence of oxygen has
been established (Phillips et al., 1992; Plumb & Workman, 1994; Robertson
et al., 1994; Smitskamp-Wilms et al., 1994; Collard et al., 1995;
Fitzsimmons et al., 1996). The role of DT-diaphorase may explain the
dose-limiting toxicity proteinuria observed during the clinical trials due
to high expression of the enzyme in human kidney (Schlager & Powis,
1990).
39
In comparison there is little evidence, as yet, to support the role of DT-
diaphorase with the in vivo solid tumour activity of E09. Walton et al.
(1992a) however, have demonstrated such a correlation using the
transplantable mouse adenocarcinoma of the colon (MAC) tumours MAC
16 and MAC 26 and intraperitoneal administration of E09. MAC 16 which
exhibits a 15-fold higher level of DT-diaphorase than MAC 26 was found
to be more responsive to E09 than MAC 26 suggesting an important role
for DT-diaphorase in vivo.
Under hypoxia the exact role of DT-diaphorase is unclear. Using the
human colon cell lines HT-29 and BE, high and deficient in DT-
diaphorase respectively, Plumb & Workman (1994) demonstrated a 1000-
fold enhancement in E09 cytotoxicity under hypoxia in the BE cell line
compared to aerobic conditions. HT-29 only showed a 2 to 5-fold shift in
hypoxic sensitivity. This was later supported by data obtained with breast,
non- and small-cell lung cancer and additional colon cell lines (Robertson
et al., 1994). Such an observation may implicate one-electron reductases in
E09 cytotoxicity (Bailey et al., 1993).
There are few studies detailing the metabolism of E09. Acid-catalysed
degradation may be a possible activation step of E09 in the process of
binding to DNA, in a manner analogous to mitomycin C (Beijnen, 1986a).
Acid-catalysed degradation was shown to result in a number of products
(de Vries et al., 1993). Essentially, protonation of the trivalent nitrogen in
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the aziridine ring results in the formation of an aziridinium ion. This
electrophilic centre is then open to attack by nucleophilic species ie: water
leading to the production of a degradation product possessing an
ethanolamine group at C-5. This process is accompanied by a number of
spectral changes.
This breakdown product has been identified as the aziridine ring open
product E05A (Workman et al., 1992) and has been observed in patient
samples (Schellens et al., 1993; Verweij et al., 1994). However, E05A is
very much less cytotoxic than E09 and a poor substrate for DT-diaphorase
(Bailey et al., 1992b). Other metabolites have been detected by HPLC but as
yet have not been further characterised (Maliepaard et al., 1995).
Clinically E09 has a number of possible uses. The use of E09 as a post-
irradiation sensitiser has proved beneficial with enhanced hypoxic
cytotoxicity observed with E09 administered immediately after a 10 Gy
dose of x-rays (Adams et al., 1992). In addition, when used in
combination with the vasoactive agent hydralazine, the previously
observed E09 inactivity in the well vascularised MAC 26 murine
adenocarcinoma is rendered active (Bibby et al., 1993). Other uses may
include the use of E09 with interstitial photodynamic therapy, although
only a minor improvement in tumour regression was seen when
compared to mitomycin C (Baas et al., 1994).
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The high specificity of E09 for DT-diaphorase-dependent bioactivation
and an HCR of 33 (Adams et al., 1992) makes it an ideal candidate for
enzyme-directed bioreductive drug therapy. Its unique structure may aid
in the development of structurally modified third generation analogues
(Bailey et al., 1992b; Philips, 1996 unpublished).
1.5.2 Benzotriazine-di-N-oxide SR 4233
SR 4233 (3-amino-l,2,4-benzotriazine 1,4-dioxide, WIN 59075) or
tirapazamine is the lead compound of the benzotriazine di-N-oxide
bioreductive drugs and is currently undergoing Phase I clinical testing.
First reported by Zeman and colleagues (1986), it was found to exhibit
differential hypoxic cytotoxicity against a number of mammalian cell
lines with HCR varying from 25 to 500. As with other bioreductive drugs
SR 4233 exhibits a complex mechanism of metabolic activation.
Essentially, SR 4233 is metabolised via a one-electron reduction step to the
radical anion SR 4233*". At this point the reaction can proceed in a
number of directions. In the presence of oxygen the radical is back
oxidised to the parent molecule in conjunction with the production of
superoxide radicals. Under hypoxia the radical can either disproportionate
resulting in SR 4233 and the stable two-electron reduction product SR
4317 or abstract hydrogen from cellular molecules producing an oxidised
target and SR 4317. The damaging species of SR 4233 has been shown to be
the radical anion. This is supported by evidence that SR 4317 is non-toxic
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to both aerobic and hypoxic cells (Baker et al., 1988; Costa et al., 1989) and a
decrease in hypoxic cytotoxicity is observed with the addition of DMSO, a
known radical scavenger (Brown, 1990a).
The enzymes responsible for SR 4233 metabolic activation remains
unclear. Initially, studies utilising mouse liver microsomes identified
cytochrome P-450 as the major reductase involved based on the inhibitory
effects of carbon monoxide (Walton & Workman, 1990; Walton et al.,
1992b). This was consequently confirmed in tumour/cell line
homogenates (Wang et al., 1993). However, Cahill & White (1990) and
Lloyd et al. (1991) found no carbon monoxide-dependent inhibition using
rat liver microsomes as the enzyme source and subsequently identified
NADPH:cytochrome P-450 reductase as the major enzyme involved.
Similar activity has also been demonstrated in a number of human breast
cell lines under hypoxia and chronic exposure to air (Patterson et al.,
1995).
The role of other enzymes in particular DT-diaphorase remains unclear
and may only play a minor part in SR 4233 bioactivation (Cahill et al.,
1993).
DNA is thought to be the major site of SR 4233 toxicity as a result of
hydrogen atom abstraction (Baker et al., 1988) and production of single
strand breaks in DNA co-incubated with SR 4233 in the presence of
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NADPH.-cytochrome P-450 reductase have been demonstrated
(Fitzsimmons et al., 1994).
The use of SR 4233 has numerous potential clinical uses. Combination
with vasoactive drugs such as flavone acetic acid, its analogue 5,6-
dimethylxanthenone acetic acid, and hydralazine have all potentiated SR
4233 cytotoxicity in preclinical models (Sun & Brown, 1989; Cliffe et al.,
1994; Brown, 1987). Alternatives include combining SR 4233 with
radiation (Brown & Lemmon, 1990b) and conventional chemotherapy.
The latter has been found to markedly potentiate the tumouricidal effect
of a number of alkylating agents with an overall therapeutic gain with
minimal toxicity (Hoiden et al., 1992). Although none of the above
techniques have yet to be demonstrated in human tumours, all remain
viable strategies for improving cancer treatment.
1.5.3 Nitroimidazoles
The concept of radiosensitisation using the 'oxygen mimetic' 5-
nitroimidazole, metronidazole, was discovered in 1974 (Sutherland, 1974)
and subsequently entered clinical trials. However, such agents displayed
weak potency compared to the 2-nitroimidazoles. The initial 2-
nitroimidazole, misonidazole, went through a number of clinical trials in
combination with irradiation (Dische et al., 1976; Thomlinson et al., 1976)
but dose-limiting toxicities, mainly neurotoxicity, prevented its use at
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doses high enough to produce a beneficial effect. This disappointing result
led to the development of etanidazole (SR 2508) (Brown & Lee, 1980) and
with its lack of neurotoxicity higher doses were achieved in vivo
(Coleman et al., 1986). Pimonidazole, a more potent agent, entered Phase
III clinical trials for cervical cancer but the results were once again
dissappointing.
A promising approach stemming from the above compounds has been
the development of RSU 1069 (a-(l-aziridinylmethyl)-2-nitro-lH-
imidazole-l-ethanol) (Stratford et al., 1986). This compound acts as a very
potent 'mixed function' sensitiser due to the presence of the sensitising
nitro-group and an alkylating aziridine moiety and has demonstrated i n
vitro and in vivo radiosensitiser and bioreductive drug characteristics
(Hill et al., 1986; Stratford et al., 1989). However, subsequent clinical trials
showed dose-limiting gastrointestinal toxicity (Horwich et al., 1986). In
order to maintain the advantageous antitumour activity but reduce dose-
limiting toxicities of RSU 1069, the analogue RB 6145 (a[2-bromo-
ethyl)amino]) containing a masked aziridine moiety was developed
(Jenkins et al., 1990). The compound, a prodrug for RSU 1069, displayed
the required radiosensitiser/bioreductive drug properties with reduced
dose-limiting toxicity (Jenkins et al., 1990; Sebolt-Leopold et al., 1992).
Preclinical investigations have demonstrated that RB 6145's
radiosensitiser/bioreductive properties can be potentiated in a number of
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ways. These include x-rays (Cole et al., 1990), physical clamping of the
tumour, use of agents affecting oxyhaemaglobin dissociation and
vasoactive agents such as hydralazine (Bremner, 1993). However, the use
of RB 6145 in combination with PDT induced the largest increase in
antitumour activity (Bremner et al., 1994).
1.5.4 Miscellaneous Agents
Often structurally based on exisiting bioreductive agents, numerous new
agents are being developed, each with their own specific mechanism of
action. The mitomycin C analogues BMS-181174, previously designated
BMY 25067 and KW-2149, have both entered clinical trial exhibiting a
greater spectrum of activity including activity against mitomycin C
resistant tumours in addition to reduced myelosuppression (Verweij et
al., 1993; Talbot et al., 1994).
Other agents include the 4-alkylamino-5-nitroquinolines which have
demonstrated varying degrees of hypoxic-selective toxicity (Denny et al.,
1992). The various chemical substitutions within the series have
provided the opportunity to study the determinants of hypoxia-selectivity
(Siim et al., 1994). Also the novel fused pyrazine mono-N-oxides, the lead
compound of which is RB90740, has shown a 20-fold enhancement in
cytotoxicity under hypoxia and show great potential (Naylor et al., 1993,
1995).
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Other interesting compounds such as dimethyl-diaziridinyl-
benzoquinone, MeDZQ, were designed specifically with DT-diaphorase
activation in mind. Unlike other bioreductive agents it shows little
hypoxic enhancement in vitro but exhibits very potent in vivo
antitumour activity against non-small cell lung cancer xenografts known
to be highly refractory to most cytotoxic drugs (Cummings et al., 1996).
The DNA intercalation and structural properties of the anthraquinones
has led to the development of the alkylaminoanthraquinone N-oxide
A4QN, a prodrug analogue of mitoxantrone (Patterson, 1989). This agent,
upon hypoxia-dependent reduction to A4Q, in common with other
bioreductive drugs, mediates its cytotoxic effects through high affinity
drug-DNA binding but additionally possesses topoisomerase II inhibitory
effects (Patterson, 1993). A4QN itself has no intrinsic binding affinity for
DNA and low toxicity. A4QN may have potential when used in
combination with radiation therapy (McKeown et al., 1995).
Another recent approach to potentiate bioreductive therapy has been in
the development of hypoxia-selective prodrugs of diffusible cytotoxins
which are capable of back diffusing to kill surrounding oxygenated cells in
addition to hypoxic regions (Denny & Wilson, 1993). The nitobenzyl
mustard quaternary salt SN 25246 and the cobalt (in)-nitrogen mustard
complex SN 42771 both show potential (Denny et al., 1994; Wilson et al.,
1994).
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1.5.5 Enzyme-Directed Bioreductive Drug Development
The general concept of enzyme-directed bioreductive drug development
was first expressed in 1989 and subsequently reported a year later
(Workman & Walton, 1990) and consists of two major elements. Firstly, it
can be used to facilitate medicinal chemists in tailoring drugs and hence
optimise prodrug activation by a particular reductase. This may be aided
by the use of three-dimensional crystal structures of the reductases in
association with advanced computational chemistry techniques (Li et ah,
1995). Secondly, so-called enzyme profiling of tumour specimens used in
association with other parameters such as tumour hypoxia and pH
measurement may aid in the selection of patients most likely to respond
to a specific bioreducive drug. The net result is therefore to promote
rational drug design/development whilst individualising patient
treatment.
The concept can be approached by a variety of directions. The use of a
drug against a specific tumour type known to express high levels of a
particular reductase is the simplest approach. Alternatively, one could
base the choice of drug on the analysis of a tumour biopsy specimen.
Which ever approach is used, a number of criteria must be fulfilled:-
a. Knowledge of a particular reductase predominating in the
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activation of the drug concerned.
b. Knowledge of the expression and activity of the reductase in
tumour cell lines and biopsy specimens from patients with
different tumour types.
c. Correlation between enzyme activity and responsiveness in in
vitro cell lines and in vivo human tumour xenografts.
d. Possibilities of clinical trials to establish if the relationship is
observed in humans and under what circumstances.
e. Individual patient profiling using methods that can be easily
incorporated and used in routine clinical practice.
The role of a specific reductase in the reductive activation of certain
bioreductive drugs has been discussed throughout. In particular DT-
diaphorase remains a very attractive target for such an approach and
elevated levels of the enzyme have been reported in tumour material
obtained from patients with lung, breast and colon cancers (Koudstaal et
al., 1975; Schlager & Powis, 1990). NADPHxytochrome P-450 reductase
and NADHxytochrome bs reductase also play important roles and with
the profiling of the NCI's human tumour cell line panel using techniques
that could possibly be used in a clinical situation (cytochrome c reduction
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assay, western blot analysis and messenger RNA expression)
(Fitzsimmons et al., 1996), it will in no doubt be a powerful asset in the
future directions of enzyme-directed bioreductive drug therapy.
1.6 Scope of the Thesis
The enzymology of mitomycin C metabolic activation has been
extensively studied with the aid of purified enzymes and cell lines. The
role of specific enzymes, in particular the two-electron reductase DT-
diaphorase, have been clarified. However, although such studies have in
no doubt provided considerable impact of the area of mitomycin
metabolic activation, little evidence exisits on the role of such enzymes in
solid tumour tissue. This formed the basis of the thesis. The following
questions were addressed:-
(1). What enzymes are responsible for mitomycin C metabolic
activation in tumour tissue in vitro and in vivo?
(2). Is there a role for the two-electron reductase DT-diaphorase?
(3). Can one predict which tumour types are optimum for mitomycin
C treatment with regards to quinone reductase activity?
These studies were carried out using two murine adenocarcinomas of the
50
colon, MAC 16 and MAC 26, known to exhibit high and low levels of DT-
diaphorase respectively.
E09 is currently undergoing microsphere encapsulation for potential use
as a locoregional drug formulation for the treatment of colorectal liver
metastases (Gardiner et al., 1996). Preliminary results indicate good
antitumour activity particularly in those tumours high in DT-diaphorase.
In contrast to mitomycin C, the metabolites of E09 have not been well
characterised. Therefore, it was of interest to determine whether the
metabolites of E09 could be detected and quantified following E09
reduction and if so, if any one metabolite correlated to the observed
antitumour activity. Also could levels of any metabolite give an
indication of E09 metabolic activation with regards to specific quinone
reductase expression. Tumour models used were once again MAC 16 and
MAC 26 in addition to the human colon xenografts, HT-29 and BE. The
latter tumours expressed high and low levels of DT-diaphorase
respectively.
Finally from a biophysical perspective, the properties of the short lived
reactive intermediates of E09 were examined in order to determine the
cytotoxic form(s) of E09 produced after bioreduction.
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CHAPTER 2
2. MATERIALS AND METHODS
2.1 MATERIALS
All reagents used were of the highest grade commercially available from
suppliers listed in Appendix 1 eg: Aristar grade from BDH Merck Ltd. and
HPLC grade from Rathburn Chemicals Ltd. Reagents were made up in
distilled water purified to Grade II (ISO 3696) equivalent to double
distilled water obtained from a Milli-UlO water purification system.
2.2 APPARATUS
All suppliers of apparatus used throughout are listed in Appendix 1.
2.2.1 High-Performance Liquid Chromatography
The liquid chromatograph used throughout was a Hewlett-Packard Model
1090 equipped with the following features; a PV5 ternary low-pressure
mixing solvent delivery system; a variable volume automatic injector
and autosampler, 10-250 pi injection volume; a heated column
compartment and multi-diode rapid scanning UV/Vis spectro¬
photometry detector. System control and data evaluation were
performed by a Hewlett-Packard Series 9000 300 "Chemstation" computer.
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2.2.2 Linear Accelerator
The linear accelerator facility was based at the Paterson Institute for
Cancer Research, Christie Hospital and Holt Radium Institute,
Manchester, U.K. The system consisted of a "L" band linear accelerator
capable of producing a beam of pulsed electrons with an energy between 8
and 12 MeV and variable pulse widths from 5 ns to 5 (is. The optical
detection system consisted of a high stability xenon arc or tungsten
halogen lamp, Kratos GM 252 high intensity quater meter
monochromator and an EMI 9558QA photomultiplier. Flow-through
capillary cells were composed of high purity fused silica cylindrical
microbore tubing, internal diameter 3 mm, with Spectrosil quartz
windows. Optical path lengths between 0.4 and 2.5 cm were used.
Signals from the photomultiplier were recorded on a dual channel
Tektronix 7612AD programmable digitiser and processed using a Hewlett
Packard Series 200 model 9836S computer. Stopped flow measurements
used an Applied Photophysics RX1000 stopped-flow apparatus coupled to
HP 8452A diode array spectrophotometer.
2.2.3 High-Performance Liquid Chromatography-Mass Spectroscopy
The high-performance liquid chromatography-mass spectroscopy facility
was based at the Paterson Institute for Cancer Research, Christie Hospital
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and Holt Radium Institute, Manchester, U.K. The system used consisted
of a Trio 2 mass spectrometer (VG MicroMass) in conjunction with a
Gilson 307 manually operated HPLC pump and Waters 484 MS UV/Vis
detector. VG Masslynx and MaxEnt were used for software purposes.
2.2.4 Human Colon Adenocarcinoma Cell Line BE and Establishment of
BE Xenograft
The human colon carcinoma cell line BE was kindly supplied by Dr. Neil
W. Gibson, Pfizer Inc. Groton, U.S.A. via Dr. Jane Plumb, CRC
Department of Medical Oncology, Glasgow, U.K. and was grown as a
monolayer culture in a 50:50 mixture of Ham's F10 and Dulbecco's
Modified Eagle's Medium (DMEM) supplemented with 2 mM glutamine
and 10% foetal calf serum. Penicillin-streptomycin solution was added to
a final concentration of 100 IU to prevent bacterial contamination. Cells
were grown in 175 cm2 tissue culture flasks in a humidified atmosphere
of 95 % oxygen and 5 % carbon dioxide at 37°C (Scotlab VSL incubator).
Once the cells had reached late log phase, cells were trypsinised with 3 mL
trypsin (0.25 %):versene (1 mM EDTA, 0.5 % phenol red) (1:1) until the
cells had rounded up and detached. Trypsinisation was neutralised by the
addition of 7 mL 50:50 Ham's F10:DMEM to each flask. Samples were
transferred into 20 mL sterile universal containers and centrifuged at
1000 g for 5 minutes to pellet down the cells. The media were discarded
and each pellet was resuspended in 5 mL sterile phosphate buffered saline
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(PBS) then all transferred into one universal container which was
centrifuged once again. The supernatant was discarded and the cell pellet
resuspended in 20 mL PBS and syringed using a 21 gauge needle and 20
mL syringe to produce a single cell suspension.
0.5 mL of the single cell suspension was added to 5 mL PBS (dilution
factor x 11), mixed thoroughly and cell number counted using an
Improved Neubauer haemocytometer. The original cell suspension was
centrifuged once again, supernatant discarded and the cell pellet was left
undisturbed covered by a few drops of PBS ready for implantation into
nu/nu nude mice. Approximately 1 x 108 cells were available for
implantation.
All of the above procedures were carried out under sterile conditions in
M.D.H. Interlab Class n tissue culture hoods.
3 nu/nu mice in total were implanted with BE cells subcutaneously into
the flank of the animal. Once the "tumour" material became palpable, the
animals were sacrificed, "tumours" removed and samples were sent to
Department of Pathology, Western General Hospital, Edinburgh, to
confirm that the tissue was of tumour origin and not due to an
inflammatory response. When establishment of the tumour was
confirmed, routine passaging of the tumour was carried out as detailed in
section 2.2.5b. At every third passage all tumours were examined
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histologically to confirm tumour status.
2.2.5 Animal Models
a. Murine Tumour Models
The murine model used was the inbred NMRI mouse and the
subcutaneously murine adenocarcinoma of the colon, MAC 16 or MAC
26, (original tumours and breeding pairs kindly supplied by Professor J.A.
Double and Dr. M.C. Bibby, Clinical Oncology Unit, University of
Bradford, Bradford U.K). All mice were fed Teklad mouse diet and water
was available freely. Tumours were maintained by passaging 1-3 mg
lumps via trochar needle to male animals weighing between 25 and 30 g.
When tumours reached 0.15-0.2 g, animals were either randomised for
experimental studies or sacrificed for tumour removal. All tumours were
stored at -80°C prior to use.
b. Human Xenograft Tumour Models
The animal model used was the nu/nu nude mouse (originally bred at
Imperial Cancer Research Fund (ICRF), London) supplied by Harlan U.K.
Ltd. and the subcutaneously human adenocarcinomas, HT-29 or BE. Mice
were housed in Morden isolators and fed on Teklad mouse diet. Water
was available freely. Tumours were maintained by passaging 0.5-1 mg
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lumps via trochar needle to male animals weighing between 20 and 25 g.
When tumours reached 0.1-0.2 g, animals were sacrificed for tumour
removal. Again all tumours were stored at -80°C prior to use.
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2.3 METHODS
2.3.1 Isolation of Mitochondrial, Microsomal and Cytosolic Subcellular
Fractions from MAC 16 & MAC 26 Murine Adenocarcinomas and
HT-29 & BE Human Adenocarcinomas of the Colon
Isolation of tumour subcellular fractions was carried out using a standard
differential ultracentrifugation method in 0.25 M sucrose using a
modification of the previously described method (Cummings et al, 1992).
Whole tumours, 0.5-1.5 g, were first washed in saline then transferred to
ice cold 0.25 M sucrose, 5 mM Tris-buffer, 0.5 mM EDTA (STE), pH 7.4 in
which a homogenate was produced (33% w/v). Portions of the
homogenate were either used directly for drug incubation (sections 2.3.6
& 2.3.14) or processed to isolate mitochondrial, microsomal and cytosolic
fractions. Homogenates were first centrifuged at 600 g (Beckman GPR
centrifuge) for 10 minutes to remove cellular debris and the resulting
supernatant subjected to a high speed spin of 24,000 g (Beckman L7
ultracentrifuge) for 10 minutes to isolate the mitochondria. The
supernatant was retained for microsomal isolation.
The mitochondrial pellet was resuspended in STE solution and
centrifuged once again at high speed. The final pellet was resuspended in
5 mL STE solution. Microsomes were isolated from the post-
mitochondrial supernatant by centrifugation at 80,000 g (Beckman L7
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Ultracentrifuge) for 1 hour. The supernatant was retained for isolation of
the cytosolic fraction.
The resulting microsomal pellet was resuspended in 0.1 M sodium
phosphate pH 7.4 and centrifuged once again at 80,000 g. The final pellet
was resuspended in 5 mL 10 mM Tris-HCl buffer pH 7.4 containing 20%
glycerol and 0.1 mM EDTA. The post-microsomal supernatant was
centrifuged at 80,000 g for 4 hours. The resulting supernatant, cytosol, was
made up to 10 mL with STE solution.
All centrifugation steps were carried out at 4°C and samples kept on ice at
all times to prevent enzyme degradation. Subcellular pellets were
resuspended using hand-held glass homogenisers. Samples were stored
in 1 mL aliquots at -80°C for no more than one month and freeze-thaw
repetitions avoided.
HT-29 and BE subcellular fractions were prepared purely for
determination of tumour quinone reductase levels and not for drug
incubations.
2.3.2 Protein Determination of Tumour Homogenates and Subcellular
Fractions
Protein concentrations of all homogenates and subcellular fractions were
59
determined using the Biuret method (Layne, 1957) using bovine serum
albumin (BSA) as a standard. Standards containing 0-10 mg protein were
prepared from a 10 mg/mL stock solution and test samples diluted 1 in 10
with distilled water before analysis. 4 mL Biuret reagent was then added
to 1 mL standard or diluted subcellular fraction/homogenate, vortexed
and incubated at room temperature from 30 minutes. Each sample and
standard was carried out in duplicate. The absorbance of each sample at
550 nm against distilled water was determined spectrophotometrically
using a Unicam UV/Vis spectrophotometer. The extinction AE 550 was
then calculated for all standards and samples. Sample protein
concentrations were calculated from the standard curve (AE 550 versus
mg protein) and expressed as mg protein.
2.3.3 Quinone Reductase Assessment of Tumour Subcellular Fractions
Quinone reductase activity was assessed in MAC 16 /MAC 26 and HT-
29/BE subcellular fractions following the spectrophotometric reduction of
cytochrome c at 550 nm (Unicam UV/Vis spectrophotometer) using a
modification of the method of Ernster, 1967, as described elsewhere (Riley
& Workman, 1992). The reaction mixture contained 65-100 |ig cytosolic or
17-33 pg microsomal protein, 77 jjM cytochrome c, 20 (iM menadione as
an intermediate electron acceptor, 2 mM NADH or NADPH as cofactor
and 0.14% w/v BSA. Reactions were performed at 37°C in a total volume
of 1 mL 50 mM Tris-HCl buffer, pH 7.4 in 1 mL plastic cuvettes in the
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presence or absence of 10 |iM dicoumarol. Control cuvettes contained all
reagents with the exception of the cytosolic/microsomal protein. Cuvettes
were maintained at 37°C using a water circulating Unicam Cell
Temperature Controller and Unicam UV5-220 Thermostatted cell
holders. Each reaction was carried out in triplicate.
Cytosolic and microsomal DT-diaphorase activity was taken as the activity
that could be inhibited by dicoumarol in the presence of either cofactor.
Other cytosolic activity may include xanthine dehydrogenase/oxidase and
aldoketo reductase. NADPH:cytochrome P-450 reductase was calculated as
NADPH-dependent microsomal activity. NADH:cytochrome bs reductase
was calculated as the residual NADH-dependent microsomal activity
unaffected by dicoumarol inhibition. Activities were expressed as nmol
cytochrome c reduced/min/mg protein using the extinction coefficient e
21.1xl03 M/cm. Mitochondrial quinone reductase levels were not assessed
due to the presence of cytochrome c oxidase.
2.3.4 Electron Microscopy of MAC 16 and MAC 26 Mitochondrial and
Microsomal Subcellular Fractions
Subcellular fractions were prepared as described in section 2.3.1 with the
exception of the following. After the initial spin at 24,000 g for isolation
of the mitochondria, the supernatant was retained for isolation of
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tumour microsomes. The mitochondria were resuspended in 10 mL
fixation buffer, 3% glutaraldehyde in 0.1 M sodium cadodylate/HCl pH
7.4. Samples were incubated in this solution for 30 minutes, mixing
occasionally, before subjecting to another high speed spin at 24,000 g. The
same procedure was used for isolation of the microsomes with fixative
added after the initial 80,000 g centrifugation step. Once fixation was
complete samples were stored in fixative at 4°C for a minimum of 2
hours.
Fixed samples were first washed with distilled water for 3 x 20 minutes to
remove primary fixative. This was followed by a secondary fixation step
using 1% osmium tetroxide incubated at room temperature for 45
minutes and subsequent dehydration in increasing methanol
concentrations (50, 75, 100%) and absolute ethanol. Formation of the
sections were carried out by 30 minutes propylene oxide linking,
impregnation overnight with Emix resin and polymerisation at 70°C for
18-24 hours.
90 nm sections were cut using a glass knife microtome and mounted on
copper grids. Section staining was carried out using a standard uranyl
acetate/lead citrate method.
Sections were viewed by a Jeol 100CXII transmission electron microscope
and photographed using Kodak 4489 film.
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2.3.5 In Vitro Metabolism of Mitomycin C by Tumour Subcellular
Fractions
Incubations were carried out in 50 mL tapered glass tubes at 37°C under
aerobic and hypoxic conditions. Each incubation mixture contained
approximately 1 mg MAC 16 or MAC 26 derived mitochondrial,
microsomal or cytosolic protein, 3.3 mM NADH, NADPH or
hypoxanthine acting as cofactors and 100 pg/mL mitomycin C. Both
cofactors and drug were made up in 0.1 M sodium phosphate buffer, pH
7.4. Protein and cofactor mixtures were allowed to equilibrate to 37°C for
10 minutes prior to the addition of mitomycin C. For hypoxic incubations,
mixtures were sparged with helium for 5 minutes prior to drug addition.
Hypoxic environments were maintained with a flow of helium gas
delivered via a rubber stopper and glass pastette and allowed to vent off
through an outlet hole.
In the case of inhibitor incubations, the enzyme inhibitors dicoumarol
and the polyclonal cytochrome P-450 reductase antiserum CH59 (kindly
supplied by Professor C.R. Wolf, ICRF Molecular Pharmacology Unit,
Dundee) were added. 10 pM dicoumarol, made up in 0.1 M sodium
phosphate pH 7.4: 0.1 M sodium hydroxide 50: 50 and antiserum, 1 in 100
dilution, were added 30 minutes before the start of the reaction. The
inhibitory properties of cytochrome P-450 reductase antiserum on
quinone reductase activity were assessed using the quinone reductase
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assay detailed in section 2.3.3. The concentration of antiserum giving 50 %
inhibition of NADPH-microsomal dependent cytochrome c reduction
was used (1 in 100 dilution).
After the addition of mitomycin C, a 100 pL aliquot was withdrawn from
the incubation at 15 minute intervals (0-90 minutes) and 20 pL subjected
immediately to HPLC to determine the concentration of mitomycin C and
its metabolites at 360 and 310 nm respectively. Each incubation was
carried out in triplicate. Reaction rates were calculated from the linear
portions of the reaction curves and expressed as 2,7-DM formation in
nmol/30min/mg protein.
Control incubations containing all components of the incubation
mixture, with the exception of subcellular protein, were carried out under
aerobic and hypoxic conditions in duplicate.
2.3.6 In Vitro Metabolism of Mitomycin C by Tumour Homogenates
MAC 16/MAC 26 and HT-29/BE homogenates were prepared as detailed
in section 2.3.1. Drug incubations consisted of 100 pg/mL mitomycin C
made up in 0.1 M sodium phosphate buffer, pH 7.4 and 0.9 mL tumour
homogenate. The incubation procedure follows that detailed in section
2.3.5 with the exception of the addition of enzyme inhibitors. At 15
minute intervals 100 pL samples were withdrawn, mixed with 100 pL
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methanol and centrifuged in an Eppendorf microcentrifuge at 15,000 g for
2 minutes to remove tumour protein. 20 pL of the supernatant was then
subjected to HLPC analysis monitoring at 360 and 310 nm. Each
incubation was carried out in triplicate. Reaction rates were calculated
from the linear portions of the reaction curves and expressed as 2,7-DM
formation in nmol/30min/mg protein.
Again, control incubations containing all components of the incubation
mixture with the exception of tumour homogenate, were carried out
under aerobic and hypoxic conditions.
2.3.7 High-Performance Liquid Chromatography Analysis of Mitomycin
C and its Metabolites
Chromatographic conditions were modified from those previously
described (Cummings et al, 1993). The stationary phase was a LiChrosorb
RP-18 HPLC cartridge, 7 pm particle size, column dimensions 25 cm x 4
mm and a LiChrospher 100 RP-18 precolumn, 5 pm particle size, column
dimensions 4x4 mm enclosed in a LiChrocart Manu-fix cartridge holder.
The mobile phase consisted of 10 mM sodium phosphate buffer, pH 7.5
and methanol at a ratio of 76:24. Elution was isocratic at a flow rate of 1
mL per minute with the oven temperature maintained at 40°C. The
mobile phase was filtered before use through 0.2 pm filters and sparged
continuously with helium throughout chromatographic analyses. Results
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were recorded vising the diode array detector at 360 nm for the parent drug
and 310 nm for its metabolites.
The assay was standardised using mitomycin C and its primary
metabolites 2,7-DM, trans- and cis-hydro as synthesised and purified in
section 2.3.8.
2.3.8 Synthesis And Purification of Mitomycin C Primary
Metabolites
Production of the major metabolite 2,7-DM was achieved by irradiation of
mitomycin C. This was kindly carried out by Dr. John Butler, Paterson
Institute for Cancer Research, Christie Hospital and Holt Radium
Institute, Manchester, U.K. using the linear accelerator facility. The
mitomycin C/metabolite mixture was initially concentrated using solid
phase extraction. Essentially, a 5 g C2 Bondesil column was prepared and
activated using 1 column volume of methanol. The column was then
washed with distilled water immediately followed by the mitomycin
C/metabolite mixture. The column was washed once again with distilled
water to remove any unretained products, dried under vacuum and the
sample eluted with approximately 15 mL methanol. The sample was
concentrated to 3-5 mL under a stream of nitrogen. 2,7-DM was isolated
from this concentrated mixture by preparative HPLC using the conditions
described in section 2.3.7. Each distinct peak was collected using an online
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Gilson fraction collector. The peak corresponding to 2,7-DM, retention
time approximately 12 minutes, was purified from the HPLC mobile
phase by solid extraction as above. The final methanol eluant was dried
under nitrogen, checked for purity by HPLC and stored at 4°C.
The hydrolysis products trans- and cis-hydro were synthesised in house.
10 mg mitomycin C was subjected to acid hydrolysis by addition of 2 mL
0.1 M hydrochloric acid. The sample was maintained at room
temperature for 25-35 minutes before stopping the reaction by placing the
sample on ice. Retrieval of the sample was by the solid phase extraction
method described above. Fractionation was essentially the same with the
peaks of interest eluting at approximately 5 minutes for trans-hydro and
7-8 minutes for cis-hydro. Samples were purified once again using solid
phase extraction, dried and stored at 4°C.
2.3.9 Extraction of Mitomycin C and its Metabolites from Tumour
Tissue and Plasma
a. Tumour Tissue
MAC 16 and MAC 26 tumours were partially thawed on ice, weighed and
to a known tumour weight, 154 mM potassium chloride solution added
in proportions 1:2 w/v. Tumours were homogenised using a tissue
homogeniser rinsing the cutting device between each tumour. 1 mL of
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the resulting homogenate was extracted with 5 mL chloroform:propan-2-
ol:ethyl acetate (2:2:1) in 50 mL tapered glass centrifuge tubes by vortexing
constantly for 15 minutes at room temperature. Samples were centrifuged
at 1000 g (Beckman GPR centrifuge) for 15 minutes at 4°C prior to
removal and retention of the drug containing solvent layer. The
remaining aqueous layer was extracted once again with a further 5 mL of
solvent. The combined solvent layers were then evaporated to dryness
under a stream of nitrogen and the resulting residues reconstituted with
300 pi 10 mM sodium phosphate pH 7.5:methanol, 74:26. Finally, samples
were vortexed for 2 minutes, centrifuged at 15000 g in an Eppendorf
microcentrifuge and filtered before HPLC analysis of 100 pL.
b. Plasma
Plasma samples were totally thawed prior to extraction of mitomycin
C/metabolites. The procedure was essentially the same with the total
volume of plasma obtained extracted twice with 2 mL chloroform:
propan-2-ol:ethyl acetate (2:2:1) rather than 5 mL.
2.3.10 Pharmacokinetics of Mitomycin C in MAC 16 and MAC 26 Murine
Adenocarcinomas of the Colon
MAC 16 or MAC 26 bearing NMRI mice were maintained as described in
section 2.2.5a. Animals were randomized into groups of 3 and injected i.t.
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with 500 |ig free mitomycin C in a final volume of 0.25 mL distilled water.
Mitomycin C consisted of preweighed vials containing 2 or 10 mg as a
sterile powder. The animals were then sacrificed at the following times
after drug administration:- 0, 1, 5, 15, 30, 45, 60, 120 and 360 minutes for
both MAC 16 and MAC 26, tumours removed and immediately placed in
liquid nitrogen.
Blood samples collected were centrifuged at 15000 g for 5 minutes in an
Eppendorf microcentrifuge to obtain plasma. Plasma was removed,
transferred to a cryotube and placed in liquid nitrogen. Plasma samples
were not collected for the following time points:- 0 and 1 minutes since
the time taken to sacrifice the animal and remove the blood sample
exceeded 5 minutes. All samples were stored at -80°C for a maximum of 2
weeks prior to parent drug and metabolite extraction.
Peak levels and time to peak levels of mitomycin C and its metabolites
were taken directly from concentration-time profiles. Area under
concentration/time curves (AUCo-360min) was calculated by the trapezoidal
rule. Clearance was calculated as dose/AUC. The in vivo metabolic
conversion of mitomycin C to 2,7-DM in both tumour types was
calculated as the AUC ratio MMC:2,7-DM.
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2.3.11 Antitumour Activity of Mitomycin C in MAC 16 and MAC 26
Murine Adenocarcinomas of the Colon
Tumour bearing animals were randomised into 5 groups of 8 consisting
of the following dosage/control groups:- 50, 75, 125, 250, 500 and 1000 jig
mitomycin C, vehicle control (distilled water) and untreated control.
Mitomycin C or distilled water were injected i.t. as a single dose in a total
volume of 0.25 mL. Approximately every two days, the mice were
weighed and tumour volume (V) determined by measuring two
diameters at right angles and calculated in cm3 using the formula V = tc/6
x length x width2. Once the study was complete, the animals were
sacrificed, tumours removed and stored at -80°C.
Antitumour activity for a treatment group was expressed as percentage
increase/decrease in tumour volume compared to day 0 (100%). The
antitumour activity of mitomycin C compared to control,
tumour/control (T/C) values, were calculated for each dose at day 7.
2.3.12 Histological Preparation of MAC 16 and MAC 26 Murine
Adenocarcinomas of the Colon
Tumours no less than 0.5 cm diameter were initially fixed in 4%
paraformaldehyde solution for a minimum of 24 hours and subsequently
embedded in paraffin wax ready for sectioning. 12 sections of each tumour
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type (3 per slide), approximately 3 |im thickness were prepared, mounted
on non-coated glass slides and dried at 60°C overnight. Sections were then
ready for staining with haematoxylin and eosin.
Sections were de-waxed in xylene for 2x4 minutes followed by rinses in
decreasing alcohol concentrations (absolute, 74%, 64%) and water. The
rehydrated sections were first stained with Harris's haematoxylin for 3-4
minutes or until the nuclei were stained and then rinsed once again in
water. Excess haematoxylin was removed by rinsing in acid alcohol for 10-
15 seconds followed by a water wash until all alcohol had been removed.
Sections were placed in lithium carbonate until a colour change from red-
brown to blue was observed, then washed in water for 2-3 minutes.
Counterstaining was achieved by staining with alcoholic Y eosin solution
for 1 minute. Slides were rinsed in water, dehydrated in increasing
concentrations of alcohol (64%-absolute), rinsed in xylene, air dried and
mounted using DPX mounting media. Sections were then ready for
morphological assessment. Sections were examined using a Leitz Dialux
20 microscope equipped with Leitz 10, 40 and 100 objectives and light box.
Sections were optimally seen using a blue filter to reduce the redness of
the section. Photographs were taken with a Wild 51 S camera and MPS 45
photoautomatic controller using Kodak Ektar 25 tungsten balanced film at
a magnification of 12.5.
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2.3.13 High-Performance Liquid Chromatography Analysis of
Indoloquinone E09
Chromatographic conditions were essentially the same as those used for
mitomycin C analysis as described in section 2.3.7 with the exception of
the following. Results were recorded using the diode array detector at 280
run for both E09 and its metabolites. The assay was standardised with E09
only.
2.3.14 In Vitro Metabolism of Indoloquinone E09 by Tumour
Homogenates
MAC 16/MAC 26 and HT-29/BE homogenates were prepared as detailed
in section 2.3.1. Drug incubations consisted of 100 (ig/mL E09 made up in
0.1 M sodium phosphate buffer, pH 7.4 and 0.9 mL tumour homogenate.
Incubations were carried out under both aerobic and hypoxic conditions
as described in section 2.3.6. At 45 minute intervals, 100 |iL samples were
withdrawn, mixed with 100 pL methanol and centrifuged in an
Eppendorf microcentrifuge at 15,000 g for 2 minutes to remove tumour
protein. 20 pL of the supernatant was then subjected to HLPC analysis.
Each incubation was carried out in triplicate.
Control incubations containing all components of the incubation
mixture, with the exception of tumour homogenate, were carried out
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under aerobic and hypoxic conditions in duplicate.
2.3.15 Degradation of Indoloquinone E09 under Alkaline Conditions
Reactions were carried out using an adaptation of the method of de Vries
et al. (1993). Essentially, a 1 mM solution of sodium hydroxide, pH 12,
containing 100 pg E09 was incubated at room temperature. At 30 minute
intervals, a 100 pL aliquot was withdrawn from the reaction mixture and
20 pL analysed by HPLC for the presence of any degradation products.
2.3.16 Reaction of Indoloquinone E09 with Reduced Glutathione
PBS containing 2 mM reduced glutathione was sparged with helium for
10 minutes. The PBS was previously filtered and degassed using 0.2 pM
filters. 100 pg E09 was subsequently added. At 30 minute intervals a 100
pL aliquot was withdrawn from the reaction and 20 pL analysed by HPLC.
All reactions were carried out at room temperature and solutions
continuously sparged with helium throughout.
2.3.17 High-Performance Liquid Chromatography-Mass Spectroscopy of
Indoloquinone E09 and Intermediates Generated by Irradiation
High-performance liquid chromatography-mass spectroscopy was carried
out at the Paterson Institute as described in section 2.2.3. A sub-saturated
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solution of E09 in 10 mM phosphate buffer pH 7 containing 0.1M
isopropanol was sparged with argon and subsequently irradiated with 500
Gy using the linear accelerator described in section 2.2.2. The irradiated
sample was mixed with air and 100 pL injected into the mass
spectrophotometer. Samples were initially analysed by the mass
spectrophotometer via a LiChrosorb RP-18 HPLC cartridge, 7 pm particle
size, column dimensions 25 cm x 4 mm and LiChrospher 100 RP-18
precolumn, 5 pm particle size, column dimensions 4x4 mm and Waters
484 MS UV/Vis detector. The mobile phase consisted of water in 25%
acetonitrile. Analyses were carried out at room temperature at a flow rate
of 1 mL per minute. Additional samples were injected directly into the
mass spectrophotometer. For both analyses, the following positive
atmospheric pressure chemical ionisation (APCI +ve) parameters were
used:-
Probe voltage 3.48 KV
Counter voltage 0.43 KV
Cone voltage 32 V
Lens 2 40 V




2.3.18 Generation of Indoloquinone E09 Reactive Intermediates by Pulse
Radiolysis
Pulse radiolysis experiments were conducted at the Paterson Institute
linear accelerator facility as described in section 2.2.2. All pulse radiolysis
solutions contained 0.1 M sodium formate buffered using 10 mM
phosphate, pH 4.5 - 9.0 or 10 mM borate/sodium hydroxide, pH 8.5-10.0.
Pulse lengths were less than 0.1 ps. Kinetic analysis was carried out using
the Fig P program assuming second order kinetics. All experiments were
performed at 21 ± 2°C.
Generation of free radical intermediates was initially carried out in argon
saturated solutions containing 20 |jM - 2 mM E09 in 100 mM sodium
formate solution pH 4.5 - 10.0. Pulses of 20 ps were used.
The reduction potential of E09 was assessed at pH 7.4 and was determined
by setting up an equilibrium between the semiquinone free radicals of
E09 and mitomycin C monitoring at 415 and 490 nm. 100 |iM mitomycin
C was used in conjunction with varying concentrations of E09, 10-40 pM.
Autoxidation of E09 was studied using 20-50 pM E09 initially reduced in
one half of a stopped flow mixing chamber with 0.6 U xanthine oxidase,
100 pM hypoxanthine in 0.1 M phosphate buffer, pH 7.4, until the
solution became colourless. All solutions were argon saturated. The
reduced solution was then rapidly mixed with an air saturated solution
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containing 200 pM allopurinol and 2 pM EDTA in 0.1 M phosphate
buffer, pH 7.4. Total time for the initial reduction and subsequent
exposure to air was less than 10 minutes.
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CHAPTER 3
3. RESULTS AND DISCUSSION
3.1 Characterisation of a Novel Mitochondrial Reductase
The aim of this section of the thesis was to characterise the enzyme(s)
responsible for mitomycin C bioreduction in MAC 16 and MAC 26
murine adenocarcinomas to provide an insight into the drug's in vivo
mechanism of action. MAC 16 and MAC 26 subcellular fractions were
prepared as detailed in section 2.3.1 and subsequently used for quinone
reductase determination and mitomycin C bioreduction studies.
The quinone reductase profile of the cytosolic and microsomal fractions
isolated from both tumours are shown in table 3.1. MAC 16 exhibited a 22-
fold higher level of cytosolic DT-diaphorase but similar levels of
microsomal NADPH:cytochrome P-450 reductase to those of MAC 26,
consistent with previously published data (Walton et al, 1992a). 'Other7
cytosolic enzymes, which may include xanthine oxidase and aldoketo
reductase were also calculated, with MAC 16 possessing approximately 8-
fold greater levels of these enzymes compared to MAC 26. In addition,
both tumour types exhibited similar levels of microsomal
NADH:cytochrome fc5 reductase. No microsomal DT-diaphorase was
present in MAC 26. Mitochondrial quinone reductase activity could not
be assessed due to the presence of cytochrome c oxidase. As the assay relies
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Mitomycin C bioreduction in MAC 16 and MAC 26 subcellular fractions
was measured by monitoring the formation of the principle metabolite
2,7-DM. This metabolite was used as an indicator of the rate of metabolic
activation of mitomycin C as it can only be formed after quinone
reduction rather than acid catalysed degradation (Beijnen et al., 1986b). In
addition, levels of 2,7-DM have been demonstrated to correlate with
cytotoxicity in human colon carcinoma cell lines (Siegel et al., 1990a) and
antitumour activity in MAC 16 (Cummings et al., 1994) and Sp 107 rat
mammary carcinoma (Chirrey et al., 1995). Table 3.2 and 3.3 illustrate
mitomycin C bioreduction in MAC 16 and MAC 26 subcellular fractions
and revealed a number of enzyme activities present within all three
fractions of MAC 16 compared to one in MAC 26.
MAC 16 cytosolic activity utilised both NADH and NADPH as cofactors,
showing similar activity under aerobic and hypoxic conditions. The
chromatographic profiles of mitomycin C metabolism by MAC 16 cytosol
under aerobic and hypoxic conditions in the presence of NADH or
NADPH are illustrated in figure 3.1 and 3.2 respectively. 2,7-DM could be
clearly seen at approximately 10.2 minutes. Significant levels of other
metabolites were not seen. The addition of 10 (iM dicoumarol, a known
inhibitor of the two-electron reductase DT-diaphorase (Lind et al., 1982a),
resulted in 100 % inhibition of 2,7-DM formation. Addition of
cytochrome P-450 reductase antiserum had no inhibitory effect. No
cytosolic activity was observed in MAC 26.
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Figure 3.1. In vitro pattern of mitomycin C metabolism in MAC 16
cytosolic fractions under aerobic (B) and hypoxic (C) conditions using
NADH as cofactor. Samples were analysed at 0 (A) and 60 (B, C) minutes
and metabolite levels measured by HPLC. Chromatographic peaks were
plotted as retention time (min) against UV milliabsorbance units (mAU)
and applies to all subsequent chromatographic figures throughout.
Peaks: I, zwitterion form of mitomycin C; III, mitomycin C; VI, 2,7-
diaminomitosene.
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Figure 3.2. In vitro pattern of mitomycin C metabolism in MAC 16
cytosolic fractions under aerobic (B) and hypoxic (C) conditions using
NADPH as cofactor. Samples were analysed at 0 (A) and 60 (B, C) minutes
and metabolite levels measured by HPLC.
Peaks: I, zwitterion form of mitomycin C; III, mitomycin C; VI, 2,7-
diaminomitosene.
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No cytosolic activity was recorded in either tumour when hypoxanthine
was utilised as cofactor under both aerobic and hypoxic conditions.
MAC 16 microsomal activity had an absolute requirement for NADPH
and hypoxia and 100 % inhibition was achieved with the addition of
antiserum. Figure 3.3 illustrates the chromatographic profile of
mitomycin C metabolism by MAC 16 microsomes and the inhibitory
effect of cytochrome P-450 reductase antiserum. In addition to 2,7-DM,
small amounts of cis-hydro and the secondary metabolite 10-decarbamoyl
2,7-diaminomitosene could be seen at 8 and 9.5 minutes respectively. The
co-elution of trans-hydro with the zwitterion form of mitomycin C may
be responsible for the increase in peak height observed in the 60 minute
uninhibited sample. Co-incubation with dicoumarol had no effect on the
rate of mitomycin C metabolism. Again as with the cytosol, no
microsomal activity was present in MAC 26 despite cytosolic and
microsomal activity being demonstrated using the cytochrome c
reduction assay, table 3.1.
DT-diaphorase and NADPH:cytochrome P-450 reductase have both been
shown to metabolise mitomycin C in a number of cellular systems (Pan et
al., 1984; Ross et al., 1993; Fitzsimmons et al., 1996). Their identification in
many cases has relied upon comparison of their characteristics with those
of purified enzymes in conjunction with specific enzyme inhibitors.
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Figure 3.3. In vitro pattern of mitomycin C metabolism in MAC 16
microsomal fractions under hypoxia using NADPH as cofactor in the
absence (B) and presence (C) of cytochrome P-450 reductase antiserum.
Samples were analysed at 0 (A) and 60 (B, C) minutes and metabolite
levels measured by HPLC.
Peaks: I, zwitterion form of mitomycin C; II, 1,2-trans-l-hydroxy-2,7-
diaminomitosene; III, mitomycin C; IV, l,2-cis-l-hydroxy-2,7-
diaminomitosene; V, 10-decarbamoyl 2,7-diaminomitosene VI, 2,7-
diaminomitosene.
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Probably the most widely studied enzyme, DT-diaphorase,
characteristically utilises both NADH and NADPH as cofactor and with
certain substrates can show equivalent activity under aerobic and hypoxic
conditions. This latter characteristic is associated with its ability to act as
an obligate two-electron reductase. In addition, its activity can be inhibited
by relatively low concentrations of the coumarin derivative dicoumarol
(Lind et al., 1982a). Using these characteristics, the results presented in
table 3.2 have identified an enzyme present within the cytosol of MAC 16
exhibiting these properties. This, along with the high level of DT-
diaphorase observed in the cytosolic quinone reductase assay, table 3.1,
leads one to the reasonable conclusion that the cytosolic enzyme in MAC
16 is possibly the two-electron reductase DT-diaphorase.
The cytosolic enzyme is unlikely to be xanthine dehydrogenase. Although
this enzyme is predominantly located within the cytosol and activates
mitomycin C in a similar manner to DT-diaphorase, it requires a different
cofactor (NAD+) and readily converts to xanthine oxidase during the
process of tissue homogenisation (Gustafson & Pritsos, 1992a, 1993). In
addition, mitomycin C activation by xanthine oxidase is solely by one-
electron reduction pathway and is inhibited by oxygen (Pan et al., 1984;
Gustafson & Pritsos, 1992a). Other cytosolic enzymes such as carbonyl
reductase, a member of the aldoketo reductase family, have been
demonstrated to play a role in quinone-mediated oxidation (Forrest et al.,
1991,1994; Jarabak, 1991). However, carbonyl reductase has been reported
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not to reduce mitomycin C and therefore it is an unlikely candidate
(Wermuch et al., 1986).
Early studies using rat liver preparations have implicated a microsomal
reductase utilising NADPH as cofactor in mitomycin C metabolism under
hypoxic conditions (Schwartz, 1962). Similar experiments later confirmed
the possible role of the one-electron reductase NADPH:cytochrome P-450
reductase (initially referred to as NADPH:cytochrome c reductase) in liver
(Kennedy et al., 1982), EMT6 mouse mammary tumour cells (Keyes et al.,
1984) and purified enzyme preparations (Bachur et al., 1979; Pan et al.,
1984). A rat liver microsomal system was also used to generate mitomycin
C metabolites, particularly with reference 2,7-DM (Tomasz & Lipman
1981). More recently, Chinese hamster ovary cells transfected with the
gene for this enzyme and hence overexpressing NADPHxytochrome P-
450 reductase have demonstrated differential mitomycin C toxicity under
hypoxia (Belcourt et al., 1996).
Activity characteristic of the one-electron reductase NADPH:cytochrome
P-450 reductase was observed in MAC 16. Localised within the
microsomal fraction, it had an absolute requirement for NADPH and
hypoxia and it is this inhibitory effect of oxygen which is considered to be
indicative of one-electron reduction. Activity was completely inhibited by
the addition of cytochrome P-450 reductase antiserum, which has been
previously shown to inhibit the biotransformation of doxorubicin to
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doxorubicin 7-deoxyglycone by purified rat liver NADPH:cytochrome P-
450 reductase (Cummings et al., 1992). This, in conjunction with the
results presented in table 3.1 demonstrating NADPH:cytochrome P-450
reductase activity in MAC 16, suggests that microsomal activity is due to
this enzyme. Despite DT-diaphorase and NADPH:cytochrome P-450
reductase activities being confirmed in MAC 26 by cytochrome c reduction
assays, table 3.1, there was no indication of any involvement of these
enzymes in cytosolic and microsomal mitomycin C metabolism
respectively. Reasons for this remain unclear.
The majority of mitomycin C metabolism on a per mg protein basis was
associated with the mitochondrial fraction from both MAC 16 and MAC
26, table 3.2 and 3.3 respectively. NADPH combined with hypoxia
produced the greatest formation of 2,7-DM with specific activities being
similar in both tumour types. NADH-dependent mitomycin C
metabolism was only seen in MAC 16 and activity was approximately 4-
fold less than that seen with NADPH. The presence of oxygen resulted in
complete inhibition of metabolism in both tumour types. In contrast to
the other enzyme activities detected, the addition of 10 (iM dicoumarol
and cytochrome P-450 reductase antiserum failed to produce any
inhibitory effect. The chromatographic profiles of mitomycin C
metabolism by MAC 16 and MAC 26 mitochondria in the presence of
NADPH and hypoxia are shown in figure 3.4.
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Figure 3.4. In vitro pattern of mitomycin C metabolism in MAC 16 (C)
and MAC 26 (B) mitochondrial fractions under hypoxic conditions using
NADPH as cofactor. Samples were analysed at 0 (A) and 60 (B, C) minutes
and metabolite levels measured by HPLC.
Peaks: I, zwitterion form of mitomycin C; II, l,2-frans-l-hydroxy-2,7-
diaminomitosene; III, mitomycin C; IV, l,2-os-l-hydroxy-2,7-
diaminomitosene; V, 10-decarbamoyl 2,7-diaminomitosene; VI, 2,7-
diaminomitosene.
89
Again 2,7-DM can be clearly seen at 10.8 minutes as well as small amounts
of cis- and trans-hydro and the secondary metabolite 10-decarbamoyl 2,7-
diaminomitosene at approximately 8, 5 and 9 minutes respectively.
The inability of dicoumarol and cytochrome P-450 reductase antiserum to
inhibit NADPH-dependent activity suggests that the enzyme is neither
DT-diaphorase or NADPH:cytochrome P-450 reductase respectively. In
addition the enzyme's dependency for hypoxia suggests it is a one-
electron reductase rather than a two-electron reductase. Similar inhibitory
patterns were observed with the NADH-dependent enzyme present in
MAC 16 only.
Although quinone reductase assessment of the mitochondria was not
performed due to the presence of cytochrome c oxidase, the presence of
mitochondria was confirmed by electron microscopy, figure 3.5 and 3.6.
Mitochondria can be clearly seen exhibiting the classic double outer
membrane and cristae, but due to the nature of the fractionation process,
the method did not prevent mitochondrial membranes from a degree of
disruption (Wehrle & Pedersen, 1981; Cummings et ah, 1984). This has
the advantage of allowing the inner mitochondrial membranes access to
exogenously added nicotinamide cofactors. For comparison, the
microsomal fraction is shown in figure 3.7. The microsomes appeared as
dark bodies. No microsomal contamination could be seen within the
mitochondrial fractions.
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Figure 3.5. Electron micrograph of mitochondria isolated from MAC 16
murine adenocarcinoma of the colon. Magnification x 28080.
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Figure 3.6. Cross-sectional electron micrograph of a mitochondrion
isolated from the tumour mitochondrial fraction. Magnification x 138240.
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Figure 3.7. Electron micrograph of microsomes isolated from MAC 26
murine adenocarcinoma of the colon. Magnification x 41040.
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It has previously been suggested that mitochondria (Pritsos & Sartorelli,
1986) and mitochondrial reductases (Butler & Hoey, 1987; Workman et al.,
1989) are capable of metabolising mitomycin C and other quinones.
However, no experimental data, as yet, has been published to support this
statement. In addition, recent in vitro and in vivo data studying
mitochondrial function after mitomycin C treatment has shown that
considerable mitochondrial damage occurred after drug administration
(Pritsos & Vimalachandra, 1995). This implies for the first time that this
mitomycin C-mitochondrial interaction may contribute to mitomycin C's
mechanism of toxicity.
Also, quinone metabolites derived from the environmental pollutant
benzo[fl]pyrene have also been shown to exhibit the capacity to deplete
cellular ATP and induce morphological changes within mitochondria in
treated stromal cells, suggesting that benzo[a]pyrene quinones may elicit
their toxicity through directly disrupting mitochondrial energy
metabolism (Zhu et al., 1995).
One enzyme that exhibits similar properties to the NADPH-dependent
activity identified in MAC 16 and MAC 26 is NADPH-linked
aquacobalamin reductase [EC 1.6.99.8] (NADPH-linked AqCbl reductase)
which catalyses the reduction of aquacobalamin to cob(III)alamin in the
synthesis of cobalamin enzymes (Watanabe et al., 1990). First studied in
bacterial systems (Walker et al., 1969), this enzyme has now been
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identified in mammalian tissues (Watanabe et al., 1990). After further
characterisation of this enzyme from rat liver microsomes, results
indicated that it was NADPH:cytochrome c reductase, more commonly
known as NADPH:cytochrome P-450 reductase (Watanabe et al., 1992a).
At this time a NADPH-linked AqCbl reductase had been reported to occur
in mitochondrial membranes although its purification and
characterisation were yet to be carried out (Watanabe et al., 1989).
Subsequent isolation from rat liver mitochondrial membranes revealed
similarities, but also distinct differences to its microsomal counterpart,
namely molecular weight, 65 kDa compared to 79 kDa for the microsomal
enzyme, and peptide elution profile (Saido et al., 1993). However, similar
to the microsomal enzyme, the mitochondrial enzyme was specific for
NADPH and had the ability to reduce artificial electron acceptors such as
cytochrome c and 2,6-dichlorophenolindophenol (Saido et al., 1993). In
addition, the mitochondrial enzyme immunoreacted with an antibody
against microsomal NADPH-linked AqCbl reductase (NADPH:
cytochrome P-450 reductase) indicating that the two enzymes have
common antigenic determinants. This, in association with evidence
showing the same high specific activity and identical submitochondrial
location, the outer membrane, led the authors to conclude that the
purified rat liver mitochondrial NADPH-linked AqCbl reductase may be
NADPH: cytochrome c reductase (NADPH: cytochrome P-450 reductase).
This hypothesis was supported by an early observation that NADPH:
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cytochrome c reductase had been reported to occur, not only in
microsomes, but also the mitochondrial outer membranes (Brunner &
Bygrave, 1969).
This enzyme may be capable of metabolising mitomycin C in MAC 16 and
MAC 26 tumour tissue and may be a good candidate for the NADPH-
dependent enzyme identified in this study although identification and
localisation in tumours has not yet been addressed. The lack of
immunoreactivity of the cytochrome P-450 reductase antiserum (CH59)
may be explained by the different antigenic determinants found between
the mitochondrial enzyme and the enzyme to which the antibody has
been raised.
Rat liver NADH-linked AqCbl reductase activity derived from the
cytochrome bs/cytochrome bs reductase complex has also been identified
(Watanabe et al., 1992b) and subsequently isolated in rat liver
mitochondria within the outer membrane (Saido et al., 1994). This
enzyme may represent the NADH-dependent mitochondrial activity
observed in MAC 16. Other possibilities include mitochondrial NADH-
dehydrogenase which has been linked to the metabolism of the
anthracycline doxorubicin (Davies & Doroshow, 1986; Thornally et al.,
1986) and mitochondrial ubiquinol-cytochrome c reductase (Hatefi, 1985).
No published evidence, as yet, exists to support the role of these enzymes
in mitomycin C metabolic activation.
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Both NADPH- and NADH-linked AqCbl reductase activities have been
located in a variety of human tissues ranging from liver and kidneys to
brain and bone marrow (Watanabe et al., 1991). Interestingly, the colon
expresses both enzymes with the NADH-linked enzyme displaying the
highest specific activity, although exact cellular localisation was not
identified. Human liver NADPH- and NADH-linked AqCbl activity was
observed in both microsomes and mitochondria. This, in association with
its localisation within the colon, suggests that these enzymes may exist
within tumours derived from this tissue.
It is interesting to note the different pattern of metabolites produced by
the different fractions. MAC 16 cytosolic activity produced predominantly
2,7-DM. This had been previously demonstrated to occur in vivo
(Cummings et al., 1994) and in vitro (Siegel et al., 1990a, 1992), with the
latter study demonstrating that 2,7-DM was the major metabolite formed
as pH decreased from pH 7 to 5.8. This is thought to be characteristic of
DT-diaphorase and two-electron reduction. In contrast, MAC 16
microsomal activity produced a spectrum of metabolites, namely 2,7-DM,
cis-hydro and 10-decarbamoyl 2,7-diaminomitosene. The trans-hydro
metabolite is possibly co-eluting with the zwitterion form of mitomycin
C, peaks I/n, figure 3.3. A similar pattern of metabolism was observed
using rat liver microsomes in the presence of NADPH and hypoxia to
activate mitomycin C (Tomasz & Lipman, 1981). This pattern of
metabolism was replicated using purified rat liver NADPH:cytochrome P-
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450 reductase showing increasing levels of cis- and trans-hydro and
decreasing 2,7-DM levels with increasing pH (Pan et al., 1984).
The mitochondrial fractions isolated from MAC 16 and MAC 26 both
showed a similar spectrum of metabolites to those seen with MAC 16
microsomes. This supports the theory that the mitochondrial enzyme is
possibly a form of NADPH:cytochrome P-450 reductase as discussed
above.
In summary, the implications of the presence of a new enzyme capable of
metabolising mitomycin C are important. With its high level of specific
activity and activation under hypoxia, it provides an attractive target for
enzyme-directed bioreductive drug therapy utilising drugs that are
selectively toxic under hypoxic conditions and indeed provides a new
insight into the metabolic activation of mitomycin C itself.
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3.2 Role of DT-diaphorase in the Metabolic Activation of Mitomycin C
In the light of the three enzyme activities present in MAC 16 versus one
in MAC 26, the role of these enzymes was investigated in whole tumour
homogenates. This was considered to be a more representative tumour
system where all enzyme activities were present together. Figure 3.8
shows the formation of the principle metabolite 2,7-DM in MAC 16 and
MAC 26 homogenates under aerobic and hypoxic conditions. No added
cofactors were required. In agreement with the subcellular incubations,
MAC 26 homogenates exhibited an increase in metabolic activity under
hypoxia similar to that seen with the mitochondrial fraction from this
tumour. In contrast, MAC 16 homogenates did not show hypoxic
enhancement displaying similar activity under both aerobic and hypoxic
conditions. Table 3.4 details the specific activities produced by the tumour
homogenates under both conditions clearly showing hypoxic
enhancement in MAC 26.
The presence of the mitochondrial enzyme(s) may explain this hypoxic
enhancement of mitomycin C metabolism in MAC 26 homogenate
incubations. Although no aerobic metabolic activation was observed in
the purified mitochondrial fraction of MAC 26, aerobic homogenate
metabolism may rely upon the presence of these enzymes in the whole
tumour environment that may, in turn, occur in vivo. The inability of
hypoxia to potentiate mitomycin C metabolism in MAC 16 despite the
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Figure 3.8. In vitro production of the principle mitomycin C metabolite
2,7-diaminomitosene in MAC 16 and MAC 26 tumour homogenates
under aerobic (—) and hypoxic (—) conditions. Each point represents the
mean±SE from three separate experiments.
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TUMOUR 2,7-DM FORMATION EFFECT OF
HOMOGENATE (nmol/30min/mg protein) OXYGEN
AEROBIC ANAEROBIC
MAC 16 0.22±0.04 0.14±0.07 No inhibition
MAC 26 0.80+0.06 1.45+0.18 45% inhibition
Table 3.4. Specific activities of mitomycin C metabolism by MAC 16 and
MAC 26 tumour homogenates under aerobic and hypoxic conditions.
Specific activity is expressed as 2,7-diaminomitosene formation in
nmol/30min/mg protein. Each value represents the mean±SE from three
separate experiments.
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presence of the NADPH-dependent mitochondrial enzyme, suggests
preferential metabolism by other enzyme(s).
The metabolite profiles seen in these incubations were similar to those
observed with the subcellular fractions. Figures 3.9 and 3.10 illustrate the
HPLC profiles produced by MAC 16 and MAC 26 homogenates incubated
under aerobic and hypoxic conditions respectively.
Again the principle metabolite formed under both aerobic and hypoxic
conditions was 2,7-DM with clear hypoxic enhancement observed in
MAC 26. This hypoxic enhancement was accompanied by a clear decrease
in mitomycin C when compared to oxic conditions where levels of parent
drug were similar at 60 minutes in both tumour types. MAC 26 also
showed significant levels of additional metabolites suggesting the role of
a one-electron reductase as detailed in section 3.1. MAC 16 homogenate
however produced different metabolite levels. Similar levels of 2,7-DM
but lower levels of additional metabolites were seen under both
conditions similar to the cytosolic-dependent metabolism in figures 3.1
and 3.2. Metabolite profiles were monitored at 310 nm and hence the
mitomycin C peak appears reduced compared to 360 nm. The retention
time of 2,7-DM in figures 3.9 and 3.10 was approximately 13.5 minutes,
slightly prolonged compared to previous figures. This was due to column
ageing and should be taken into account throughout.
102
T1 me (mln. )
Figure 3.9. In vitro pattern of mitomycin C metabolism in MAC 16 and
MAC 26 tumour homogenates under aerobic conditions. Samples were
analysed at 60 minutes and metabolite levels measured by HPLC.
Peaks: I, zwitterion form of mitomycin C; n, 1,2-frans-1 -hydroxy-2,7-
diaminomitosene; III, mitomycin C; IV, l,2-cis-l-hydroxy-2,7-
diaminomitosene; V, 10-decarbamoyl 2,7-diaminomitosene, VI; 2,7-
diaminomitosene.
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Figure 3.10. In vitro pattern of mitomycin C metabolism in MAC 16 and
MAC 26 tumour homogenates under hypoxic conditions. Samples were
analysed at 60 minutes and metabolite levels measured by HPLC.
Peaks: I, zwitterion form of mitomycin C; II, l,2-frans-l-hydroxy-2,7-
diaminomitosene; III, mitomycin C; IV, l,2-cis-l-hydroxy-2,7-
diaminomitosene; V, 10-decarbamoyl 2,7-diaminomitosene, VI; 2,7-
diaminomitosene.
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The phenomenon of hypoxic enhancement has been previously observed
in the human colon adenocarcinoma cell line BE, a cell line that lacks DT-
diaphorase activity due to mutation in the DT-diaphorase gene NQOl
(Traver et al., 1992). BE displayed approximately a 10-fold increase in
sensitisation to mitomycin C under hypoxia compared to that in the
presence of air (Plumb & Workman, 1994). In addition, Beall et al. (1994)
demonstrated potentiation of mitomycin C toxicity under hypoxia in the
same cell line. This result was in contrast to that seen with another
human colon adenocarcinoma cell line, HT-29, expressing a DT-
diaphorase specific activity of 60 nmol/min/106 cells at the time of drug
exposure. HT-29 did not show any increase in sensitivity when exposed to
mitomycin C under hypoxic conditions, a result similar to that observed
above in MAC 16 (high in DT-diaphorase, table 3.1). In the same study,
similar results were obtained using the mitomycin C analogue
indoloquinone E09 with BE showing a 1000-fold increase in sensitisation
to the drug. HT-29 in combination with E09 and hypoxia produced no
enhancement.
Plumb and colleagues (1994) proposed that one-electron reduction was
responsible for the hypoxic activity seen in BE. Such activity may be due
to the presence of the mitochondrial reductase characterised and
discussed in section 3.1.
The use of dicoumarol (200 pM) in conjunction with HT-29 cells under
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hypoxia markedly increased their sensitivity to E09, suggesting that due
to possible enzyme inhibition, a one-electron reductase may now prevail
over other enzymes present (Plumb & Workman, 1994). Similar hypoxic
enhancement in the presence of dicoumarol (100 (iM) has also been
observed in EMT6 murine mammary tumour cells (Keyes et al., 1985) and
L1210 murine leukaemia cells (Keyes et al., 1989), again suggestive of one-
electron reductase activity. Such activity may again be due to the
mitochondrial enzyme identified. It should be noted that neither HT-29
nor BE cell lines were shown to have detectable levels of the one-electron
reductase xanthine oxidase (Siegel et al., 1990b).
Bizanek et al. (1993) extended the studies of Keyes and colleagues (1985,
1989) examining the effect of dicoumarol on adduct patterns generated by
mitomycin C in EMT6 murine mammary tumour cells. Mitomycin C-
DNA adduct frequencies were increased 1.5 fold under hypoxia in the
presence of dicoumarol (300 pM). A decrease of 1.6 fold was observed
under aerobic conditions. Such a result has a number of implications.
Firstly, the enhancement of DNA adduct formation under hypoxia may
be due to mitochondrial-dependent metabolism as seen in the MAC
tumours. Secondly, the decrease under aerobic conditions may be due to
DT-diaphorase inhibition and thirdly that this enzyme might be
predominating under aerobic conditions.
Although the above results present some intriguing findings concerning
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the role of quinone reductase in mitomycin C metabolic activation, they
were generated using extremely high concentrations of dicoumarol (100-
300 pM). These should be viewed with caution as dicoumarol itself can
also inhibit NADHxytochrome bs reductase (Ross et al., 1993), and
NADPHxytochrome P-450 reductase (Cummings et al., 1992), stimulate
xanthine dehydrogenase (Pan et al., 1984; Gustafson & Pritsos, 1992a,b)
and induce the formation of unique DNA covalent adducts (Bizanek et
al., 1993). Additional effects include inhibition of xanthine oxidase (Hajos
& Winston, 1991), glucuronyl transferases (Segura-Aguilar et al., 1986)
and uncoupling of mitochondrial oxidative phosphorylation (Ernster,
1987).
However, the following questions arise from these observations. What
enzyme is predominating over the identified mitochondrial enzyme in
MAC 16 and thus preventing increased metabolism under hypoxia and
does this apply to the observations above? With this lack of metabolic
enhancement under hypoxia and the identification of an enzyme
exhibiting similar properties in the cytosol, it appears that the enzyme
responsible for mitomycin C metabolism in MAC 16 predominating
under all conditions, is DT-diaphorase. Plumb and colleagues (1994) also
suggested a dominant role for DT-diaphorase in HT-29.
If DT-diaphorase is predominating over other enzyme(s) present within
tumour, why? And why is less mitomycin C metabolism seen with DT-
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diaphorase when compared to the mitochondrial one-electron reductase?
The first documented report of DT-diaphorase [NAD(P)H:(quinone
acceptor) oxidoreductase (EC 1.6.99.2)] was by Ernster and Navazio, who in
1958 described activity of a highly active diaphorase in the soluble fraction
of rat liver microsomes. DT-diaphorase is a unique flavoenzyme in a
number of ways. Firstly, it exhibits nonspecific reactivity to NADH and
NADPH reacting with equal but low maximal velocities (Ernster et al.,
1962), although the Km value for NADH is a little higher than that for
NADPH, 45 and 85 pM respectively. The very low affinity constant, Km,
also applies to mitomycin C bioreduction via DT-diaphorase and the
other major enzymes involved. Xanthine oxidase and NADPH:
cytochrome P-450 reductase both have a Km of 2 mM (Pan et al., 1984,
1986), whilst xanthine dehydrogenase has a Km of 299 pM (Gustafson &
Pritsos, 1993). DT-diaphorase also has a low Km, 1 mM (Walton et al.,
1992c). This suggests that neither one will show preference for mitomycin
C as a substrate at concentrations used in the homogenates and hence the
enzyme present in the largest quantity is likely to carry out the majority of
mitomycin C bioreduction irrespective of the enzymes intrinsic catalytic
activity. The pattern of metabolic activation produced will therefore
parallel the biochemical properties of that particular enzyme.
In the case of MAC 16, DT-diaphorase accounts for 66 % of the cytosolic
and microsomal combined quinone reductase activity, table 3.1. Although
the contribution of mitochondrial DT-diaphorase and the additional
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mitochondrial enzyme(s) identified in section 3.1 are not accounted for in
this calculation, it is likely that DT-diaphorase is present in the largest
quantity since the pattern of metabolism is consistent with DT-diaphorase
activity. It is therefore possibly responsible for the majority of mitomycin
C metabolic activation in MAC 16 under both aerobic and hypoxic
conditions, hence its predomination over other enzyme(s) present and
the characteristic pattern of metabolism.
DT-diaphorase accounts for considerably less of total quinone reductase
activity in MAC 26 (30 %). This may contribute towards the aerobic
metabolism seen in this tumour, figure 3.8 and table 3.4. Under hypoxia,
the identified one-electron mitochondrial reductase, perhaps present in
the greatest quantity when compared to DT-diaphorase, predominates.
A second feature of DT-diaphorase is that it is extremely sensitive to
dicoumarol (Ernster et al., 1960), a property which initiated research to
ascertain whether the enzyme was involved in the metabolism of
vitamin K (Wallin et al., 1978). Third, and perhaps the most important
property is the ability of DT-diaphorase to catalyse obligatory two-electron
reduction, a feature which is crucial to the enzymes' cytoprotective
properties (Lind et al., 1982b; Preusch et al., 1991).
DT-diaphorase is a cytosolic enzyme, although activity has been isolated
to the endoplasmic reticulum (Danielson et al., 1960), mitochondria
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(Conover & Ernster, 1963) and golgi apparatus (Edlund et al., 1982). The
mitochondrial enzyme reacts only with intramitochondrial NADH and
NADPH, therefore it is located within the mitochondrial inner matrix or
the inner surface of the inner membrane (Conover & Ernster, I960, 1962).
It is widely distributed throughout the organs of the body with liver,
kidney and gastrointestinal tract expressing high levels (Schlager & Powis,
1990). Similar patterns of expression are also observed in tumour material
taken from patients (Koudstaal et al., 1975; Schor & Cornelisse, 1983) with
the exception of kidney and stomach tumours which show the reverse
trend (Schlager & Powis, 1990).
The dimeric enzyme, molecular weight approximately 55,000, exists as a
number of isoforms with mouse and rat livers possessing two and three
variants respectively (Prochaska & Talalay, 1986; Segura-Aguilar & Lind,
1987). Genetic investigations in humans indicated that the various forms
of DT-diaphorase appeared to be encoded by four gene loci, DIA 1 to 4
(Edwards et al., 1980). Diaphorase 4, now known as NQOi, has recently
been characterised (Shaw et al., 1991). With gene localisation on
chromosome 16, this form of DT-diaphorase accounts for the majority of
the enzyme expressed and shows 84% homology compared to the rat
NQOi protein (Jaiswal et al., 1988). The NQO2 gene located on
chromosome 6 shares 54 % homology to NQOI and in contrast to NQOI,
is only expressed in heart, lung liver, brain and skeletal muscle (Jaiswal et
al., 1990; Jaiswal, 1994). Its exact function has yet to be determined.
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Like many flavoproteins, DT-diaphorase reacts with its electron donor
and acceptor, in this case quinones, according to a 'ping-pong' mechanism
(Hosoda et ah, 1974), figure 3.11. This is also known as the binary-complex
mechanism and the quinone acts as the second substrate. It is interesting
to note that both substrates, cofactor and quinone, display competitive
inhibition of the enzyme with respect to each other. This may suggest a
cooperative relationship between the donor and acceptor binding sites of
the enzyme.
Perhaps DT-diaphorase's most important function is its capability to
function as a two-electron transfer enzyme. This was first demonstrated
by Iyanagi and Yamazaki (1970). In the case of mitomycin C and other
quinone-containing compounds, this leads to the production of the
hydroquinone. The fate of the hydroquinone determines whether DT-
diaphorase acts in an antioxidant/protective or prooxidant capacity, the
latter leading to toxicity (Cadenas, 1995). Three types of hydroquinone can
theoretically exist, redox-stable and redox-labile hydroquinone and
hydroquinones that finally participate in bioalkylation, figure 3.12.
Although all share common production by DT-diaphorase, the inherent
chemical reactivity of a particular hydroquinone is determined by the
substitution pattern of the quinone. The formation of redox-stable
hydroquinones (figure 3.12, pathway I) and subsequent manifestation of a













Figure 3.11. Reaction sequence of DT-diaphorase (E) via the 'ping-pong'


































Figure 3.12. Antioxidant and prooxidant functions of DT-diaphorase in
quinone metabolism, (a) Autoxidation inhibited by superoxide dismutase;
(b) Autoxidation stimulated by superoxide dismutase. Adapted from
Cadenas, 1995.
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Prevention of quinone toxicity occurs via aromatisation of the quinone
ring by DT-diaphorase thus decreasing its electrophilic character. This
prevents its participation in certain arylation reactions. Therefore, DT-
diaphorase indirectly protects against cytotoxicity arising from such
reactions. Conjugation of hydroquinones with glucuronide or sulphide
groups may also facilitate metabolic inactivation. The use of dicoumarol
to inhibit glucuronidation of benzo[a]pyrene-2,6-quinone suggests a
possible role for DT-diaphorase in this process (Lind, 1985). Another body
of evidence supporting an antioxidant role for DT-diaphorase has been
derived from studies utilising the metabolism of benzene in a number of
bone marrow stroma cells, macrophages and fibroblastoid cells (Ross,
1989; Thomas et al., 1990).
In common with other detoxification or so-called phase II enzymes, DT-
diaphorase is induced by a number of xenobiotics, due to up regulation of
at a transcriptional level (Bayney et al., 1989; Spencer et al., 1990). This
leads to additional antioxidant activity.
It is unlikely that the above formation of redox-stable hydroquinones
applies to DT-diaphorase dependent protection from mitomycin C
cytotoxicity.
A second type of hydroquinone formed during DT-diaphorase dependent
catalysis is the redox-labile hydroquinone (figure 3.12, pathway n). Potent
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antioxidant properties of this hydroquinone can be achieved in
association with superoxide dismutase. Autoxidation of the
hydroquinone via superoxide free radicals is inhibited by this enzyme.
This results in the inhibition of semiquinone and hydrogen peroxide
formation leading to subsequent enhancement of redox-stable
hydroquinone concentrations (figure 3.12, pathway Ha). Such antioxidant
activity has been demonstrated using a dopamine-derived o-quinone
resulting in the suppression of oxygen radical formation (Segura-Aguilar
& Lind, 1989).
In contrast to the above inhibitory effects the converse applies.
Superoxide dismutase also has the capacity to elicit toxic effects through
the formation of oxygen free radicals via enhanced hydroquinone
autoxidation (figure 3.12, pathway lib). Such toxicity has proved
important in the mechanism of action of the diaziridinylbenzoquinones
(O'Brien et al., 1990) and anthraquinone-based antitumour agents (Fisher
et al, 1992).
However, in the context of mitomycin C, perhaps the most important
hydroquinones formed are those that readily rearrange to potent
electrophiles which subsequently participate in bioalkylation reactions
(figure 3.12, pathway III). The protective/predominant role of DT-
diaphorase observed by Plumb and colleagues (1994) gave rise to two valid
propositions concerning the role of such hydroquinones: (i) one-electron
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reductases are more efficient at metabolising mitomycin C than two-
electron reductases such as DT-diaphorase, although DT-diaphorase
prevails under aerobic conditions; and (ii) the semiquinone form of
mitomycin C is more toxic than the hydroquinone, product of DT-
diaphorase metabolism, under hypoxic conditions.
The latter proposition can be discounted as under hypoxic conditions the
hydroquinone form of mitomycin C is considered to be a common
intermediate after both one- and two-electron reduction due to the rapid
disproportionation of the semiquinone radical (Hoey et al., 1988; Ross et
ah, 1993). Regarding the former proposition, this can be supported by an
emerging body of evidence indicating that DT-diaphorase is less effective
at metabolising mitomycin C than one-electron reductases. Firstly, the pH
dependency of DT-diaphorase is more pronounced than one-electron
reductases. Siegel and colleagues (1992, 1993) demonstrated that while
mitomycin C was reduced effectively at pH 5.8, total enzyme inhibition
was observed at pH 7.8. This has been explained by the ambivalent nature
of the quinone methide where it acts as an electrophile at alkaline pH (pH
8.0), while at more acidic pH (pH 6.5) it can act as a nucleophile (Petersen
& Fisher, 1986). The latter results in the production of 2,7-DM. Ross and
colleagues (1993) subsequently demonstrated alkylation of DT-diaphorase
by mitomycin C at pH 7.8 but not pH 5.8 resulting in enzyme inhibition. It
was then suggested that the 7-NH2 group of the enzyme may play an
essential role in this inhibitory process. However, it should be noted that
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bioactivation of mitomycin C by DT-diaphorase at physiological pH, pH 7
to 7.4, can occur leading to DNA cross-linking (Siegel et ah, 1992).
Secondly, DT-diaphorase produces predominantly monofunctional N-7
guanine DNA adducts which are believed to be less cytotoxic than the
bifunctional adducts formed by one-electron reductases (Bizanek et ah,
1993). The formation of such adducts also follows the pH dependency of
DT-diaphorase bioactivation of mitomycin C suggesting that a fewer
number of cross-links will be formed at physiological pH compared to
acidic pH (Prakash et al., 1993). The reduced toxicity of mitomycin C
monoadducts however has recently been challenged by Rockwell & Kim
(1995) based on evidence that decarbamoyl mitomycin C, which is
incapable of forming bisadducts, was at least as toxic as mitomycin C to
EMT6 mouse mammary cells and DNA repair-deficient Chinese hamster
ovary cells.
Therefore in conclusion, although DT-diaphorase is present in MAC 16 in
the greatest quantity it is less efficient at metabolising mitomycin C.
Hence, this results in less metabolism compared to the mitochondrial
one-electron reductase responsible for metabolism in MAC 26.
The precise role of DT-diaphorase in mitomycin C metabolic activation
has been somewhat controversial and unresolved for a number of years
(Workman et ah, 1989; Doroshow, 1992). The use of tumour cell lines
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with contrasting high and low DT-diaphorase levels have provided
evidence that this enzyme may be responsible for aerobic mitomycin C
bioactivation (Begleiter et al., 1988; Siegel et al., 1990a; Marshall et al.,
1991). In contrast, mitomycin C was shown not to be activated by purified
kidney or rat liver DT-diaphorase but was in fact acting as a powerful
inhibitor of the enzyme (Schlager & Powis, 1988). Incubation with a
DT-diaphorase rich preparation isolated from the Walker 256 tumour
also led to a negative result (Workman et al., 1989). Both studies were
carried out at the non-optimum pH for mitomycin C, pH 7.8, and shed
doubt on the tissue culture studies which indirectly proposed a significant
role for this enzyme in aerobic mitomycin C bioactivation. pH was in fact
finally found to be the crucial determinant of purified DT-diaphorase
-dependent mitomycin C metabolism (Siegel et al., 1990a), with
metabolism nevertheless occuring at pH 7.0, albeit at reduced levels.
The effect of hypoxia on the DT-diaphorase catalysed metabolism of
mitomycin C remained unknown. Until recently studies using the
murine lymphoblasts L5178Y and L5178Y/HBM10, having low and high
DT-diaphorase levels respectively, established a limited role for
DT-diaphorase in mitomycin C bioactivation under hypoxia (Begleiter et
al., 1992). In contrast, using the DT-diaphorase rich and deficient cell lines,
HT-29 and BE, results concluded that bioactivation of mitomycin C by
DT-diaphorase was similar under both aerobic and hypoxic conditions
(Beall et al., 1994), as one would expect.
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The results discussed within this section have shed some light on the
above uncertainties of DT-diaphorase. DT-diaphorase remains a very
important enzyme. With its predomination over other quinone
reductases and equivalent activity under both aerobic and hypoxic
conditions, DT-diaphorase probably plays a unique and central role in the
metabolic activation of mitomycin C in tumour tissue.
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3.3 Pharmacokinetics and Metabolism of Mitomycin C In Vivo:
Implications for In Vivo Drug Treatment
The next question that arises is what implications do the observations in
section 3.2 have for the metabolism of mitomycin C in vivo and can one
predict what tumour types are optimum for mitomycin C drug treatment
with regards to the levels of quinone reductases? In order to assess the
above question, the pharmacokinetics, in vivo metabolism and
antitumour activities of mitomycin C in MAC 16 and MAC 26 were
studied.
In both pharmacokinetic and antitumour studies, mitomycin C was given
as a direct i.t. injection. Although i.t. drug treatment is not the normal
route of drug administration, it has previously been employed in the
treatment of human pancreatic cancer with mitomycin C (Moriai et al.,
1989) and has been the chosen route for a number of additional anticancer
agents and biological response modifiers (Brincker, 1993; Dubinett et al.,
1993). For the purpose of these experiments, it was necessary to achieve
the highest concentration of mitomycin C within the tumour in order to
study the formation of metabolites. This method has previously been
employed successfully in MAC 16 and the rat Sp 107 mammary carcinoma
(Cummings et al., 1994; Chirrey et al., 1995).
The dose of mitomycin C, 500 pg, was chosen as it has previously been
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used in such studies both as free drug and encapsulated into human
albumin microspheres (Allan et al., 1993; Cummings et al., 1994). The
primary metabolite 2,7-DM was once again used as the principle indicator
of mitomycin C metabolic activation.
The pharmacokinetics of mitomycin C in tumour tissue and plasma are
illustrated in figures 3.13 and 3.14 respectively. Pharmacokinetic
parameters are summarised in table 3.5. Both MAC 16 and MAC 26
showed similar patterns of drug distribution, peak levels at 0 minutes
with levels steadily decreasing with time. However, the initial peak level
of mitomycin C seen at 0 minutes was approximately 2-fold lower in
MAC 26 when compared to MAC 16. Indeed on calculation of the area
under the curve (AUC), drug exposure levels were considerably less in
MAC 26, 195.60 compared to 318.79 pg/total tumour content x hour for
MAC 16. This may suggest a number of possibilities. Firstly, that
mitomycin C in MAC 26 is rapidly cleared from the tumour or secondly,
metabolism is occurring at such a high rate that levels of parent drug are
immediately reduced.
The first statement can be supported by the pharmacokinetics of
mitomycin C in plasma, figure 3.14 and table 3.5. The levels of mitomycin
C in plasma derived from MAC 26 bearing mice followed a similar profile
to that seen in tumour tissue, ie. steady decreasing levels over time. In
comparison, plasma derived from MAC 16 bearing mice displayed a peak
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Figure 3.13. Concentration-time profiles of mitomycin C in MAC 16 and
MAC 26 murine adenocarcinomas of the colon after a direct i.t. injection
of 500 pg mitomycin C. Results are expressed as jig/total tumour content




Figure 3.14. Concentration-time profiles of mitomycin C in plasma form
MAC 16 and MAC 26 bearing animals after a direct i.t. injection of 500 pg
mitomycin C. Results are expressed as pg/mL and represent the mean±SE








Peak level (pg/TTC) 103.42 5.85 57.77 5.12
Time to peak (min) 0 0 0 5
AUCo_360min (pg/TTCxhr) 318.79 19.57 195.60 49.92
2,7-DM : MMC ratio 0.06 0.26
PLASMA
Peak level (pg/mL) 15.03 ND 15.23 ND
Time to peak (min) 30 5
AUCo_360min (pg/mLxhr) 129.50 88.09
Clearance (pg/mL) 3.86 5.68
Table 3.5. Pharmacokinetics and metabolic conversion of mitomycin C
(MMC) to the principle metabolite 2,7-diaminomitosene (2,7-DM) in
MAC 16 and MAC 26 murine adenocarcinomas of the colon. TTC = total
tumour content; ND = not detected.
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level of mitomycin C at 30 minutes. Both observations support greater
immediate tumour clearance of mitomycin C in MAC 26 compared to
MAC 16.
The underlying morphology of the tumours may explain this 'clearance'
effect. The MAC tumours are similar to human colon tumours in that
they display varying histological characteristics and are active mucin
producers (Cowen et al., 1980). However, significant histological
differences exist between MAC 16 and MAC 26. MAC 16 is a highly
necrotic chemoresistant tumour which causes severe cachexia in its host
(Double & Bibby, 1989). MAC 16 shows little differentiation, figure 3.15. In
contrast, MAC 26 is a very well differentiated but slow growing
adenocarcinoma with an extensive blood supply (Double & Bibby, 1989),
figure 3.16.
It is this blood supply which may contribute to the clearance of
mitomycin C from the tumour. As mitomycin C was injected i.t., a
significant amount will immediately enter directly into the tumour
capillary system. In comparison, MAC 16 may display slower tumour
clearance due to its necrotic nature. This is supported by the different
plasma AUCs. As it was difficult to obtain a 0 minute plasma sample, it
can be proposed that a large amount of mitomycin C was removed from
the plasma via metabolism and excretion in MAC 26 bearing mice in the
first 5 minutes, shown by the high clearance and low AUC, table 3.5.
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Figure 3.15. Histological appearance of MAC 16 murine adenocarcinoma
of the colon. Haematoxylin and eosin preparation. Magnification x 12.5.
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Figure 3.16. Histological appearance of MAC 26 murine adenocarcinoma
of the colon. Haematoxylin and eosin preparation. Magnification x 12.5.
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MAC 16 however had a lower clearance and higher AUC indicating a
slower rate of clearance and overall increased plasma concentrations.
The second possibility for low parent drug levels in MAC 26, is significant
immediate metabolism. Figure 3.17 illustrates the concentration-time
profiles of 2,7-DM in both tumour types. The formation of 2,7-DM
differed significantly in both tumour types. Peak levels were achieved
within the first minutes in MAC 16 then followed by a steady decline. In
contrast, MAC 26, again showing early metabolism albeit lower than
MAC 16, displayed a steady increase reaching peak levels over the first 5
to 10 minutes greater than those seen in MAC 16 at the same time points.
Calculation of AUCs revealed greater tumour exposure to 2,7-DM in
MAC 26 than MAC 16 suggesting that a significantly greater conversion to
2,7-DM was occurring in MAC 26. This is supported by the 4-fold increase
in the 2,7-DM:MMC ratio in MAC 26 when compared to MAC 16. Overall,
the well vascularisation of MAC 26 and rapid metabolism to 2,7-DM may
both contribute to the reduced levels of parent drug.
However, more important is the elevated levels of metabolism seen in
MAC 26 with respect to MAC 16 and what implications this may propose.
Figure 3.18 illustrates the metabolite profile of MAC 16 and MAC 26, 15
minutes after mitomycin C administration. These metabolite profile can







Figure 3.17. Concentration-time profiles of 2,7-diaminomitosene in MAC
16 and MAC 26 murine adenocarcinomas of the colon after a direct i.t.
injection of 500 pg mitomycin C. Results are expressed as pg/total tumour
content and represent the mean±SE of three separate animals per time
point.
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Figure 3.18. In vivo metabolite profile of MAC 16 and MAC 26 murine
adenocarcinomas of the colon 15 minutes after a direct i.t. injection of 500
pg mitomycin C.
Peaks: I, zwitterion form of mitomycin C; II, l,2-fraMS-l-hydroxy-2,7-
diaminomitosene; III, mitomycin C; IV, l,2-ds-l-hydroxy-2,7-
diaminomitosene; V, 10-decarbamoyl 2,7-diaminomitosene; VI, 2,7-
diaminomitosene.
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tumours. MAC 16 exhibits predominantly 2,7-DM with only trace levels
of trans- and cis-hydro. This has previously been seen in MAC 16 after a
similar dose of mitomycin C (Cummings et al., 1994). Such a profile, in
particular to the predomination of 2,7-DM, is similar to that observed in
the cytosolic fractions, figures 3.1 and 3.2 and tumour homogenates,
figures 3.9 and 3.10, suggesting DT-diaphorase-dependent metabolism.
In comparison, MAC 26 showed significant levels of all metabolites, an
identical profile to that observed in the mitochondrial fraction, the only
enzyme activity detected in MAC 26.
From these metabolite profiles, it can be proposed that in MAC 16 DT-
diaphorase is once again predominating over other enzymes present,
resulting in significant but low levels of mitomycin C metabolism. MAC
26 metabolism however, is likely to be due to the mitochondrial enzyme
identified in section 3.1. Such mitochondrial-dependent metabolism
results in significant and comparable levels of 2,7-DM to MAC 16. This
casts yet another doubt on the efficiency of DT-diaphorase to metabolise
mitomycin C, this time in vivo and raises the possibility of a role for
mitomycin C drug treatment in tumours low in DT-diaphorase and high
in one-electron reductases.
With such observations, studies were extended to assess the antitumour
activity of mitomycin C to ascertain if a corresponding increase in
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antitumour activity can be achieved in tumours low in DT-diaphorase
compared to those high in the enzyme.
The antitumour activity of mitomycin C in both MAC 16 and MAC 26
was assessed as described in section 2.3.11. Figures 3.19 and 3.20 illustrate
the antitumour activity of the lower doses of mitomycin C against
untreated and vehicle control groups. The data represent a number of
combined investigations hence the differing measurement days. Tumour
volumes at the time of injection ranged from 0.005-0.114 cm3 (median =
0.022 cm3) and 0.090-0.190 cm3 (median = 0.075 cm3) for MAC 16 control
and drug treated groups respectively. Similarly, values for MAC 26
control and drug treated groups tumours ranged from 0.010-0.305 cm3
(median = 0.082 cm3) and 0.021-0.388 cm3 (median = 0.098 cm3)
respectively. A clear antitumour response could be seen in both tumour
types at all doses, with MAC 16 exhibiting end point tumour sizes of
0.058-0.720 cm3 (median = 0.225 cm3) for controls and 0.003- 1.267 cm3
(median = 0.083 cm3) for drug treated groups. MAC 26 controls ranged
from 0.188-3.897 cm3 (median = 2.630 cm3) and drug treated from 0.017-
1.675 cm3 (median = 0.444 cm3). It is interesting to note that MAC 26 has
responded significantly to mitomycin C treatment. This is in contrast to
the data of Double & Bibby (1989) where no significnat growth inhibition
was observed. The drug was however administered systemically
suggesting that high local tumour levels of mitomycin C are required to
elicit an antitumour response.
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Figure 3.19. Antitumour activity of mitomycin C in MAC 16 murine
adenocarcinoma of the colon at doses of 50, 75, 125 and 250 |ig.
Treatments were administered in a volume of 250 pL sterile water by
direct i.t. injection. Controls consisted of untreated and vehicle (water)
treatment groups. Each point represents the mean±SE of seven/eight
separate animals.
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Figure 3.20. Antitumour activity of mitomycin C in MAC 26 murine
adenocarcinoma of the colon at doses of 50, 75, 125 and 250 pg.
Treatments were administered in a volume of 250 pL sterile water by
direct i.t. injection. Controls consisted of untreated and vehicle (water)
treatment groups. Each point represents the mean±SE of seven/eight
separate animals.
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However, both tumour types showed no significant dose response. This
suggests that the maximum effect has been achieved at 50 pg mitomycin
C. It would therefore be appropriate to extend studies using lower doses.
Toxicity was noted in both MAC 16 and MAC 26 bearing mice and was
particularly evident in MAC 16 at 500 and 1000 pg (data not shown). This
may possibly be related to the greater plasma AUC seen in MAC 16 (129.50
pg/mLxhr) compared to MAC 26 (88.09 pg/mLxhr), table 3.5. The cachexic
nature of MAC 16 may also have contributed (Double & Bibby, 1989).
T/C values for a treatment group compared to vehicle control calculated
at day 7 after treatment are shown in table 3.6. The vehicle control group
was used as it takes into account the effect of the i.t. injection such as
cellular destruction and general tumour distention.
On assessing this data, results showed that there was no significant
difference between the antitumour effect of mitomycin C in tumours
high and low in DT-diaphorase. Therefore no firm conclusion can be
drawn from this study concerning the role of DT-diaphorase in in vivo
mitomycin C metabolism and antitumour activity. Using lower doses of
mitomycin C and taking into account the doubling time of each tumour,
calculating specific antitumour activity may be a more appropriate
measurement.
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Table 3.6. Antitumour activity of i.t. mitomycin C in MAC 16 and MAC 26
murine adenocarcinomas of the colon at doses 50, 75, 125 and 250 jig.
Results are expressed in tumour volume as a percentage of the vehicle
(sterile water) control group, T/C value. Values were calculated at day 7
after treatment.
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In conclusion, despite the presence of the highly active mitochondrial
reductase and the greater metabolising capacity of MAC 26, this tumour
failed to produce a greater antitumour response compared to MAC 16.
The rapid metabolism and significant tumour clearance of parent drug
may have contributed to this reduced antitumour activity.
Therefore, it appears from this study that tumours high and low in DT-
diaphorase (the latter being correspondingly high in one-electron
reductases) are equally responsive to mitomycin C in vivo if given by the
i.t. route of administration. This provides an unclear conclusion to the
role of solid tumour DT-diaphorase levels and activity in enzyme
directed bioreductive drug therapy and which tumours are optimum for
mitomycin C drug treatment. Taking into account the limitations and
reservations of the above study and making the suggested modifications
may provide significant and interesting advances in this area of research.
What conclusions concerning the role of DT-diaphorase can be drawn
from a human perspective? This was examined by assessing the
metabolism of mitomycin C in two human colon xenografts, HT-29 and
BE.
Both tumours have previously been employed in a number of studies
using mitomycin C and indoloquinone E09 due to their differing levels
of DT-diaphorase (Siegel et al., 1990a; Traver et al., 1992; Beall et al., 1994;
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Plumb & Workman, 1994; Plumb et al., 1994). However, as the majority of
studies used cell lines, no evidence exists on metabolic studies carried out
using tumour tissue.
The quinone reductase profiles of HT-29 and BE are shown in table 3.7.
Consistent with the above studies, HT-29 possessed significant levels of
DT-diaphorase which was the main enzyme found in the tumour. In
contrast, BE possessed no DT-diaphorase activity, both cytosolic and
microsomal, due to the point mutation in the NQOi gene (Traver et al.,
1992). 'Other' enzymes represented a lower proportion of the total enzyme
activities of HT-29, approximately 49-fold less than cytosolic DT-
diaphorase.
In comparison, such enzymes accounted for the only cytosolic activity
seen in BE. Both tumour types have previously shown undetectable
levels of the one-electron reductase xanthine oxidase, although this was
assessed in cell lines not tumour tissue (Siegel et al., 1990b).
NADPH:cytochrome P-450 reductase and NADH:cytochrome bs reductase
activities in HT-29 were approximately 44- and 50-fold less than that of
total DT-diaphorase respectively. Low activities of both these enzymes
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Mitomycin C metabolism by HT-29 and BE tumour homogenates was
assessed under both aerobic and hypoxic conditions to give an indication
of the role of DT-diaphorase. Figure 3.21 and table 3.8 illustrate the
formation of 2,7-DM under these conditions. In many respects, these
tumours exhibited similar metabolism characteristics to those seen in
MAC 16 and MAC 26 homogenates.
Firstly, HT-29, high in DT-diaphorase, showed no significant hypoxic
enhancement similar to MAC 16. Secondly, BE, with no detectable DT-
diaphorase activity, in common with MAC 26, did show hypoxic
enhancement suggestive of one-electron reduction. However, the
absolute amount of change in 2,7-diaminomitosene formation under
hypoxia was greater in HT-29 (0.18 pg/mL) compared to BE (0.11 pg/mL).
This suggests a possible limited role for one-electron reductases, such as
the NADPH-dependent mitochondrial enzyme, in the hypoxic
enhancement of mitomycin C metabolic activation observed BE.
It is interesting to note the elevated level of metabolism in HT-29
compared to BE both in the absence and presence of oxygen in contrast to
MAC 16 and MAC 26. This is undoubtably due to the very high activity of


















Figure 3.21. In vitro production of the principle mitomycin C metabolite
2,7-diaminomitosene in HT-29 and BE human colon xenograft
homogenates under aerobic (—) and hypoxic (—) conditions. Each point
represents the mean±SE from three separate experiments.
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TUMOUR 2,7-DM FORMATION EFFECT OF
HOMOGENATE (nmol/30min/mg protein) OXYGEN
AEROBIC ANAEROBIC
HT-29 0.99±0.09 1.17±0.19 15% inhibition
BE 0.13±0.05 0.24±0.03 46% inhibition
Table 3.8. Specific activities of mitomycin C metabolism by HT-29 and BE
human colon xenograft homogenates under aerobic and hypoxic
conditions. Specific activity is expressed as 2,7-diaminomitosene
formation in nmol/30min/mg protein. Each value represents the
mean±SE from three separate experiments.
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The metabolite profiles of mitomycin C metabolism under hypoxia by
HT-29 and BE are illustrated in figure 3.22. Both tumours showed
significant levels of all metabolites, both primary and secondary, although
2,7-DM once again was the major metabolite, particularly in HT-29. In
contrast to MAC 16 cytosolic fractions, homogenates and in vivo
metabolism which yield predominantly 2,7-DM (with trace levels of other
metabolites) suggesting DT-diaphorase activity, HT-29, possessing
approximately 7-fold greater DT-diaphorase activity, yielded significant
levels of all metabolites. This may be due to additional metabolism by
one-electron reductases (Tomasz & Lipman, 1981; Pan et al., 1984) or
metabolism of 2,7-DM itself to further metabolites (Pan et al., 1984; Siegel
et al., 1992). BE metabolism appeared to be characteristic of one-electron
reduction similar to that seen in MAC 26.
What relevance do such results have in a clinical situation? In the first
instance, tumours low in DT-diaphorase and high in one-electron
reductases appear to be an attractive target for mitomycin C over those
with high DT-diaphorase activities if a significant degree of hypoxia can
be achieved. In fact, the specific activity of MAC 26 under hypoxia, table
3.4, was greater than that seen with HT-29 under similar conditions, table
3.8. Indeed, it would be appropriate to examine the expression and activity
of the one-electron mitochondrial reductase in a wider spectrum of
tumours and normal tissues, particularly those of human derivation, and
to assess whether its activity can be exploited for therapeutic benefit.
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This is currently being examined with respect to the mitomycin C
analogue indoloquinone E09 in a panel of cell lines transfected with
NADPH:cytochrome P-450 reductase where varying levels of expression
have been observed (Saunders et al., 1996).
Two major obstacles hinder this notion. Firstly, such enzymes require
hypoxia for activation. Although solid human tumours possess
significant areas of central hypoxia, peripheral well oxygenated cells may
remain less responsive or perhaps resistant to mitomycin C treatment.
This may however be circumvented to a certain extent by the use of
mitomycin C in conjunction with hypoxia-potentiating agents as
discussed in section 1.3.1. Secondly, very few tumours have very low or
lack DT-diaphorase activity. This has been demonstrated using the NCI
tumour cell line panel which revealed that the majority possessed
significant levels of the enzyme in association with reduced levels of
NADPH:cytochrome P-450 reductase and NADH:cytochrome bs reductase
(Fitzsimmons et al., 1996). In addition, extensive data obtained directly
from human tumour samples now indicate predominantly high levels of
DT-diaphorase compared to normal tissue and is particularly applicable to
colon cancer (reviewed in Smitskamp-Wilms et al., 1996).
Therefore, are there any benefits of treating high DT-diaphorase tumours
with mitomycin C? Mitomycin C has been shown to be metabolised by
DT-diaphorase under both aerobic and hypoxic conditions. The presence
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of this enzyme can lead to metabolism in areas of varying oxygen
tensions within a tumour unlike the hypoxia-dependent one-electron
reductases. However, if hypoxia is a prerequisite for a particular drug's
mechanism of activation, then clearly such tumours may not be ideal
since DT-diaphorase can successfully compete against one-electron
reductases for substrates and resulting in a lower rate of metabolic
activation as seen in MAC 16.
The ideal scenario would be in some way to prevent predomination of
DT-diaphorase under hypoxia allowing one-electron reductase-dependent
metabolism to prevail in conjunction with aerobic metabolism via DT-
diaphorase. This may prove a somewhat difficult goal to achieve.
As the majority of human tumours possess considerable levels of DT-
diaphorase, one can conclude that in reality tumours high in the enzyme
are optimum for mitomycin C drug therapy.
The role of one-electron reductases and hypoxic enhancement should not
be discounted however. With the use of patient tumour enzyme
profiling, the measurement of tumour hypoxia and a greater
understanding of the interaction between all quinone reductases within
themselves and with hypoxia, this observation may prove a successful
exploitable parameter.
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3.4 Properties of Indoloquinone E09 Intermediates Generated by
Irradiation
Although significant progress has been made in defining the enzymology
of E09 bioreductive activation (reviewed in Bailey et al., 1996;
Smitskamp-Wilms et ah, 1996), little data exists on the following key areas
(a) generation of reactive intermediates, (b) formation of drug metabolites
and (c) structure of DNA adducts. Pulse radiolysis of E09 provides a
controlled in vitro reduction of the drug without the need of reductive
enzymes and cofactors, and also allows reductive processes to be studied
as well as the formation of potential metabolites. Chemical properties of
reductive products can then be characterised by HPLC and UV/Vis
spectrophotometry (Salmon & Sykes, 1993).
E09 was subjected to irradiation and subsequent HPLC analysis as
described in sections 2.3.17 and 2.3.13 respectively. Reduction occurs via a
series of free radical reactions, ultimately resulting in the formation of an
isopropanol ion which reduces E09. Figure 3.23 illustrates the pattern of
E09 related chromatographic peaks generated by a single dose of
irradiation compared to an unirradiated sample. Both samples were
analysed approximately 18 hours after irradiation due to sample
transportation. The parent drug, E09, could be clearly seen with a
retention time of approximately 14-16 minutes and was the predominant
peak in both samples.
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Figure 3.23. In vitro pattern of Indoloquinone E09 related chromato¬
graphic peaks generated by a single 500 Gy irradiation dose (A). Results
were compared to the unirradiated control (B). Samples were analysed by
HPLC.
Peaks I, Ilia, IITb and V correspond to previously unidentified products.
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The open aziridine ring hydrolysis product E05A was observed in both
irradiated and unirradiated samples and eluted before E09 in a similar
manner to previous HPLC protocols (Binger & Workman, 1990; Schellens
et al., 1993). The presence of both parent drug and E05A was confirmed
by their different UV/Vis absorption spectra, figure 3.24. Consistent with
previous spectral studies (Binger & Workman, 1990), E09 showed
characteristic UV absorption at 268 nm with a shoulder at 313 nm and
visible absorption at 505 nm. In contrast, the spectra of E05A exhibited a
bathochromic shift resulting in UV absorption at 280 and 321 nm and
visible absorption at 550 nm. This shift in spectral characteristics has been
proposed to be a result of hydrogen bonding and conjugation of the
quinone moiety by a lone pair of electrons (Griffiths, 1967; Binger &
Workman, 1990).
It is interesting to note the presence of E05A in the unirradiated and
sample. This is most likely to be a result of the general instability of E09
in aqueous solution < pH 7 (de Vries et al., 1993). Also, as the samples
were not analysed immediately, this may have enhanced this effect
resulting in the hydrolysis of E09 and hence the formation of E05A. The
similar levels of E05A seen in the control may suggest that this product is
a result of acid catalysed degradation rather than irradiation.
In addition to E05A, an additional peak, peak I in figure 3.23, arose in
both samples. With spectral characteristics similar to E05A, figure 2.34,
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Figure 3.24. UV/Visible absorption spectra of Indoloquinone E09 and
related products of irradiation. Products were identified during HPLC
analysis of irradiated and unirradiated samples as shown in figure 3.23.
Spectrum 1, E09; Spectrum 2, E05A; Spectrum 3, peak I unirradiated
sample; Spectrum 4, peak I irradiated sample.
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and elution at the solvent front, retention time 3 minutes, such peaks are
possibly aziridinyl adducts formed with phosphate buffer constituents.
No further peaks were observed in the unirradiated sample. However,
together with E09, E05A and peak I, three additional intermediates were
identified in the irradiated sample, peaks nia, nib and V. With retention
times 8.2, 9.4 and 27 minutes respectively, these peaks are likely to be a
direct result of E09 irradiation due to their absence in the control sample.
The effect of time on the levels of these identified products was also
studied to assess their stability. Figure 3.25 illustrates the effect of time on
the pattern of E09 related products generated by irradiation as measured
by HPLC. Samples were analysed at 18 hours and 20 days. The variation in
retention times between samples was due to the use of a new HPLC
column.
The effect of time had dramatic results. The loss of E09 was accompanied
by a corresponding increase in E05A, possibly again due to significant
hydrolysis. However, what is interesting was the reduction in peaks Ilia
and inb, increase in peak I and V and appearance of peak VI, retention
time 4 minutes. The effect of time on peak area can be seen more clearly
in figures 3.26 and 3.27, with additional samples taken on days 2 and 5.
The steady reduction in peaks ma and mb suggest that such products are
relatively unstable and possible breakdown into additional peaks may
occur. This may result in the formation of peak VI which appears
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Figure 3.25. Effect of time on the in vitro pattern of Indoloquinone E09
related products generated by a single 500 Gy irradiation dose. Samples




Figure 3.26. Effect of time on the stability of Indoloquinone E09 and the
major hydrolysis product, E05A. Results are expressed as increase or
decrease in peak area at 18 hours, 2, 5 and 20 days after irradiation.
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Figure 3.27. Effect of time on the stability of Indoloquinone E09 related
products of irradiation. Results are expressed as increase or decrease in
peak area at 18 hours, 2,5 and 20 days after irradiation.
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between day 2 and 5 and increases sharply with time. This peak was not
observed in the control and previous E09 stability studies (data not
shown) suggesting its formation results from degradation of products
generated by irradiation. Little increase in peak V suggests it is relatively
stable. The rise in peak I is consistent with increased formation of
phosphate adducts over time.
The spectral characteristics of peaks I, Ilia, nib, V and VI are illustrated in
figure 3.28. Peak I spectrum, obtained from the day 20 sample, was
identical to that seen in figure 3.24 suggesting an increase in the adduct(s)
not coelution of peaks bearing a different chromophore. Both peaks V
and VI had similar spectra to E09 and E05A respectively. However, peaks
Ilia and Illb, which exhibited identical spectra, possess significant
differences to those spectra observed above. Firstly, UV absorption was
seen at 240 and 340 nm, wavelengths far removed from E09 and the other
products. Secondly, the characteristic shoulders seen in previous spectra
were not present. And thirdly, perhaps the most important difference was
the lack of visible absorption.
In conclusion, E09 can be converted to several distinct chemical entities
via irradiation. Such intermediates display both similarities and
differences compared to the parent drug. The characteristics of E09 and all
these products produced as a result of irradiation and time are




Figure 3.28. UV/Visible absorption spectra of Indoloquinone E09 related
products of irradiation. Products were identified during HPLC analysis as
shown in figure 3.25.
















E09 14-16 268,313 505 Decrease
E05A 12 280,321 550 Increase
I 3 280,321 550 Increase
Ilia 8.2 240, 340 nil Decrease
mb 9.4 240,340, nil Decrease
V 27 268,313 505 Increase
VI 4 280,321 550 Increase
Table 3.9. Characterisation of Indoloquinone E09 related products
generated via irradiation.
157
3.5 Characterisation of the Metabolites Produced by Enzymatic
Reductive Activation of Indoloquinone E09
The antitumour activity of E09 given i.t. has been studied in both MAC
16 and MAC 26 murine adenocarcinomas of the colon and HT-29 and BE
human colon xenografts (Gardiner et al., unpublished). Table 3.10 shows
the antitumour activity of E09 in each tumour type. Clearly it can be seen
that HT-29 was the most responsive to E09 followed by BE, MAC 16 and
MAC 26. Relating such results to the quinone reductase profiles of these
tumour types, tables 3.1 and 3.7, it is likely that DT-diaphorase is
responsible for E09 metabolism in HT-29 and MAC 16. The latter tumour
has previously been shown to be more responsive to E09 than MAC 26
when given intraperitoneally and the levels of DT-diaphorase
hypothesised to be responsible for this differential sensitivity (Walton et
al., 1992a). The low levels of DT-diaphorase in BE and MAC 26 resulted in
decreased antitumour activity.
However, E09 did show significant antitumour activity in BE with
comparable T/C to MAC 16. This may be due to the different reductive
capacities of human and murine quinone reductases. Murine DT-
diaphorase has previously been shown to be less effective at reducing E09
than the human variety (Lewis et al., 1994). This may apply to other
quinone reductases such as one-electron reductases which may be








Table 3.10. Antitumour activity of Indoloquinone E09 in MAC 16 and
MAC 26 murine adenocarcinomas of the colon and HT-29 and BE human
colon xenografts. Measurements were taken on day 14 for the MAC
tumours and day 21 for HT-29 and BE. E09 was given as a single 250 |ig i.t.
dose. Results are expressed as tumour volume as a percentage of the
vehicle control group, T/C value. Consent has been given by Dr. Gardiner
to use these results.
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With these antitumour results and the results presented in section 3.4
regarding the generation of E09 intermediates, can such tumours
generate similar E09 intermediates, now termed metabolites, and is it
possible to relate the production such metabolites to DT-diaphorase
activity and E09 chemosensitivity?
This was studied using the tumour homogenate system previously used
for mitomycin C as discussed in sections 3.2 and 3.3. Metabolism of E09
was carried out under both aerobic and hypoxic conditions for all tumour
types as described in section 2.3.14.
Figure 3.29 illustrates the in vitro metabolite profile generated by MAC 16
and MAC 26 tumour homogenates under aerobic and hypoxic conditions.
It should be noted that the retention times of both the parent drug and
E05A vary to those in section 3.4. This is due to further optimisation of
the HPLC technique.
A number of metabolites could be detected in both tumour types,
although there was little difference in peak levels between incubations
carried out under aerobic and hypoxic conditions. Once again E05A could
be seen eluting approximately 7 minutes before E09. Four additional
metabolites were also detected. Metabolites I and III were the
predominant peaks seen in MAC 16 with trace levels of metabolite II.
Metabolite IV was only observed under aerobic conditions.
160
A
le 20 30 40
TImm (gin.)
B
Figure 3.29. In vitro pattern of E09 metabolism in MAC 16 and MAC 26
tumour homogenates under aerobic (A) and hypoxic (B) conditions.
Samples were analysed at 45 minutes and metabolite levels measured by
HPLC.
Peaks I, n, HI and IV represent previously unidentified metabolites.
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In contrast, MAC 26 produced higher levels of metabolites I, II and in
under all conditions. Metabolite IV was present in aerobic incubations
only.
A similar metabolite profile was observed in HT-29 and BE homogenates
under aerobic and hypoxic conditions, figure 3.30. Once again metabolites
I, II and in in addition to E09 and E05A were observed. Similar profiles
were seen under aerobic and hypoxic conditions for each tumour type. In
contrast to MAC 16, HT-29 displayed significant levels of metabolite II
under all conditions. Metabolism in the BE homogenate resulted in
considerably lower levels of this metabolite similar to MAC 16. Metabolite
IV was not observed in either tumour type.
Metabolites of E09 generated via purified DT-diaphorase have previously
been detected. Maliepaard et al. (1995) observed three possible metabolites
under hypoxic conditions similar to those seen in HT-29, figure 3.30. The
high level of DT-diaphorase in HT-29, table 3.7, may be responsible for
these metabolites and due to the lower DT-diaphorase activity in MAC 16,
table 3.1, this may lead to reduced levels of metabolites. However, these
metabolite profiles are also similar to MAC 26 and BE respectively,





Figure 3.30. In vitro pattern of E09 metabolism in HT-29 and BE tumour
homogenates under aerobic (A) and hypoxic (B) conditions. Samples were
analysed at 45 minutes and metabolite levels measured by HPLC.
Peaks I, II and in represent previously unidentified metabolites.
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With the presence of such metabolites after enzymatic reduction of E09,
do any correspond to those generated via irradiation and do levels change
with time? Figure 3.31 illustrates the absorption spectra of E05A and
metabolites I, II and in. These spectra, although obtained from metabolites
generated in HT-29 homogenate incubations due to their high levels, are
the same as those spectra from MAC 16, MAC 26 and BE derived
metabolites.
Metabolite I showed UV absorption at 280 nm (spectrum 2). No visible
absorption was seen. This differed slightly to peak I observed after
irradiation which had additional absorption at 321 and 550 nm. Therefore
metabolite I and peak I are not the same product. However, as suggested
in section 3.4, peak I is possibly an adduct formed with buffer constituents
due to its presence in the control sample. A similar adduct, but of protein
origin, may result in the drug-homogenate incubations. Retention times
for both metabolite and peak I were 4 and 3 minutes respectively.
Metabolite II (spectrum 4) possessed a spectra similar to E05A (spectrum
3) UV absorption 280 and 321 nm, visible absorption 550 nm. This
metabolite, retention time approximately 6 minutes for all tumour
incubations, was not present after irradiation indicating that it is
generated by the bioreductive activation of E09.
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Figure 3.31. UV/Visible absorption spectra of Indoloquinone E09
metabolites produced by HT-29 tumour homogenate. Metabolites were
identified during HPLC as shown in figure 3.30.
Spectrum 1, metabolite HI; Spectrum 2, metabolite I; Spectrum 3, E05A;
Spectrum 4, metabolite n.
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Metabolite ID (spectrum 1) had the most interesting spectrum. Identical to
peaks nia and nib generated via irradiation, figure 3.28, this metabolite
exhibited UV absorption at 240 and 340 nm only, distinct from any other
metabolite. Therefore, metabolite III, retention time approximately 8
minutes, is possibly related chemically to peaks Ilia and nib from the
irradiation studies. Metabolite IV, only observed in MAC 16 under
aerobic conditions, figure 3.29, appeared in two out of the three repeat
experiments. No further characterisation of this metabolite was carried
out. Peak V produced via irradiation, retention time 27 minutes, could
not be detected in any of the homogenate incubations.
The increase or decrease in the formation of E09 metabolites was
investigated in all tumour types. This was carried out to assess whether it
was possible to correlate metabolite formation to the antitumour profile
in observed in table 3.10 and hence identify a marker for E09 metabolic
activation. Figures 3.32 and 3.33 illustrate the changing levels of
metabolites in MAC 16 and MAC 26 respectively.
Clearly it can be seen that there was little difference in the levels of all
metabolites produced under aerobic and hypoxic conditions in both MAC
16 and MAC 26. Metabolite I in both tumours was present at 0 minutes,
supporting the theory that this is a chemical adduct not requiring
metabolic activation and not a direct result of E09 metabolism. Levels of
metabolite II were higher in MAC 26 than MAC 16 under both conditions.
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Increasing in the first 45 minutes, little increase or decrease in levels of
this metabolite were seen once standard errors were taken into account. A
similar scenario applies to metabolite in, although levels did genuinely
decrease with time implying possible instability.
E05A formation was consistent throughout all experiments increasing
steadily with time. Maximal levels were once again similar for both MAC
16 and MAC 26 under aerobic and hypoxic conditions.
From these results, no single metabolite could be identified to indicate if
any difference in E09 metabolism occurred under either aerobic or
hypoxic conditions. This was particularly evident in MAC 26, low in DT-
diaphorase, which exhibited enhancement in mitomycin C metabolic
activation under hypoxia, sections 3.1 and 3.2.
In the context of quinone reductase levels, particularly DT-diaphorase, no
correlation could be found between the formation of the above
metabolites and quinone reductase activity, table 3.1. No hypoxic
enhancement, analogous to that seen with mitomycin C, was observed in
MAC 26 possibly suggesting a limited role for the mitochondrial one-
electron reductase identified in section 3.1. However in contrast, levels of
metabolites I, n and HI did increase under hypoxia in MAC 16 incubations






Figure 3.32. In vitro formation of Indoloquinone E09 metabolites I, II, HI
and E05A in MAC 16 tumour homogenate under aerobic (A) and hypoxic
(B) conditions during the 90 incubation. Results are expressed as mean






Figure 3.33. In vitro formation of Indoloquinone E09 metabolites I, II, HI
and E05A in MAC 26 tumour homogenate under aerobic (A) and hypoxic
(B) conditions during the 90 incubation. Results are expressed as mean
peak area±SE for three separate experiments.
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Do such observations apply to the human colon xenografts HT-29 and
BE? Figures 3.34 and 3.35 illustrate the formation of E09 metabolites
during the 90 minute incubation period. Once again metabolite I was
present at 0 minutes in both HT-29 and BE incubations. Levels of
metabolite ID and E05A followed patterns similar to those seen in MAC
16 and MAC 26, although E05A did decrease sharply in HT-29 possibly
due to further metabolism. However, in contrast to the MAC tumours
and BE, levels of metabolite II increased in HT-29 over the first 45
minutes to levels greater than other metabolites produced. This was
particularly enhanced under hypoxia. Taking into account standard errors
however, this metabolite failed to increase significantly over the last 45
minutes of the incubation period and in fact decreased slightly.
Therefore, in parallel with MAC 16 and MAC 26, no single metabolite can
be identified to represent chemosensitivity and therefore the extent of
E09 metabolic bioactivation. Although levels of metabolite II were higher
in HT-29 than BE, possibly indicating DT-diaphorase dependent
metabolism, this did not extend to MAC 16. In fact, MAC 26 exhibited
greater levels of this metabolite under aerobic conditions compared to
MAC 16. Therefore in conclusion, no correlation between human
tumour xenografts high and low in DT-diaphorase levels and the





Figure 3.34. In vitro formation of Indoloquinone E09 metabolites I, II, HI
and E05A in HT-29 tumour homogenate under aerobic (A) and hypoxic
(B) conditions during the 90 incubation. Results are expressed as mean





Figure 3.35. In vitro formation of Indoloquinone E09 metabolites I, II, HI
and E05A in BE tumour homogenate under aerobic (A) and hypoxic (B)
conditions during the 90 incubation. Results are expressed as mean peak
area±SE for three separate experiments.
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Although it is disappointing that no one metabolite was found to be
indicative of E09 metabolic activation in tumour tissue, it is nonetheless
important to propose their possible identities. Previous to the work
detailed within this thesis, Binger & Workman (1990) detected four urine
and nine plasma E09 metabolites and were characterised on the basis of
their spectral qualities. No further studies as yet have been carried out.
Similarly, Maliepaard et al. (1995), although detecting three possible
metabolites in addition to E05A after E09 reduction by DT-diaphorase,
did not investigate these metabolites further. It is therefore of potential
interest to speculate on the possible identities of the metabolites.
Metabolite I, as discussed throughout, is possibly a drug-protein adduct. A
similar adduct, possibly derived from phosphate buffer constituents,
could be seen after irradiation. However, due to the presence of both
possible adducts in the control sample and 0 minute time point of the
irradiation and homogenate studies respectively, such adducts are not a
result of E09 reductive activation. It is interesting to note that the
spectrum of the adduct in the irradiation studies was identical to that of
E05A suggesting the presence of an open aziridine ring (Binger &
Workman, 1990). The loss of visible absorption of metabolite I may in
some way be a consequence of the absorption spectrum of the protein
masking that of the adducted E09 metabolite.
Metabolite II again exhibited an absorption spectrum identical to that of
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E05A indicating the opening of the aziridine ring. The metabolite could
potentially be a number of possibilities. The first is a hydroxy metabolite,
de Vries et al. (1993) demonstrated the formation of such a metabolite
after E09 degradation in alkaline solution, pH>10. In common with
metabolite II, this hydroxy metabolite eluted close to the solvent front
demonstrating increase absorption at 280-290 nm. Formation of this
metabolite may follow the pathway outlined in figure 3.36. Essentially,
the aziridine ring is substituted by a hydroxyl ion at the C5 position of the
molecule. This results in the loss of ethanolamine. Similar degradation
pathways have been observed with mitomycin C (Beijnen et al., 1985) and
aziridinylbenzoquinone (Kusai et al., 1981, 1982).
To assess whether metabolite II is potentially a hydroxy metabolite, E09
was incubated with sodium hydroxide, pH 12 (section 2.3.15) and any
metabolite production assessed by HPLC. The use of contrasting HPLC
conditions to those use by de Vries et al. (1993) may reveal different
retention times and confirm or refute the hypothesis of such metabolite
formation.
Figure 3.37 illustrates the profile of metabolites formed via alkaline
degradation of E09. In agreement with de Vries and colleagues (1993), the
hydroxy metabolite eluted at 3 minutes and exhibited a spectrum similar
to E05A. In contrast, metabolite II possessed a retention time of 6









Figure 3.36. The proposed degradation pathway of Indoloquinone E09 to
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Figure 3.37. In vitro degradation profile of Indoloquinone E09 to the
hydroxy metabolite under alkaline conditions. The sample was analysed
at 60 minutes and metabolite levels measured by HPLC.
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Metabolite II is therefore not a hydroxy metabolite. If a hydroxy metabolite
was formed during the homogenate incubations, it would coelute with
the solvent front and not be seen. The abnormal E09 peak was due to the
effects of sodium hydroxide on the HPLC column packing material.
A second possibility is the formation of a glutathione-aziridinyl E09
adduct. Such adducts have been previously shown to form with
mitomycin C (Sharma et ah, 1994) and benzoquinones (Butler & Hoey,
1992).
Figure 3.38 illustrates the metabolite profile generated during co-
incubation of E09 with reduced glutathione. Reactions were carried out
as described in section 2.3.16. Three possible 'adducts' were formed:- b, c
and d. Adduct a appeared in both time 0 and 120 minutes samples and is
likely to be once again a E09-phosphate adduct analogous to that seen in
the irradiation studies, figure 3.23. Of all the possible adducts, adduct d,
was a likely candidate with a retention time similar to metabolite II,
approximately 5.75 minutes.
Further similarities or differences were examined spectrally as shown in
figure 3.39.
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Figure 3.38. In vitro formation of potential glutathione-aziridinyl E09





Figure 3.39. UV/Visible absorption spectra of potential glutathione-
aziridinyl E09 adducts. Potential adducts were identified during HPLC
analysis as shown in figure 3.38.
Spectrum 1, adduct c; Spectrum 2, adduct b; Spectrum 3, adduct d.
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No adduct showed spectra identical to that of metabolite n (280, 321, 550
nm). Although the likely candidate, adduct d, exhibited spectra at 280 and
321 nm corresponding to that of metabolite n, additional absorption was
seen at 390 nm. This was not observed with metabolite II. Therefore,
despite the formation of three potential glutathione-aziridinyl E09
adducts, none corresponded to metabolite n.
Metabolite II is therefore speculated to be an aziridinyl adduct of
unknown identity formed during the reduction process. This is supported
by its spectrum characteristic of an open aziridine ring product and its
significant water solubility resulting in earlier retention time to E05A.
However, it is metabolite III which proposes the most interest. This
metabolite appeared to decrease over time in both the irradiation and
metabolite studies. This suggests that it is a possible unstable
intermediate. Its absorption spectrum, distinct from any other metabolite,
gives an indication of its identity. The lack of visible absorption observed
has been demonstrated to be characteristic of certain hydroquinone
intermediates (Land et al, 1985; Cummings & Morrison, 1986) which can
be detected using HPLC in association with a diode array detector
(Cummings & Morrison, 1986). Although in theory, continuous
generation of the hydroquinone of E09 could be occurring throughout
the 90 minute incubation period whilst parent drug is available for
reduction, it is unlikely that the native hydroquinone of E09 would
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survive intact during HPLC, since it only has a half life of 1.5+0.3 seconds
(refer to section 3.7).
Metabolite III also corresponds to peaks Ilia and Illb seen in the irradiation
studies (section 3.4). Such peaks, although decreasing, were present for a
significant period of time after irradiation and could still be detected at 20
days. It is more plausible that metabolite III (peaks Ilia and Illb) is a
hydroquinone adduct.
The additional intermediates observed in the irradiated sample, peak V
and VI also display distinct properties. Peak V, retention time 27 minutes,
has a spectrum identical to that of E09, table 3.9. In contrast to metabolites
II and III, this suggests the aziridine ring has remained intact. It is possible
that it is a dimeric form of E09. In contrast, peak VI, possessing an open
aziridine ring, is undoubtably a product formed via the degradation of
E09 and other intermediates over a significant period of time and is
possibly another aziridinyl adduct.
Although the characterisation of E05A structure and formation has been
carried out, its formation within the different tumour types does differ. In
HT-29 tumour homogenate incubations under aerobic conditions
increased levels of E05A occurred within the first 45 minutes. This was
then followed by a sharp decline. Further metabolism was proposed as the
potential degradation pathway. This is supported by work carried out by
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Binger & Workman (1990), in which E05A derived metabolites were
detected in both plasma and urine from animals after a intravenous dose
of E05A. Such an observation in addition to its formation as a result of
E09 hydrolysis, indicates that E05A is not a suitable maker for E09
metabolic activation. It is unlikely however that such degradation is
mediated via DT-diaphorase as E05A has been demonstrated to be a very
poor substrate for the enzyme (Bailey et ah, 1992b).
The characteristics and proposed identities of the E09 metabolites are
summarised in table 3.11.
In conclusion, the metabolism of E09 in tumour tissue results in the
formation of a number of complex and somewhat unstable metabolites.
No one metabolite was found to be significantly affected by the presence
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3.6 Identification of Indoloquinone E09 Metabolites by High-
Performance Liquid Chromatography-Mass Spectroscopy.
In this section, an attempt was made to characterise the chemical identity
of the putative metabolites of E09. This was carried using high-
performance liquid chromatography in conjunction with mass
spectroscopy. The facility was based at the Paterson Institute for Cancer
Research as detailed in section 2.2.3. E09 was irradiated as described in
section 2.3.17 to generate a spectrum of metabolites similar to those in
figure 3.23.
Figure 3.40 illustrates the HPLC profile of E09 related products generated
via irradiation. E09 and E05A exhibited retention times of 28.25 and 35.13
minutes and were the predominant peaks. These were extended
compared to previous figures due to the differing mobile phase
constituents, water in 25 % acetonitrile and temperature. Analyses were
carried out at room temperature. The use of phosphate and formate
containing mobile phases was avoided as the subsequent formation of
phosphate and formate ions has been demonstrated to interfere with the
mass spectroscopy.
A number of potential metabolite peaks could be seen. Without the aid of
a diode array detector however, it was difficult to assign a particular peak
to a specific metabolite.
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Figure 3.40. In vitro pattern of Indoloquinone E09 related products
generated by a single 500 Gy irradiation dose. Results as measured using
the modified HPLC method.
Peaks at 3.11, 11.05 and 13.03 minutes correspond to previously
characterised intermediates. Peaks at 28.25 and 35.13 minutes correspond
to E05A and E09 respectively.
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However, taking into consideration the extended retention times, it is
likely that the major peaks seen at 3.11, 11.05 and 13.03 minutes,
correspond respectively to peaks I, Ilia and nib seen in figure 3.23. Peaks
ma and Mb subsequently correspond to metabolite m observed after E09
metabolism. Additional peaks at 5.47, 7.46, 8.56 and 22.10 minutes were
extremely small and therefore were considered not to be major products
of E09 reduction via irradiation.
Subsequent mass spectroscopy produced disappointing results. Only E09
and E05A could be detected. E09, molecular weight 288.30, produced a
protonated molecular ion (M + H+) of 289. Similarly, the open aziridine
ring hydrolysis product E05A, molecular weight 306, possessed a
protonated molecular ion of 307, ie. (M + H+) + H2O. Similar mass spectral
properties have been observed (Phillips et al., 1992). The extremely low
levels of the additional peaks in the sample may have rendered then
undetectable by mass spectroscopy giving no clear signal. If peaks Ilia
(11.05 minutes) and Illb (13.03 minutes) are the native hydroquinones of
E09 and E05A, then they should possess a molecular ion of 291, (M + H+)
+ 2H and 308, (M + H+) + 2H + H2O, respectively. No such molecular ion
was observed.
In order to increase the sensitivity of the procedure, a similar highly
concentrated/sub-saturated solution of E09 was injected directly into the
mass spectrometer. A control unirradiated sample was investigated.
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Figure 3.41 illustrates the mass spectral analysis of the control
unirradiated sample. The molecular ion of E09 could be clearly seen.
E05A could not be detected showing that hydrolysis had not occurred.
In conjunction with E09, several major additional ions were generated.
Firstly, the loss of water resulted in the formation of molecular ion 271,
(M +H+) - H2O. A dimeric form of this ion could also be seen with a
nominal molecular weight of 559. Secondly, similar dimeric forms of E09
were also formed, molecular ion 577. The formation of dimers during the
ionisation process has been associated with the use of highly concentrated
solutions. The presence of dehydration products may be a result of the
extremely high temperatures used throughout.
The mass spectral analysis of irradiated E09 is illustrated in figure 3.42. A
molecular ion of E09, M+ = 288, was observed, in addition to a single
dehydration product, (M + H+) - H2O = 269. No dimeric forms were
formed. The inconsistency between the molecular ions of these products
in the unirradiated and irradiated samples, may be an anomaly of the
ionisation process.
Although additional ions were formed, no possible metabolite could be
derived from these results. Such ions may result from fragmentation of
parent ions to form so-called daughter ions.
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Figure 3.41. Mass spectral analysis of unirradiated Indoloquinone E09.
The sample was analysed by-passing the high-performance liquid
chromatography column.
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Figure 3.42. Mass spectral analysis of irradiated Indoloquinone E09. The
sample was analysed by-passing the high-performance liquid
chromatography column.
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In summary, identification has proved unsuccessful. The purification of
substantial quantities of these metabolites from both irradiated and
metabolised E09 and subsequent mass spectroscopy as single agents rather
than as a combined entity, may circumvent such problems.
Although the formation and preliminary characterisation of E09
metabolites is in no doubt of interest, the fact remains that no appropriate
parameter has been found to correlate to chemosensitivity of E09
observed in table 3.10. In association with the formation of these
metabolites which only represent a small fraction of the drug, the
overwhelming majority of E09 disappears into products which are not
detected by HPLC. This process may be more indicative of E09
bioactivation and may therefore correlate to chemosensitivity.
The ability of the MAC 16, MAC 26, HT-29 and BE tumour homogenates
to metabolise E09 is shown in table 3.12. Metabolism under both aerobic
and hypoxic conditions has been calculated.
A number of observations can be drawn from these results. Firstly, in
contrast to the metabolites detected in section 3.5, the loss of E09
corresponds to the antitumour activity of the drug shown in table 3.10.
Loss of E09 was greatest in HT-29 followed by BE, MAC 16 and MAC 26. In
addition, the same order applies for both aerobic and hypoxic conditions.
From this it can be seen that the tumours most sensitive to E09 are those
190
that are high in DT-diaphorase, confirming numerous studies showing
such a correlation (Walton et al., 1992a; Robertson et al., 1994; Smitskamp-
Wilms et al., 1994; Fitzsimmons et al., 1996) . This applies to both murine
and human tumour types.
Secondly, once standard error was taken into account, no enhancement
under hypoxia was seen in those tumours low in DT-diaphorase, BE and
MAC 26. Particularly in the case of HT-29 and BE, this does not follow the
observations of Plumb and colleagues (1994) in which BE exhibited
significant hypoxic enhancement. Similar hypoxic enhancement has been
seen in a number of cell lines including T47D breast cells (Adams et al.,
1994; Robertson et al., 1994) and the mitomycin C resistant non-small cell
lung cancer cell line PC-9/MC4 (Bando et al., 1995). Both have low levels
of DT-diaphorase.
Also, in vivo E09 chemosensitivity has been enhanced in MAC 26 using
the vasoactive agent, hydralazine (Bibby et al., 1993). Such treatment
resulted in 63% vascular shutdown (Quinn et al., 1992), increasing
tumour hypoxia and potentiating E09 cytotoxicity.
This suggests that measuring the loss of E09 may not be the best indicator
of metabolic activation under aerobic and hypoxic conditions in vitro. A
technique measuring the direct consequence of E09 metabolic activation,










MAC 16 4.1010.15 3.9110.95 33
MAC 26 2.4110.86 2.0910.75 60
HT-29 13.7613.22 8.9510.13 15
BE 5.6612.93 7.1312.24 27
Table 3.12. Specific activities of Indoloquinone E09 metabolism by MAC
16, MAC 26, HT-29 and BE tumour homogenates under aerobic and
hypoxic conditions and correlation with antitumour activity. Specific
activity is expressed as nmol E09 metabolised/45 min/mg protein. Each
value represents the mean±SE from three separate experiments.
Antitumour activity was expressed as tumour volume as a percentage of
the vehicle control, T/C value.
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as measuring the rate of disappearance of E09 takes into account the sum
of all the processes under consideration ie: metabolism and DNA,
protein, protein and glutathione adduct formation etc.
The use of in vitro chemosensitivity assays may still provide a better
indication of E09 antitumour activity in vivo. However, caution should
be taken when examining in vitro chemosensitivity data. Although such
studies are ideal for examining preliminary chemosensitivity, such 'clean'
systems do not take into account the complex tumour environment. In
addition, although good correlation was achieved between DT-diaphorase
levels and in vitro chemosensitivity, no correlation was seen in vivo
(Collard et al, 1995).
In conclusion, although no metabolite produced after E09 metabolic
activation correlated to E09 antitumour activity, the loss of E09 via such
metabolism was found to give a better correlation. However, such
parameters failed to indicate the extent of hypoxic enhancement, if any, in
those cell lines low in DT-diaphorase.
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3.7 Properties of Indoloquinone E09 Reactive Intermediates: A Pulse
Radiolysis Study
Since it now appears that E09 and not a drug metabolite is possibly the
active form of the drug, it became important to understand which
reactive intermediates of E09 are responsible for cytotoxicity, how they
were formed, their properties and the optimal conditions for their
formation. This was carried out using the linear accelerator facility at the
Paterson Institute for Cancer Research as detailed in section 2.3.18.
The pulse irradiation of quinone (Q) in an argon saturated buffered
solution leads to the following reactions.
H20—> *OH, *H, eaq", H2O2, H2 (1)
•OH (*H) + HCO2"—> H20 (H2) + C02*~ (2)
C02- + Q —> Q*~ + C02 (3)
Essentially, the primary water free radicals reduce the quinone to produce
the semiquinone, Q*~. Spectral properties of the semiquinone of E09 are
illustrated in figure 3.43. The so-called difference spectrum was calculated
as the absorbance of the semiquinone minus that of E09. The spectrum of
the radical was essentially the same at both pH 7.4 and 10.
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Figure 3.43. The difference spectrum of Indoloquinone E09 semiquinone
recorded at 20ps after pulse irradiation. All absorbances were normalised
to a radical concentration of 6.5 pM in a 2.5 cm optical cell.
Insert: Typical trace produced by pulsing 150 pM E09 in 0.1 M formate, 10
mM phosphate buffer, pH 7.4 monitored at 400 nm. Radical concentration
= 5.7 pM, 20 ps/division, 1.8% transmission/division.
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Figure 3.43 (insert) depicts a typical trace produced during the reduction
process.
However, the absorbance was found to decrease in the range of 350 and
450 nm at less than pH 6. This pH dependency of the semiquinone free
radical can be seen more clearly in figure 3.44. pH values through 6, 5.5, 5
and 4.5 led to a corresponding decrease in absorbance. Due to the
instability of E09 in both acidic and alkaline solutions (de Vries et al.,
1993), it was not possible to examine the effect of pH outside the pH 4.5-10.
The inability of pH values 6.5 - 10 to change the spectrum of the
semiquinone has a number of implications. Firstly it indicates that the
aziridine group on the semiquinone free radical does not have a
dissociation constant, pK, in this region. Secondly, the decrease in
absorbance between pH 4.5 and 6.5 probably results from the protonation
of the aziridine moiety on the semiquinone free radical.
Figure 3.44, insert A, shows the decay of the semiquinone radical in the
absence of oxygen. This occurred over a period of milliseconds and occurs
via the following reaction.
Q*~ + Q*" + 2H+—> QH2 +Q (4)
1%
4.5 5.5 6.5 7.5 8.5 9.5 10
PH
Figure 3.44. The variation of the absorbance of the semiquinone of
Indoloquinone E09 in relation to pH. All values were normalised to a
radical concentration of 6.5 |iM in a 2.5 cm optical cell.
Insert A: The decay of the semiquinone of Indoloquinone E09 in the
absence of oxygen at pH 7.4.
Insert B: The formation of an equilibrium at pH 9.
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This forms the hydroquinone, QH2, and the parent quinone, E09. The
rate constant for this disproportion reaction was calculated to be 5.2±1.6
xlO7 M-i s-i. At alkaline pH, pH 8-10, the reaction was found to be at
equilibrium. This is illustrated in figure 3.44, insert B, reaction 5.
Equilibrium follows the following reactions.
Q*" + Q*" + 2H+ <=> QH2 + Q (5)
The equilibrium constant, K4, was calculated as 84±12 at pH 9 and 8±2 at
pH 10. Using a higher concentration of E09, the equilibrium constant at
pH 7.4 was greater than 4000, in favour of the hydroquinone. Although
this could not be accurately calculated, there is no reason to suppose that
this does not occur.
The possibility of such an equilibria at pH 7.4 is supported by the detection
of semiquinone radicals via electron spin resonance spectroscopy (ESR),
formed from DT-diaphorase dependent reduction (Bailey et al., 1993).
Similar equilibria have been observed with other quinones such as
simple benzoquinones (Baxendale & Hardy, 1953), napthoquinones
(Mukherjee et al., 1988) and adriamycin (Mukherjee et al., 1989).
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The semiquinone radicals formed at this pH (pH 7.4) were unstable in the
presence of oxygen as follows:-
Q*~ + 02—> Q + 02*~ (6)
The variation in rate with oxygen concentration leading to decay of E09
semiquinone radicals is shown in figure 3.45. This was determined by
adding small concentrations of oxygen and observing subsequent decay at
400 nm. A clear relationship between rate of decay and oxygen
concentration could be seen with greatest decay achieved at levels of
oxygen greater than 200 x 10-6 M. The rate constant for this reaction was
calculated to be 1.3±0.15 x 108 M-i s-h This suggests that the semiquinone
free radical is expected to be removed in well oxygenated cells.
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Figure 3.45. The dependence of the rate of decay of Indoloquinone E09
semiquinone free radicals on oxygen concentration.
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The reduction potential of the quinone/semiquinone couple, E(Q/Q®"),
was determined by setting up an equilibrium between E09 semiquinone
free radicals and mitomycin C (MMC) at pH 7.4 as follows:-
MMC*" + E09 <=> MMC + E09®" (7)
This reaction was investigated at 415 nm, where E09*~ radicals have a
higher absorbance than that of MMC®". This was extended to 490 nm
where the MMC®" have a much higher absorbance than E09®" radicals
(Hoey et al., 1988).
The equilibrium constant, K, can be shown to equal the following
formula (Swallow, 1982):-
K= (Ae-AMMC)/(AE09-Ae) x [MMC] / [E09] (8)
where Ae is the absorbance value at equilibrium, Ammc is the absorbance
of mitomycin C radicals in the absence of E09 and AEo9 is the absorbance
of E09 radicals in the absence of mitomycin C. The equilibrium constant
is subsequently related to reduction potential as follows (Swallow, 1982;
Wardman, 1989):-
E(MMC/MMC®") = E(E09/E09®") - 59 logK (9)
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The absorbance values at equilibrium (Ae) for a given wavelength and
concentration of E09 and subsequent K values are summarised in table
3.13. Each value was normalised to a radical concentration of 6.5 jiM. The
absorption of E09 radicals at 415 and 490 nm were 49.5 and 0.7 x 10*3 per
6.5 pM radicals respectively in the absence of mitomycin C. In addition,
the absorption of mitomycin C radicals were 0 and 70.4 x 10-3 per 6.5 pM
radicals at the same wavelengths respectively in the absence of E09.
Using the average value of K, 9.33, derived from table 3.13, and assuming
E(MMC/MMC*~) = -310±6 mV (Wardman, 1989), it can be shown that the











10 490 37.4 9.0
415 24.2 9.6
20 490 25.0 9.3
415 31.8 9.0
40 490 15.1 9.6
415 39.2 9.5
Table 3.13. Absorbance of Indoloquinone E09 semiquinone free radicals at
equilibrium, Ae x 10-3, for a given concentration of E09 at 415 and 490 nm
and corresponding equilibrium constants, K.
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The effect of oxygen on the product of two-electron reduction, the
hydroquinone, was investigated by rapidly mixing the hydroquinone
(produced by xanthine oxidase) with air. Results indicated that the
hydroquinone was unstable in air leading to autoxidation and
regeneration of the parent drug.
QH2 + 02—> Q + H202 (10)
The autoxidation of the E09 hydroquinone is illustrated in figure 3.46.
Clear differences could be seen in the spectrum of the hydroquinone with
increasing exposure to oxygen. Particularly absorbance within the
wavelength range 440 - 600 nm which increases steadily with time. Loss of
visible absorbance has previously been associated with hydroquinones
(Land et al., 1985; Cummings & Morrison, 1986). Appearance of
absorbance here suggests the production of the parent drug E09, which
has been shown throughout this thesis to absorb in the visible end of the
spectrum. The loss of visible absorbance also supports the hypothesis
proposed in section 3.5, that metabolite in is a form of the hydroquinone,
possibly an adduct.
The rate constant for this reaction was calculated to be 2.1±0.4 x 103 M-i s-L
The hydroquinone at low concentration subsequently exhibited a half life




Figure 3.46. The autoxidation of the Indoloquinone E09 hydroquinone.
Spectra was measured at 2 second intervals.
Insert: Decay of Indoloquinone E09 hydroquinone at 514 nm in the
presence of 110 |iM oxygen.
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The semiquinone reduction potential was -253±6 mV. Therefore,
according to previous studies on the dependence of enzyme rates and
reduction potentials (Clarke et al., 1980, 1982; Butler & Hoey, 1993), E09
should undergo enzymatic reduction via one-electron reductases such as
NADPHxytochrome P-450 reductase and xanthine oxidase more readily
than mitomycin C. This has been demonstrated with xanthine oxidase
(Maliepaard et al., 1995) and NADPH:cytochrome P-450 reductase (Bailey
et al., 1993).
Therefore, although E09 is an excellent substrate for DT-diaphorase,
selective toxicity may also be mediated thorough one-electron reductase
enzymes within tumour cells both in vitro and in vivo. This may be
significant in those cell lines that possess low or deficient levels of DT-
diaphorase which show significant sensitivity to E09 (Walton et al.,
1992a; Plumb & Workman, Plumb et al., 1994; Robertson et al., 1994).
A number of studies have demonstrated the formation of DNA strand
breaks as a result of DT-diaphorase-dependent E09 metabolism in the
presence of oxygen (Walton et al., 1991; Bailey et al., 1994). Walton et al.
1991, proposed that the strand breaks were a result of direct DNA
alkylation by E09. This was supported by the failure of superoxide
dismutase, a enzyme known to inhibit hydroquinone oxidation hence
leading to increase concentrations of such hydroquinone species and
inhibition of hydrogen peroxide formation (Cadenas, 1995), reaction 10, to
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affect this cross-linking process. However, the effect of catalase was not
investigated and therefore such strand breaks may have been a direct
result of hydrogen peroxide formation.
In addition, the formation of E09-DNA cross-links produced via DT-
diaphorase under hypoxia has been demonstrated (Maliepaard et ah,
1995). This may explain the enhanced cytotoxicity of E09 seen in a
number of cell lines under hypoxia (Plumb & Workman, 1994; Robertson
et al., 1994). If it is assumed that aerobic toxicity is predominantly due to
hydrogen peroxide and superoxide radicals, then such products are
expected to be less damaging to the cell than the formation of DNA cross¬
links and strand breaks.
Plumb et al., (1994) and Workman (1994) proposed that the semiquinone
free radical of E09 may be the more toxic reactive species, both predicting
that the formation of the semiquinone free radical would activate the
aziridine group more effectively than the hydroquinone. This is not the
case as shown by figure 3.44. The pK of the aziridine group on the
semiquinone free radical must be less than 5.5. The pK of the aziridine of
E09, although not yet reported, is expected to be similar to mitomycin C,
2.8 (McClelland & Lam, 1985), and the diaziridinylbenzoquinones,
between 2.5 and 4.0 (Butler et ah, unpublished). The predicted order in
pK's of the aziridines is quinone<hydroquinone<semiquinone, therefore
it is unlikely that the difference in pK between hydroquinone and
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semiquinone is responsible for the different reactivities. However, the
semiquinone may be more reactive than the hydroquinone towards DNA
alkylation due to factors such as different hydrogen bonding between
DNA bases which may favour the formation of cross-links (Hartley et al.,
1991; Mayalarp et al., 1996). In addition, selective activation of the
vinylogous side chains may occur. This could be assessed with the aid of
the DNA cross-links structures generated from reduced E09. These, as yet,
are not known.
The role of the E09 semiquinone in relation to DT-diaphorase levels was
also assessed (Workman, 1994).
Examining the first scenario, a cell line expressing one-electron reductases
in association with low levels of DT-diaphorase, the predominant species
was predicted to be the semiquinone. In the presence of oxygen its
formation will be reversed leading to the generation of the parent
molecule and superoxide anion both of which will enter futile redox
cycling. This has been demonstrated in reaction 6 and figure 3.45. In the
absence of oxygen, enhanced toxicity in such cell lines was therefore
predicted to be due to the semiquinone free radical. However, this is not
clear cut as the semiquinone has been demonstrated to be unstable under
hypoxic conditions resulting in the formation of the hydroquinone and
E09, reaction 4, figure 3.44, insert A. Indeed the equilibrium at pH 7.4 is in
favour of the hydroquinone, K4>4000, reaction 5. However, at alkaline pH
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the equilibrium favours the semiquinone. For simple quinones this is
often associated with the deprotonation of the hydroquinone (Baxendale
& Hardy, 1953). Thus, in association with the increase in DNA cross-links
between pH 5 and 7 (favouring a greater presence of semiquinone)
observed after DT-diaphorase and xanthine oxidase dependent E09
reduction (Maliepaard et al., 1995), suggests that the semiquinone may be
the active form of the drug.
The alternative scenario is a cell line high in DT-diaphorase in addition
to one-electron reductase expression. Under aerobic conditions Workman
(1994) proposed that the hydroquinone will initially predominate and
then generate semiquinone free radicals as a result of autoxidation. This
does occur with the hydroquinone rapidly autoxidising possibly via the
following semiquinone mediated reactions:-
Q*" + Q*" + 2H+ <=> QH2 + Q (5)
Q*~ + 02—> Q + 02*" (6)
02- + Oz- + 2H+ —> H202 + 02 (11)
02*" + Q*~ + 2H+—> Q + H202 (12)
Therefore, toxicity under aerobic conditions could potentially be mediated
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through oxygen free radical and hydrogen peroxide formation in
association with the transient appearance of the semiquinone (Plumb &
Workman, 1994).
Under hypoxic conditions, Workman (1994) proposed that the balance of
the ratio of semiquinone and hydroquinone was in favour of the
hydroquinone resulting in protection under hypoxia. This can be
supported once again by the equilibrium constant K4>4000, reaction 5.
In summary, the following conclusions can be drawn. Firstly, under
aerobic conditions, whether after one- or two-electron reduction, E09 is
most likely to redox cycle and generate reactive oxygen species. Secondly,
under hypoxic conditions, again after one- or two-electron reduction, the
hydroquinone free radical intermediate could predominate. The
hydroquinone can potentially be detoxified and excreted following
glucuronidation and sulphonation (Cadenas, 1995). However, although
the hydroquinone ultimately predominates under hypoxia after one-
electron reduction, the initial formation of the semiquinone on balance
possibly produces a more toxic effect that the hydroquinone, hence
hypoxic enhancement. In addition, at high alkaline pH, the equilibrium
shifts in favour of the semiquinone. This, in association with increased
DNA cross-links with corresponding increasing pH, pH 5 to 7 (Maliepaard
et al., 1995), suggests that the semiquinone is the active form of E09.
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3.8 Summary
The studies detailed in this thesis have led to the following conclusions.
Firstly, the enzymology of mitomycin C metabolic activation in solid
tumour tissue involves a complex interplay between several quinone
reductases. The identification of a novel one-electron mitochondrial
reductase exhibiting activity under hypoxia has provided a new insight
into mitomycin C metabolism. Such enzymes have the potential to be
exploited in the activation of hypoxia dependent bioreductive drugs. Full
identification, expression, cloning, transfection and metabolism studies
will in no doubt be of benefit. The two-electron reductase DT-diaphorase
occupies a unique and central role in mitomycin C metabolic activation
in tumour tissue both in vitro and in vivo. Its apparent predomination
over one-electron reductases in vitro, equal antitumour activity of
mitomycin C observed in tumours both high and low in the enzyme and
its increased expression in numerous tumour types, still make DT-
diaphorase a very attractive target for enzyme directed bioreductive drug
therapy using mitomycin C.
Secondly, the mitomycin C analogue Indoloquinone E09 has a complex
but distinct pattern metabolism giving rise to a number of metabolites.
However, the appearence of no single metabolite correlated to tumour
chemosensitivity. Rate of metabolism of the parent drug rather than
specific metabolite formation was found to correlate to antitumour
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activity. However, purification and identification of metabolites would
indeed provide important information regarding the drug's activation
and mechanism of action. A study of free radical processes identified the
reactive intermediates of Indoloquinone E09 most likely to be responsible
for its therapeutic efficacy.
The role for specific quinone reductases present within tumour tissue
remains unclear in the context of Indoloquinone E09 metabolic
activation. The use of additional techniques such as DNA adduct
formation and characterisation will facilitate and perhaps provide a good
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Evidence That Neither DT-Diaphorase Nor Cytochrome P-450 Reductase
Are The Major Enzymes Involved In The Metabolic Activation Of
Mitomycin C In Vivo In Tumour Tissue.
V.J.Spanswick*, J. Cummings, A.A. Richie and J.F. Smyth.
Medical Oncology Unit, Imperial Cancer Research Fund, Western General
Hospital, Edinburgh, EH4 2XU, U.K.
There is controversy as to the role of DT-diaphorase in the metabolic
activation of mitomycin C (MMC). Metabolism of MMC has been studied
in NMRI mice bearing one of 2 adenocarcinoma tumour models, one
having a 15-fold higher DT-diaphorase (DTD) activity (MAC 16) than the
other (MAC 26). Cytochrome P-450 reductase activity was similar in both.
MMC (500jig), was administered by direct intratumoural injection and
bioreductive metabolites were measured by high performance liquid
chromatography in tumour and plasma after extraction.
Peak level of MMC was approximately 19-fold lower in MAC 26
(5.1|ig/TTC MAC 26, 98.4(ig/TTC MAC 16) and plasma levels were higher
indicating faster tumour clearance. A greater degree of conversion to 2,7-
diaminomitosene was observed in MAC 26, (AUC 11.4(ig/TTC x hr in
contrast to MAC 16, AUC 5.69|ig/TTC x hr), despite the low level of
parent drug. High levels of 1,2-trans- and 1,2-ci's-l-hydroxy-
diaminomitosene were also detected.
Results indicate that MAC 26, despite its lower DTD activity, has a greater
capacity to metabolise MMC than MAC 16. Preliminary results obtained
from in vitro enzymology studies also suggest that MAC 26 has a greater
capacity to metabolise MMC particularly under anaerobic conditions,
when cytochrome P450 reductase might be expected to predominate.
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It is concluded that neither DTD nor Cytochrome P-450 reductase are
principally responsible for MMC metabolism in the MAC tumours. The
identification of the enzyme(s) involved is currently underway.
^Presented at the International Conference on Bioreductive Drug
Activation, Lake Tahoe, U.S.A., August 1994.
248
Identification Of New Mitomycin C Metabolising Enzymes In Tumour
Tissue.
V. J. Spanswick*, J. Cummings, A. A. Ritchie and J.F. Smyth.
Medical Oncology Unit, Imperial Cancer Research Fund, Western General
Hospital, Edinburgh, EH4 2XU, U.K.
Mitomycin C (MMC) requires bioreductive activation in order to exert its
cytotoxic effects. Numerous enzymes have been implicated in the
activation pathway including DT-diaphorase (DTD) and cytochrome P450
reductase, although their exact role is under much debate. To establish
their importance, the metabolism of MMC has been studied in NMRI
mice bearing one of 2 adenocarcinoma tumour models, one having a 15-
fold higher DTD activity (MAC 16) than the other (MAC 26). Cytochrome
P450 reductase activity was similar in both. MMC (500[ig) was
administered by direct intratumoural injection and bioreductive
metabolites were measured by high performance liquid chromatography
in tumour and plasma after extraction.
Peak level of MMC was 19-fold lower in MAC 26 (5.1jig/total tumour
content (TTC) MAC 26, 98.4(ig/TTC MAC 16) and plasma levels were
higher indicating faster tumour clearance. A greater degree of conversion
to the principle metabolite 2,7-diaminomitosene was observed in MAC 26
(AUC 11.80pg/TTC x hr in contrast to MAC 16, AUC 25.39|ig/TTC x hr),
despite the low level of parent drug.
Results indicate that MAC 26, despite its lower DTD activity, has a greater
capacity to metabolise MMC than MAC 16. Preliminary results obtained
from MAC 16 and MAC 26 in vitro enzymology studies also suggest that
DTD and cytochrome P-450 reductase are not the major enzymes
involved in the metabolic activation of MMC. Although low levels DTD
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and cytochrome P-450 reductase dependent activity were seen in MAC 16,
the majority of metabolism was associated with the mitochondrial
fraction utilising both NADH and NADPH optimally under anaerobic
conditions. Only mitochondrial activity was seen in MAC 26.
The above findings may give an insight to MMC activation in human
tumours and have important implications in the development of
enzyme directed drug therapy.
^Presented at the 36th Annual Meeting of the British Association for
Cancer Research, Nottingham, U.K., April 1995.
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The Enzymology of Mitomycin C Bioactivation in Tumour Tissue - Is
There a Role for DT-diaphorase?
V.J. Spanswick*, J.Cummings and J.F. Smyth.
Medical Oncology Unit, Imperial Cancer Research FUnd, Western
General Hospital, Edinburgh, EH4 2XU, U.K.
AIM
The role of DT-diaphorase (DTD) in the bioactivation of mitomycin C
(MMC) has been the subject of intensive research and is under much
debate. We have studied the in vitro biotransformation of MMC in order
to establish the enzymology of MMC bioactivation in tumour tissue and
explore the nature of the role of DTD. This information may in turn have
important in vivo implications in the development of enzyme directed
drug therapy.
BACKGROUND
The in vivo mechanisms of MMC have previously been studied in 2
murine adenocarcinomas of the colon, MAC 16 & MAC 26, chosen for
their contrasting enzyme profiles (Spanswick et al., 1995, British Journal
of Cancer, 71, suppl XXIV, 39). MAC 16 contains 15-fold higher levels of
DTD compared to MAC 26. Cytochrome P-450 reductase activity was
similar in both. Results showed that MAC 26, despite its lower DTD
activity and equivalent cytochrome P450 reductase activity, had a greater
capacity to metabolise MMC than MAC 16. These results indicated the
presence of different metabolising enzyme(s) apart from DTD and
cytochrome P-450 reductase and the possibility of a minor role for DTD.
METHODS
The animal model consisted of inbred NMRI mice and the
subcutaneously growing MAC 16 and MAC 26 murine adenocarcinomas.
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Once tumours became palpable, they were removed and immediately
placed in liquid nitrogen. All tumours were stored at -80°C prior to use.
Homogenates and subcellular fractions incubations with MMC were
prepared as described in detail, Cummings et al., 1992, Biochemical
Pharmacology, 44, 2175-2183, after which quinone reductase activity was
assessed. In vitro incubations were performed at 37°C under aerobic and
anaerobic conditions. Each incubation contained 100 (ig/mL MMC,
approximately 1 mg subcellular protein and 3.3 mM cofactor (NADH,
NADPH & Hypoxanthine) in 0.1 M sodium phosphate buffer pH 7.4.
Tumour homogenate incubations contained 100 pg/mL MMC only. At 15
minute intervals, an aliquot was withdrawn and analysed via HPLC to
determine the presence of MMC and its metabolites (Cummings et al.,
1993, Journal of Chromatography, 612,105-113).
RESULTS
Fraction 1
Tumour Condition Cofactor Homogenate
Cytosol Microsomes Mitochondria
NADH 0.6410.06 ND ND
Aerobic 0.23±0.04
NADPH 0.6610.02 ND ND
MAC 16
NADH 0.7610.10 ND 0.9310.09
Anaerobic 0.14±0.07
NADPH 1.0410.17 2.0911.09 3.6710.58
NADH ND ND ND
Aerobic 0.80±0.06
NADPH ND ND ND
MAC 26
NADH ND ND ND
Anaerobic 1.4510.18
NADPH ND ND 3.8710.71
Table 1 Characterisation of MMC bioreduction in MAC 16 & MAC 26
Adenocarcinomas. Results are expressed as mean specific activity of 2,7-
diaminomitosene formation in nmol/30min/mg protein±SE.
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Subcellular fraction incubations revealed high activity associated with the
mitochondrial fraction in both MAC 16 & MAC 26, Table 1 (ND = no
activity detected). NADPH combined with hypoxia produced the greatest
level of 2,7-diaminomitosene (2,7-DM) formation, the principle
metabolite of MMC metabolism. In MAC 16 only, no mitochondrial
activity was observed until 30 minutes into the reaction. In both MAC 16
& MAC 26 activity was not inhibited by co-incubation with 10 pM
dicoumarol or cytochrome P450 reductase antiserum indicating that the
mitochondrial enzyme(s) are probably not DTD or cytochrome P-450
reductase.
In the cytosolic fractions of MAC 16 no significant increase in metabolism
occurred under hypoxia and activity was inhibited by 10 pM dicoumarol
suggesting activity characteristic of DTD. Enzyme activity characteristic of
cytochrome P450 reductase was detected in microsomes exhibiting activity
under hypoxia in the presence of NADPH. Here the addition of
cytochrome P-450 reductase antiserum resulted in complete loss of MMC
metabolism.
CONCLUSION
A new MMC metabolisng enzyme located within the mitochondria has
been indentified in MAC 16 & MAC 26 and is likely to be responsible for
MMC metabolism in MAC 26 in vitro and in vivo. The 30 minute latency
period seen in MAC 16 may suggest the enzyme is located within the
mitochondrial inner membrane resulting in slower drug uptake and
hence delayed metabolism.
The inability of hypoxia to enhance MMC metabolism and the inhibitory
effects of dicoumarol in the MAC 16 homogenate appears to be
characteristic of DTD. It suggests that if DTD is in high quantities it will
predominate over other enzyme systems present within the tumour and
effectively partially inhibit bioreduction since DTD is not as efficient as
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one-electron reductases in MMC metabolic activation (Cummings et al.,
In Press). The opposite applies to MAC 26. When DTD is absent other
enzymes will predominate.
IMPLICATIONS
The implication of this data is that tumours high in DTD should be
protected from MMC cytotoxicity, particularly under hypoxia in
aggreement with results observed by Plumb et al., 1994, British Journal of
Cancer, 70, 1136-1143, in which cell lines high in DTD resulted in little
increase in E09 cytotoxicity under hypoxia, whilst those low in DTD
showed a marked increase. Together this suggests that tumours low in
DTD are optimal for treatment with bioreductive drugs such as MMC and
its analogue E09 if hypoxia can be achieved.
However, total tumour hypoxia may be difficult to achieve clinically,
tehrefore tumours that are high in DTD, such as colon tumours, may
nevertheless still be optimal for MMC treatment.
^Presented at the 9th International Conference on Chemical Modifiers of
Cancer Treatment, Oxford, U.K., August 1995.
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The Molecular Pharmacology of Indoloquinone E09.
V.J. Spanswick*i, J. Butler2, J. Cummings1 and J.F. Smyth*.
1Medical Oncology Unit, Imperial Cancer Research Fund, Western
General Hospital, Edinburgh, U.K.; 2Paterson Institute for Cancer
Research, Christie Hospital, Manchester, U.K.
E09 is a novel bioreductive compound currently undergoing phase II
clinical trials as an anticancer drug. While considerable progress has been
made in understanding its mechanism of action, it is still unclear which
molecular forms of the drug are responsible for the induction of
cytotoxicity and how these may behave under different conditions of
oxygenation. In the present studies, pulse radiolysis was employed to
generate reactive intermediates of E09 and characterize their properties.
The one electron reduction potential of E09 was determined to be -253 ± 6
mV, which is less negative than other quinone containing anticancer
drugs and thus, E09 should undergo enzyme catalyzed bioreduction more
readily. The semiquinone free radical of E09, the product of one electron
reduction, rapidly reacted with oxygen (rate constant,1.3 ±0.15xl08 M-i s-
1) and its fate under aerobic conditions is that it will preferentially redox
cycle with oxygen. Unusually, the hydroquinone form, the product of two
electron reduction, was unstable in the presence of oxygen and
underwent rapid autoxidation back to the parent compound (half life 1.5
± 0.3 seconds; rate constant 2.1 ± 0.4 x 103 M-is-i). Hence, under aerobic
conditions, whether the drug undergoes one or two electron enzyme
catalyzed reduction the principal species formed will be reactive oxygen
species rather than drug metabolites or DNA adducts. Under anaerobic
conditions, the semiquinone free radical rapidly disproportionated into
the hydroquinone (equilibrium constant > 4000 in favour of hydro¬
quinone).
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Therefore, whether the drug undergoes one or two electron reduction
under hypoxia, the hydroquinone intermediate will predominate. These
data provide new insights into the molecular pharmacology of E09 and
will aid in the design of second generation analogues.
^Presented at the 37th Annual Meeting of the British Association for
Cancer Research, Edinburgh, U.K., March 1996.
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Enzymology of Mitomycin C
Metabolic Activation in Tumour Tissue
CHARACTERIZATION OF A NOVEL MITOCHONDRIAL REDUCTASE
Victoria J. Spanswick* Jeffrey Cummings and John F. Smyth
Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital,
Edinburgh, EH4 2XU, U.K.
ABSTRACT. In this study, the enzymology of mitomycin C (MMC) bioactivation in two murine colon
adenocarcinomas, MAC 16 and MAC 26, was examined. Subcellular quinone reductase assessment via cyto¬
chrome c reduction confirmed a number of active enzymes. MAC 16 exhibited 22-fold greater levels of cytosolic
DT-diaphorase than MAC 26, while microsomal NADPH:cytochrome P-450 reductase levels were similar in
both tumour types. Metabolism of MMC by subcellular fractions isolated from both MAC 16 and MAC 26 was
quantitated by monitoring the formation of the principle metabolite 2,7-diaminomitosene (2,7-DM) via high-
performance liquid chromatography (HPLC). In MAC 16 only, activity displaying the properties of cytosolic
DT-diaphorase and microsomal NADPHxytochrome P-450 reductase was detected and confirmed, using the
enzyme inhibitors dicoumarol and cytochrome P-450 reductase antiserum, respectively. The highest level of
MMC metabolism was associated with the mitochondrial fraction from both tumours and was the sole enzyme
activity detected in MAC 26. The greatest mitochondrial drug metabolism was achieved in the presence of
NADPH as cofactor and hypoxia (MAC 16-specific activity, 3.67 ± 0.58 nmol/30 min/mg; MAC 26 specific-
activity, 3.87 ± 0.71 nmol/30 min/mg) and was unaffected by the addition of the inhibitors dicoumarol and
cytochrome P-450 reductase antiserum. NADH-dependent mitochondrial activity was only observed inMAC 16
at approximately 4-fold less than that seen with NADPH. MAC 26 homogenate incubations displayed enhanced
metabolism under hypoxia, presumably due to the presence of the identified mitochondrial enzyme. MAC 16
homogenates showed no increase in metabolism under hypoxia, suggesting that other enzyme(s) may be pre¬
dominant. These data indicate the presence of a novel mitochondrial one-electron reductase capable of me¬
tabolising MMC in MAC 16 and MAC 26. biochem Pharmacol 51; 12:1623—1630, 1996.
KEY WORDS, mitomycin C; metabolism; mitochondria; DT-diaphorase; NADPHxytochrome P-450 reduc¬
tase; tumour tissue
The quinone-containing antitumour antibiotic MMC,t
Fig. 1, remains an important component of cancer chemo¬
therapy, exhibiting activity against a variety of solid tu¬
mours, such as breast, lung, and gastrointestinal cancers [1].
Considered to be the archetypical bioreductive alkylating
agent, MMC undergoes reduction of its quinone moiety
before it is able to covalently bond to DNA and elicit its
cytotoxic effects [2]. This process can occur through two
enzyme-catalyzed activation pathways. The first pathway, a
one-electron reduction step, results in the formation of a
semiquinone free radical intermediate which, in the pres¬
ence of oxygen, is capable of redox cycling where it con¬
sequently reacts with molecular oxygen leading to the re¬
generation of the quinone molecule [3]. The second path¬
* Corresponding author. Tel. +44-131-332-2471; FAX +44-131-332-
8494.
t Abbreviations: MMC, mitomycin C; 2,7-DM, 2,7-diaminomitosene;
cis-hydro, 1,2-cis-l-hydroxy 2,7-diaminomitosene; trans-hydro, 1,2-trans-
1-hydroxy 2,7-diaminomitosene; NADPH-linked AqCbl reductase,
NADPH-linked aquacobalamin reductase.
Received 14 November 1995; accepted 8 February 1996.
way occurs via a two-electron reduction step resulting in the
formation of the hydroquinone intermediate and, unlike
one-electron reduction, alkylating species generated by this
pathway are generally thought to be unimpeded by molecu¬
lar oxygen. Under hypoxic conditions, rapid disproportion-
ation of the semiquinone free radical suggests that the hy¬
droquinone probably acts as the common intermediate in
both one- and two-electron pathways [4, 5].
Upon reduction, the MMC C-9a methoxy group is elimi¬
nated from the parent mitosane molecule, resulting in the
formation of reduced mitosene intermediates displaying the
characteristic double bond between the C-9a and C-9 po¬
sitions of the molecule. This promotes aziridine ring open¬
ing, to expose an electrophilic carbon centre at C-l that is
capable of DNA alkylation [6]. The critical intermediate
produced in this metabolic cascade that leads to DNA
crosslinking is thought to be a quinone methide [7, 8] and
its binding to DNA at C-l promotes a second DNA at¬
tachment point producing DNA crosslinks via the produc¬
tion of a C-l0 reactive centre [8]. The quinone methide is
believed to behave differently at different pH. At low pH,









FIG. 1. Molecular structure of mitomycin C and its three principle mitosene metabolites.
the principle metabolite observed in vivo, 2,7-DM, is
formed via protonation of the quinone methide. At higher
pH, the quinone methide acts as an electrophile leading to
the formation of cis-hydro and trans-hydro [7].
Using cell-free activation systems, both enzymatic and
chemical, a number of MMC-DNA adducts have been
identified. An interstrand crosslink [9], intrastrand
crosslink [10], and three monoadducts [11, 12] have all
been isolated using HPLC, and these studies indicate that
the major alkylation site detectable is the N2 position of
guanine. Four of these DNA adducts, two monoadducts and
two bisadducts, have now been detected in EMT6 mouse
mammary tumour cells following MMC treatment [13], sug¬
gesting that they may occur in vivo.
Several enzymes have been shown to catalyse the in vitro
bioreduction of MMC, ultimately resulting in the forma¬
tion of MMC metabolites. These included one-electron re¬
ductases, such as NADPHxytochrome P-450 reductase
[14], xanthine oxidase [14], and NADPHxytochrome b5
reductase [15], and the two-electron reductases DT-
diaphorase [NAD(P)H:(quinone acceptor) oxidoreductase,
EC 1.6.99.2] and xanthine dehydrogenase [16]. The role of
these enzymes in the bioactivation of MMC under aerobic
and hypoxic conditions, particularly DT-diaphorase, has
been the subject of intense research and controversy [17,
18]. Numerous studies using cancer cell lines with high and
low DT-diaphorase activities have provided evidence that
this enzyme may be responsible for aerobic MMC bioacti¬
vation [19—21], although these results were not in agree¬
ment with those using purified enzyme preparations, in
which MMC was actually found to be an inhibitor of DT-
diaphorase [17, 22]. The effect of hypoxia on DT dia-
phorase-dependent MMC metabolism remained unknown
until studies using the DT-diaphorase-rich and -deficient
cell lines, HT-29 and BE, revealed that bioactivation of
MMC by DT-diaphorase was similar under both aerobic
and hypoxic conditions [23].
The in vivo metabolism of MMC has previously been
studied in two murine adenocarcinomas of the colon, MAC
16 and MAC 26 [24]. The tumours were chosen for two
reasons. First, their differing levels of quinone reductases:
MAC 16 exhibiting a 16-fold higher activity of DT-
diaphorase than MAC 26 and NADPHxytochrome P-450
reductase being similar in both [25], and second, their his¬
tological similarity to human tumours of that origin [26].
Despite MAC 26 having reduced levels of DT-diaphorase,
metabolism of MMC to its metabolites was comparable to
that of MAC 16. This result suggested that an enzyme(s)
other than DT-diaphorase may be catalysing MMC me¬
tabolism in vivo.
In this paper, we have studied the enzymology of MMC
bioactivation in MAC 16 and MAC 26. The following
approaches were used to identify and characterise the re-
ductase(s) involved; (1) measure levels of quinone reduc¬
tases in both tumour types; (2) incubate MMC with sub¬
cellular fractions isolated from MAC 16 and MAC 26 and
characterise their cofactor requirements, the effect of oxy¬
gen, and response to specific enzyme inhibitors, and (3)
incubate MMC with whole tumour homogenates to assess
how the identified enzyme(s), if any, will behave in the
tumour environment. This may, in turn, provide important
information on the drug's in vivo mechanism of action and
/letabolic Activation of Mitomycin C 1625































'reparation of cytosolic and microsomal fractions and enzyme activity measurements were carried out in both tumour types as described in Materials and Methods. Each value
epresents the mean from 3 separate experiments and all enzyme activities are expressed as nmol cytochrome c reduced/min/mg protein. Enzymes grouped into the 'other' category
vould include xanthine oxidase/dehydrogenase and aldoketo reductase.
have implications for the use of bioreductive alkylating
agents in enzyme-directed drug therapy.
-MATERIALS AND METHODS
•Chemicals
MMC was obtained from Kyowa Hakko Kogyo Co., Tokyo,
Japan. HPLC-grade methanol was from Rathburn Chemi¬
cals Ltd., Walkerburn, U.K. Aristar grade sodium dihydro-
gen phosphate and disodium hydrogen phosphate were
from BDH, Merck Ltd., Merck House, Poole, U.K. All
other chemicals were of the highest grade available from
Sigma Chemical Co. Ltd., Fancy Road, Poole, U.K. Cyto¬
chrome P-450 reductase antiserum (CH59) was a kind gift
from Professor C. Roland Wolf, Imperial Cancer Research
Fund, Molecular Pharmacology Unit, Dundee, U.K.
High'Performance Liquid Chromatography
All chromatographic analyses were carried out using a
Hewlett-Packard Model 1090 liquid chromatograph
equipped with a diode array detector. Chromatographic
conditions were modified from those previously described
[27]. Essentially, the stationary phase consisted of LiChro-
sorb RP-18 (7 pm particle size, column 25 cm, 4 mm in¬
ternal diameter) (supplied by BDH, Merck Ltd.). The mo¬
bile phase consisted of 10 mM sodium phosphate buffer, pH
7.5 and methanol, 74:26. Elution was isocratic at a flow rate
of 1 mL/min and the column was maintained at 40°C.
Mobile phase was filtered before use (0.2 pm filter, Waters-
Millipore, Northwich, U.K.) and continuously sparged with
helium throughout chromatography.
Animal Models and Tumours
The animal model consisted of inbred NMR1 mice and the
subcutaneously growing MAC 16 or MAC 26 murine ad¬
enocarcinoma of the colon (breeding pairs and tumours
kindly supplied by Professor J. A. Double and Dr. M. C.
Bibby, Clinical Oncology Unit, University of Bradford,
U.K.). Tumours were maintained by subcutaneous passage
of 1-3 mg lumps of viable tissue into the flank of the animal
via a trochar needle. After tumours became palpable, they
were removed and immediately placed in liquid nitrogen.
All tumours were stored at -80°C prior to use.
Subcellular Fractionation and
Quinone Reductase Assessment
MAC 16 and MAC 26 homogenates and subcellular frac¬
tions were prepared following a modification of the previ¬
ously described method [28]. Whole tumours, 0.5-1.5 g,
TABLE 2. Characterisation of mitomycin C bioreduction in MAC 16 mouse adenocarcinoma of the colon
2,7-DM
formation
Tumour (nmol/30 min/mg Cofactor Effect of Effect of 10 pM Effect of
fraction protein) requirement oxygen dicoumarol antiserum
Cytosol 0.76 ± 0.10 NADH
No effect 100% inhibition No effect
1.04 ± 0.17 NADPH
Microsomes 2.04 ± 1.09 NADPH 100% inhibition No effect 100% inhibition
Mitochondria 0.93 ± 0.09 NADH
100% inhibition No effect No effect
3.67 ± 0.58 NADPH
Homogenate 0.14 ± 0.07 No effect
The MAC 16 tumour was fractionated and all incubations were performed as described in Materials and Methods. Specific activity is expressed as 2,7-diaminomitosene formation
in nmol/30 min/mg protein. Each value represents the mean ± SE from 3 separate experiments.
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TABLE 3. Characterisation of mitomycin C bioreduction in MAC 26 mouse adenocarcinoma of the colon
2,7-DM
formation
Tumour (nmol/30 min/mg Cofactor Effect of Effect of 10 pM Effect of#1
fraction protein) requirement oxygen dicoumarol antiserum's
Cytosol ND*
Microsomes ND - - - - j
Mitochondria 3.87 ± 0.71 NADPH 100% inhibition No effect No effectl
Homogenate 1.45 ±0.18 — 45% inhibition - -
The MAC 26 tumour was fractionated and all drug incubations were performed as described in Material and Methods. Specific activity is expressed as 2,7-diaminomitosen
formation in nmol/30 min/mg protein. * ND, no activity detected. Each value represents the mean ± SE from 3 separate experiments.
were first washed in saline then transferred to 0.25 M su¬
crose, 5 mM Tris-buffer, 0.5 mM EDTA, pH 7.4 in which
a homogenate was produced (33% w/v). Portions of the
homogenate were either used directly in drug incubations
or processed to isolate the mitochondrial, microsomal, and
cytosolic fractions. Homogenates were first centrifuged at
600 g for 10 min to remove cellular debris, and the resulting
supernatant was subjected to a high-speed spin (24,000 g for
10 min) to isolate the mitochondria. The supernatant was
retained for microsomal isolation. The mitochondrial pellet
was resuspended in STE and centrifuged once again at high
speed. The final pellet was resuspended in 5 mL STE. Mi¬
crosomes were isolated from the postmitochondrial super¬
natant by centrifugation at 80,000 g for 1 hr. Again, the
supernatant was retained as the cytosolic fraction. The pel¬
let was resuspended in 0.1 M sodium phosphate buffer, pH
7.4, and centrifuged again at 80,000 g. The final pellet was
resuspended in 5 mL 10 mM Tris-HCl buffer, pH 7.4 con¬
taining 20% glycerol and 0.1 mM EDTA. The cytosolic
fraction was centrifuged at 80,000 g for 4 hr to remove
remaining cellular debris. The resulting supernatant was
made up to 10 mL with STE. All centrifugation steps were
carried out at 4°C and fractions stored at -80°C in 1 mL
aliquots. The protein concentration of all homogenate and
fractions was determined using the Biuret method [29] with
BSA as the standard.
Cytosolic and microsomal NAD(P)H: (quinone accep¬
tor) oxidoreductase (EC 1.6.99.2, DT-diaphorase) activity
was determined by following the spectrophotometric reduc¬
tion of cytochrome c using a modification of the method of
Ernster [30], as reported in detail elsewhere [31]. In brief,
the reaction mixture contained 65-100 pg cytosolic or 17—
33 pg microsomal protein, cytochrome c (77 pM), mena¬
dione (20 pM), NADH, or NADPH (2 mM) as cofactor
and BSA (0.14% w/v). Reactions were performed at 37°C
in a total volume of 1 mL 50 mM Tris-HCl, pH 7.4, in the
presence or absence of the inhibitor dicoumarol (10 pM).
DT-diaphorase activity was taken as the activity that could
be inhibited by dicoumarol in the presence of NADPH or
NADPH. All enzyme activities were calculated as nmol
cytochrome c reduced/min/mg protein (e 21.1 x 103 M/cm).
Drug Incubations
In vitro drug incubations were performed at 37°C under
aerobic and hypoxic conditions. Each incubation mixture
contained 100 pg/ml MMC, approximately 1 mg subcellu
lar protein, and 3.3 mM exogenously added cofacto
(NADH, NADPH, or hypoxanthine) in 0.1 M sodiun
phosphate buffer, pH 7.4. Tumour homogenate incubation:
contained 100 pg/mL MMC in a total volume of 1 mL. Ir
the case of hypoxic incubations, mixtures were sparged with
helium for 5 min prior to the addition of MMC, which
started the reaction. The enzyme inhibitor dicoumarol (1C
pM made up in 0.1 M sodium phosphate, pH 7.4:0.1 M
sodium hydroxide) and cytochrome P-450 reductase anti¬
serum (1 in 100 dilution) were added 30 min before the
start of the reaction. At 15-min intervals (0-90 min), a 100
pL aliquot was withdrawn from the incubation and 20 pL
subjected to HPLC to determine the concentration of
MMC and its metabolites. Reaction rates were calculated
from linear portions of the reaction curves and expressed as
nmol/30 min/mg protein.
RESULTS
Quinone Reductase Activity in
MAC 16 and MAC 26 Murine Adenocarcinomas
The quinone reductase activity of the cytosolic and micro¬
somal fraction isolated from MAC 16 and MAC 26 are
shown in Table 1. MAC 16 exhibited a 22-fold higher level
of cytosolic DT-diaphorase but similar levels of microsomal
NADPHxytochrome P-450 reductase to those of MAC 26,
which is consistent with previously published data [25].
Other cytosolic enzyme activities (Table 1) were also cal¬
culated and may include xanthine oxidase and aldoketo
reductase. MAC 16 activity possessed approximately 8-fold
greater levels of these enzymes compared to MAC 26. Both
tumours exhibited similar levels of microsomal NADHxy-
tochrome b5 reductase.
Mitomycin C Bioreduction to the Metabolite
2,7-diaminomitosene by MAC 16 and MAC 26
Subcellular Fractions and Whole Tumour Homogenates
Tables 2 and 3 illustrate MMC bioreduction in MAC 16
and MAC 26 subcellular fractions and tumour homog¬
enates under conditions described in Materials and Meth¬
ods. Subcellular data revealed a number of enzyme activities
present within all 3 fractions in MAC 16 compared to one
in MAC 26. MAC 16 cytosolic activity utilised both
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rIG. 2. In vitro pattern ofmitomycin C metabolism in MAC
16 (C) and MAC 26 (B) mitochondrial fractions at 0 (A) and
iO (B, C) min as measured by HPLC. Incubations were
terformed using NADPH as cofactor under hypoxic condi-
ions. Peaks: I, zwitterion form of mitomycin C; II, 1,2-
trans-l-hydroxy-2,7-diaminomitosene; III, mitomycin C;
■IV, 1,2-cis-l-hydroxy-2,7-diaminomitosene; V, 10-
-decarbamoyl 2,7-diaminomitosene; VI, 2,7-diaminomito-
sene.
NADH and NADPH, showing similar activity under aero¬
bic and hypoxic conditions. The addition of dicoumarol, a
known inhibitor of the two-electron reductase DT-
diaphorase [32], resulted in 100% inhibition of 2,7-DM
formation. Addition of cytochrome P-450 reductase anti¬
serum had no inhibitory effect. No cytosolic activity was
observed in MAC 26. MAC 16 microsomal activity had an
absolute requirement for NADPH and hypoxia and 100%
inhibition was achieved with the addition of antiserum.
Coincubation with 10 |xM dicoumarol had no effect on
metabolism. Again, no microsomal activity was present in
MAC 26.
The majority of MMC metabolism was associated with
the mitochondrial fraction from both tumour types.
NADPH combined with hypoxia produced the greatest for¬
mation of 2,7-DM with specific activities being similar in
both tumour types. NADH-dependent MMC metabolism
was only seen in MAC 16 and activity was approximately
4-fold less than that seen with NADPH. The presence of
oxygen resulted in complete inhibition of metabolism in
both tumour types. The addition of 10 |xM dicoumarol and
cytochrome P-450 reductase antiserum to MAC 16 and
MAC 26 mitochondria failed to produce any inhibitory
effect. The chromatographic profiles of MMC metabolism
by MAC 16 and MAC 26 mitochondria in the presence of
NADPH and hypoxia are shown in Fig. 2. The principle
metabolite, 2,7-DM, can be clearly seen at 10.8 min as well
as a small amount of cis-/trans-hydro and the secondary
metabolite 10-decarbamoyl 2,7-diaminomitosene.
In the light of three different enzyme activities being
present in MAC 16 vs one in MAC 26, the role of these
enzymes were investigated in whole tumour homogenates.
Figure 3 shows the formation of 2,7-DM in MAC 16 and
MAC 26 homogenates under aerobic and hypoxic condi¬
tions. In agreement with the subcellular incubations, MAC
26 homogenates exhibited an increase in metabolic activity
1627
under hypoxia (Table 3), similar to that seen with the
mitochondrial fraction from this tumour. In contrast, MAC
16 homogenates did not show hypoxic enhancement, de¬
spite the presence of the identified mitochondrial enzyme,
and activity was similar under aerobic and hypoxic condi¬
tions.
DISCUSSION
The aim of the present study was to identify the enzyme(s)
responsible for MMC bioreduction in the MAC 16 and
MAC 26 murine adenocarcinomas, to provide an insight
into the drug's mechanism of action in vivo. The results
have demonstrated a number of previously characterized
enzyme activities, in addition to a novel mitochondrial re-
ductase(s) capable of reductive metabolism of MMC in
both MAC 16 and MAC 26.
DT-diaphorase and NADPHxytochrome P-450 reduc¬
tase have both been shown to metabolise MMC in a num¬
ber of cellular systems [5, 14]. Their identification, in many
cases, has relied upon comparison of their characteristics
with those of purified enzymes in conjunction with specific
enzyme inhibitors. Probably the most widely studied en¬
zyme, DT-diaphorase, characteristically utilises both
NADH and NADPH as cofactors, showing equivalent ac¬
tivity under aerobic and hypoxic conditions. In addition, its
activity can be inhibited by relatively low concentrations of
the coumarin derivative dicoumarol. Using these charac¬
teristics, the results presented in Table 2 have identified an
enzyme present within the cytosol of MAC 16 exhibiting
these properties. This result, along with the high level of
DT-diaphorase observed in the cytosolic quinone reductase











0 ■ 1 1 1 * 1 < 1 ■ 1 " 1
0 15 30 45 60 75 90
Time (Minutes)
FIG. 3. In vitro production of the principle mitomycin C
metabolite 2,7-diaminomitosene in MAC 16 (A) and MAC
26 (■) tumour homogenates (33% w/v) under aerobic (—)
and anaerobic ( ) conditions. Incubations were per¬
formed as described in Materials and Methods. Each point
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possibly DT-diaphorase, an enzyme that has long been as¬
sociated with metabolism of both MMC and its analogue
E09 in MAC 16 [25, 33, 34]. Therefore, perhaps it is not
surprising that this enzyme activity was observed, although
the specific activity was considerably less than with other
enzymes identified.
Activity characteristic of the one-electron reductase
NADPHxytochrome P-450 reductase was also observed in
MAC 16. Localised within the microsomal fraction, it had
an absolute requirement for NADPH and hypoxia. Activity
was completely inhibited by the addition of cytochrome
P-450 reductase antiserum, which has been previously
shown to be capable of inhibiting the biotransformation of
doxorubicin to doxorubicin 7-deoxyaglycone by purified rat
liver NADPHxytochrome P-450 reductase [28]. Despite
NADPHxytochrome P-450 reductase and DT-diaphorase
activities being confirmed in MAC 26 by cytochrome c
reduction assays, there was no indication of any involve¬
ment in microsomal and cytosolic MMC metabolism, re¬
spectively.
The majority of subcellular MMC metabolism in MAC
16 and MAC 26 was associated with the mitochondria.
Although quinone reductase assessment of the mitochon¬
dria was impossible due to the presence of cytochrome c
oxidase, the presence of mitochondria was confirmed by
electron microscopy (data not shown). Due to the nature of
the fractionation process, the method will not prevent mi¬
tochondrial membranes from disruption and, therefore, will
allow the inner mitochondrial membranes access to exog-
enously added nicotinamide nucleotides [35, 36]. The
greatest metabolism was observed under hypoxia using
NADPH as the cofactor. The inability of dicoumarol and
cytochrome P-450 reductase antiserum to inhibit activity
suggests that the enzyme is neither DT-diaphorase or NAD¬
PHxytochrome P-450 reductase, respectively. The depen¬
dency of this enzyme for hypoxia suggests it is a one-
electron reductase rather than a two-electron reductase,
such as DT-diaphorase, which is equally active under aero¬
bic and hypoxic conditions. MAC 16 mitochondria also
showed a small amount of activity using NADH as the
cofactor; again, only under hypoxia, which may indicate
the presence ofmore than one enzyme. MAC 26 showed no
NADH-dependent activity. Again, the inhibitors failed to
produce any inhibitory effect, implying that the enzyme is
once again not DT-diaphorase or NADPHxytochrome
P-450 reductase.
It has previously been suggested that mitochondrial re¬
ductases are capable of metabolising MMC and other qui-
nones [17, 37], although no experimental data has been
published to support this statement. In addition, recent in
vitro and in vivo data studying mitochondrial function after
MMC treatment have shown that considerable mitochon¬
drial DNA damage occurred after drug administration, im¬
plying, for the first time, that this MMC-mitochondrial
interaction may contribute to MMC's mechanism of tox¬
icity [38]. Quinone metabolites derived from the environ¬
mental pollutant benzo[a]pyrene have also been shown t
exhibit the capacity to deplete cellular ATP and indue
morphological changes within mitochondria in treate*
stromal cells, suggesting that benzol[a]pyrene quinones mai.
elicit their toxicity through directly disrupting mitochon
drial energy metabolism [39].
One enzyme that exhibits similar properties to the
NADPH-dependent mitochondrial enzyme identified ij:
this study is NADPH-linked AqCbl reductase. First studie
in bacterial systems [40], this enzyme has now been ider
tified in a number of mammalian tissues [41]. After chat
acterisation of this enzyme from rat liver microsomes, re
suits indicated that it was NADPHxytochrome c reductase
now more commonly known as NADPHxytochrome P-451
reductase [42], At this time, a NADPH-linked AqCbl re
ductase had been reported to occur in mitochondrial mem
branes [43], although its purification and characterizatior
were yet to be carried out. Subsequent isolation from ra
liver mitochondrial membranes revealed similarities, bu
also distinct differences to its microsomal counterpart
namely molecular weight and peptide elution profile [44]
However, despite these differences, the identified mito¬
chondrial enzyme exhibited the same high specific activity
and identical submitochondrial location (outer membrane)
of the cytochrome c reductase, and the authors concluded
that the purified NADPH-linked AqCbl reductase may be
the NADPH-cytochrome c reductase in rat liver mitochon¬
dria. This was supported by an early observation that
NADPH-cytochrome c reductase had been reported to oc¬
cur, not only in microsomes, but also the mitochondrial
outer membranes [45]. This enzyme may be capable of me¬
tabolising MMC in tumour tissue and may be a good can¬
didate, although identification and localisation in tumours
has never been addressed.
Rat liver microsomal NADH-linked AqCbl reductase ac¬
tivity derived from cytochrome b5/cytochrome b5 reductase
complex has also been identified [46], although whether or
not a similar enzyme exists within the mitochondria re¬
mains unknown and, therefore, it is not yet a likely candi¬
date for the NADH-dependent enzyme identified in MAC
16. More likely, NADH-dependent enzymes included mi¬
tochondrial NADH dehydrogenase, which has been linked
to the metabolism of the anthracycline doxorubicin (adria-
mycin) [47, 48] and NADH-ubiquinone oxidoreductase.
The presence of the mitochondrial enzyme(s) may ex¬
plain the hypoxic enhancement of MMC metabolism ob¬
served in MAC 26 homogenate incubations. Although no
aerobic metabolism was observed in the purified mitochon¬
drial fractions, aerobic homogenate metabolism may rely
upon the presence of these enzymes in the whole tumour
environment that may, in turn, occur in vivo. In contrast,
MAC 16 homogenates showed no hypoxic enhancement,
despite the presence of mitochondrial activity, suggesting
the predomination of other enzyme(s). This phenomenon
has been previously observed in a number of cell lines con¬
taining high and low DT-diaphorase activities [49]. Because
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MAC 16 homogenates showed no increase in MMC me-
■tabolism under hypoxia, this suggests that an enzyme(s)
other than the mitochondrial enzyme(s) was predominat¬
ing. With the lack of metabolic enhancement under hyp¬
oxia and the identification of an enzyme exhibiting similar
properties in the cytosol, it appears that the enzyme respon¬
sible for MMC metabolism in the MAC 16 homogenates
under all conditions is DT-diaphorase. However, it seems
that DT-diaphorase is less effective at metabolising MMC
than the mitochondrial reductase(s) [50].
The conclusions drawn from these observations have
clear clinical implications. Many tumours are known to
have high levels of DT-diaphorase and are an attractive
target for antitumour agents such as MMC and E09 [51].
Data presented in this paper suggest that tumours low in
DT-diaphorase are optimal for treatment with such agents,
if hypoxia can be achieved, and tumours high in the enzyme
may not benefit. However, total tumour hypoxia may be
difficult to achieve in vivo and, therefore, on balance, tu¬
mours high in DT-diaphorase may, nevertheless, prove op¬
timal for treatment with MMC and related drugs.
In conclusion, we now report the presence of a novel
mitochondrial one-electron reductase(s) capable of metab¬
olising MMC in MAC 16 and MAC 26 (i.e. tumours both
high and low in DT-diaphorase, respectively). This en-
zyme(s) is possibly responsible for MMC metabolism in
MAC 26 where DT-diaphorase levels are reduced in vitro
and, possibly in vivo.
The authors are grateful to Alison Ritchie, Imperial Cancer Research
Fund, Medical Oncology Unit, Edinburgh for assistance.
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The properties of the semiquinone radical from [3-
hydroxy-5-aziridinyl-l -methyl-2-(lH-indole-4,7-indi
one)-prop-P-en-a-ol], E09, have been studied using
pulse-radiolysis techniques. The reduction potential of
the semiquinone of E09 at pH 7.4, E(E09/E09 ~), is -
253 ± 6 mV and hence this quinone can be readily
reduced by one-electron reducing enzymes such as
cytochrome P450 reductase and xanthine oxidase.
However, the radical is unstable in the presence of
oxygen (k = 1.3 ± 0.15 x 108 M-1 s_1). The semiquinone
radicals and the hydroquinone are in equilibrium,
although the formation of the semiqtrinone is favoured
at physiologically relevant pH. The hydroquinone of
E09 is also unstable in the presence of oxygen and it
is predicted that in fully aerated solutions, its half life
is 1.5 ± 0.3 seconds. These results are discussed in view
of the selective cytoxicity of E09 and its ability to
undergo bioreductive activation by one-electron re¬





indoIe-4,7-indione)-prop-P-en-a-ol] is a bioreduc¬
tive alkylating indoloquinone (Figure 1) with a
distinct activity towards solid tumours and is cur¬
rently undergoing phase I/II clinical trials.1 Sev¬
eral in vitro studies have shown that this com¬
pound is up to 1000 times more toxic towards
hypoxic cells compared to cells which are fully
oxygenated.2"3
It has been proposed that E09 undergoes
bioreductive activation and alkylates DNA. The
reduction can be produced by several one-
electron reducing enzymes including cytochrome
P450 reductase, xanthine oxidase and cytochrome
bs reductase.4,5 However, the quinone is an excel¬
lent substrate for the obligatory two-electron re¬
ducing enzyme, DT-diaphorase [NAD(P)H
quinone oxireductase, EC 1.6.99.2] and there is a
good correlation between the activity of DT-
diaphorase present in a tumour cell and the cyto¬
toxicity of the drug.6 However, recent work has
FIGURE 1 The structure of E09
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shown that this correlation is only true under oxic
conditions and indeed, it appears that under hyp¬
oxic conditions, where E09 is most toxic, DT-
diaphorase may be protecting the cells against
damage by the drug.5
In view of the conflicting mechanisms pro¬
posed for the cytotoxicity of E09, we have inves¬
tigated the chemical properties of the semi-
quinone radical and the reactivities of the radical
and the hydroquinone with oxygen.
MATERIALS AND METHODS
E09 was obtained from the EORTC under the
auspices of Kyowa Hakko, UK and was found to
be>95% pure, based on determination by HPLC.
Bovine xanthine oxidase, allopurinol and hypo-
xanthine were from Sigma (St Louis, MO, USA).
All of the pulse radiolysis solutions contained
0.1 M sodium formate and were buffered using
lOmM phosphate (pH 4.5-9.0) or 10 mM borate/
NaOH (pH 8.5-10.0). All other reagents were of
the highest grade commercially available.
The pulse radiolysis experiments were con¬
ducted at the Paterson Institute linear accelerator
facility.7 The pulse lengths were less than 0.1 us.
The optical detection system consisted of a xenon
or tungsten lamp, a Kratos monochromator and
an EMI 9558QA photomultiplier. The optical cells
were capillary cells (3mm internal diameter)with
path lengths of 0.4 and 2.5 cm. The signals from
the photomultiplierwere recorded on a Tektronix
7612AD programmable digitizer.
The stopped flow measurements used an
Applied Photophysics RX1000 stopped-flow ap¬
paratus coupled toHP8452A diode array spectro¬
photometer. The kinetic analysis were carried out
using the Fig P (registered trademark, Biosoft,
Cambridge, UK) programassuming second order
kinetics. All experiments were performed at 21 ±
2°C.
RESULTS
When an argon saturated buffered solution of
sodium formate (100mM, pH 4.5-9) and quinone














FIGURE 2 The difference spectrum of the E09 semiquinone
recorded at 20ps after the pulse. All absorbanceswere normalised
to a radical concentration of 6.5(iM in a 2.5 cm optical cell. Insert
A typical trace produced by pulsing an argon saturated solution
containing 150pM E09 in 0.1M formate, lOmM phosphate
(pH7.4) at 400nm. Radical concentration = 5.7gM, 20|is/div, 1.8%
transmission/div.
HsO -> •OH, •H, eaq~, H2O2, H2 (1)
»OH(*H) + HCCU -> HjO (H2) + CO:T (2)
C02* (eaq ) "b Q —^ Q + CO2 (3)
Hencewithin a few microseconds, all of the prim¬
ary radicals from water produce semiquinone
radicals. The difference spectrum (absorbance of
semiquinone minus absorbance of parent quin¬
one) produced at 20 jis after the pulse for the
solutions at pH 7.4 is shown in Figure 2. The
spectrumof the radical was the sameatpH7.4and
10 although at pH values below about 6, the
absorbances were found to decrease in the range
350-450 nm. The pH dependence of the absorb¬
ances at 400 nm are shown in Figure 3. Unfortun¬
ately, due to the instability of E09 in acid and
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alkaline pH, itwas not possible to do the experi¬
ments outside the pH range 4.5-10.0.
In the absence of oxygen, the semiquinone rad¬
icals were found to decay at pH 7.4 over a period
of milliseconds in a dose dependent manner. A
typical trace is included in Figure 3.
This is consistent with the well established re¬
action for semiquinone radicals:
Q" +Q" + 2FT QH2 + Q (4)
Where QH2 is the hydroquinone of E09.
This reactionwas investigated at 400 nmwhere
the rate constant was calculated to be 52 ± 1.6 x
107 M"1 s"1 at pH 7.4. This value was independent
of the radical concentration in the range 1.0-
52 |iM and quinone concentrations up to 2.0mM.
However,within the pH range ca. 8-10 the appar¬
ent rate constant for reaction 4 was found to sig¬
nificantly increase and the absorptions due to the
radicals did not disappear completely, but relaxed
to a value which remained stable for at least sev¬
eral tens ofmilliseconds. The apparent rates of the
reaction and the absorbance values at the end of
















FIGURE 3 The variation of the absorbance of EQ9 semiquinone
radicals as a function of pH. All values were normalised to a
radical concentration of 6.5 pM in a 2.5 cm optical cell. Inset A:
The decay of E09 semiquinone radicals at pH 7.4 (X = 400 nm:
radical concentration = 2.65 pM, 10 ms/division and 1.2% trans¬
mission/division). Inset B: The formation of an equilibrium with
100 pM, E09 at pH 9.0 (X = 400 nm: radical concentration =
2.6 pM, 4 ms/div and 1.2% transmission/division).
initial quinone concentration. A typical trace at
pH 9.0 is included in Figure 3. This is consistent
with reaction 4 being an equilibrium in alkaline
pH:
Q" + Q" + 2FT QH2 + Q (4')
Measurements of the final absorbance at 400 nm,
where only the semiquinone have appreciable ab¬
sorptions, enabled the concentration, R*, of the
semiquinone at equilibrium to be calculated. The








where Ac is the initial quinone concentration (50—
200 (iM) and Ro is the concentration of semi¬
quinone radicals produced immediately after the
pulse (1.7-5.6 (J.M). From these calculations itwas
found that K4 was 8 ± 2 at pH 10.0 and 84 ± 12 at
pH 9.0. By using high concentrations of quinone
(100-500 p.M) and lower concentrations of radicals
(0.4-1 7 p.M), it was observed that the equilibrium
occurred at pH 8. However, due to the relatively
small absorbance values at equilibrium, only apf
lower limit of K4 > 700 could be determined. Sim¬
ilarly, from using a much higher concentration of
quinone (2.0 mM in a 0.4 cm optical cell), the limit
on the value at pH 7.4 was found to be >4000.
The semiquinone radicals formed at pH 7.4,
were unstable in the presence of oxygen. This is
consistent with the reaction.27
Q + 02 —> Q + 02 (6)
The rate of this reaction was determined by add¬
ing small concentrations of oxygen to the argon
saturated solutions and observing the decay of the
semiquinone radicals at 400nm. The variation of
ratewith oxygen concentration is shown in Figure
4. From the slope of the line, the rate constant for
reaction 6 was calculated as 1.3 ± 0.15 x 10s M71 s 1
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FIGURE 4 The dependence of the rate ofdecay of semiquinone
radicals on oxygen concentration.
The reduction potential of the quinone/semi-
quinone couple at pH 7.4 was determined by set¬
ting up an equilibrium between the semiquinone
radicals of E09 andmitomycin C (MMC):
MMC'" + E09 MMC + E09" (7)
The equilibria were investigated at 415nm, where
the E09"~ radicals have amuch higher absorbance
than that of MMC*" radicals and at 490nm, where
theMMC"" radicals havemuch higher absorbance
than E09*" radicals10. The concentration of mito¬
mycin C was kept at 100 pM while the E09 con¬
centration was varied between 10-40 |iJM.
It can easily be shown" that at equilibrium:
K = (A, - AMMC)/(AeoS — Ae) X -g.
[MMC]/[E09]
where, A, is the absorbance value at equilibrium
and Ammc is the absorbance of Mitomycin C radi¬
cals in the absence of E09 and AEo9 is the absorb¬
ance of the E09 radicals in the absence of
Mitomycin C. The equilibrium constant, K is re¬
lated to the reduction potentials"12:
E(MMC/MMC") = (9)
E(E09/E09"-) - 59log K
TABLF. 1
Concentration X(nm) Absorbance at K
ofE09 (pM) equilibrium (A«) x 10~3
10 490 37.4 9.0
415 24.2 9.6
20 490 25 9.3
415 31.8 9.0
40 490 15.1 9.6
415 39.2 9.5
The absorptions of E09 radicals at 415 and 490 nm are 49.5 and
0.7 x 10~3/6.5 pM radicals in the absence ofMMC. The absorp¬
tion of MMC radicals are 0 and 70.4 x 10"3/6.5 pM radicals at
the same wavelengths respectively.
The absorbance values, normalised to a radical
concentration of 6.5pM, are given in Table 1. From
using the derived average value of K in Table 1
and assumingE(MMC/MMC*") = - 310 ± 6 mV10,
it can be shown that E(E09 /E09"~) = - 253 ± 6 mV.
It has recently been shown that the reduction
of E09 by the obligatory two electron reducing
enzyme, DT-diaphorase is influenced by the pres¬
ence ofoxygen." Several preliminaryexperiments
involving rapidlymixing the hydroquinone pro¬
duced in the pulse radiolysis experimentswith air
indicated that the hydroquinone is unstable with
respect to autoxidation:
QH2 + 02 -> Q + H202 (10)
This reaction was studied by initially reducing
the quinone (20-50pM) in one half of a stopped
flow mixing chamber with xanthine oxidase/'
hypoxanthine (100 pM hypoxanthine, 0.1 M
phosphate buffer (pH 7.4), 0.6U xanthine oxi¬
dase, argon saturated) until the solution became
colourless. This was then rapidly mixed with an
air saturated solution (200 pM allopurinol and
2 pM EDTA in 0.1 M phosphate buffer, pH 7.4).
The total time for the initial reduction of the
quinone and the subsequent mixing with air was
less than 10 min and it was determined by HPLC
analysis, consistent with recent studies,4 that the
reactions did not produce any changes in the
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FIGURE 5 The autoxidation of the hydroquinone ofE09. Spec¬
tra measured at 2 sec intervals. Insert: Decay of E09 hydro¬
quinone at 514nm in the presence of llOpM oxygen. The arrow
refers to a time period of 2 sec
structure of the quinone during this period. A
typical stopped-flow trace is shown in Figure 5
and the insert shows the kinetics at nM. If it
is assumed that the oxygen concentration in a
fully air-saturated solution is 220 |iM (ie. 110 |iM
in the stopped flow mix), then the rate constant
for reaction 10 is 2.1 ± 0.4 x 103 M"1 s"1. Thus the
half-life of a low concentration of the hydroqui¬
none of E09 in air is 1.5 ± 0.3 seconds.
DISCUSSION
The semiquinone radicals of E09 have a reduction
potential, E(Q/Q"~), of - 253 ± 6 mV at pH 7.4.
Hence, according to previous studies on the de¬
pendence of enzyme rates and reduction poten¬
tials,14'15'16 E09 should be readily reduced by the
one electron reducing enzymes such as cyto¬
chrome P450 reductase and xanthineoxidase. This
has recently been demonstrated and indeed E09
can be reduced by xanthine oxidase in the pres¬
ence of DNA to form crosslinks.4 Therefore, al¬
though E09 may be an excellent substrate for
diaphorase, the selectivity cytotoxicity of the
quinone should also be mediated by the levels of
the one-electron reducing enzymes within the
cells.
The spectrum of the radical did not change
between pH 6.5 and 10. (Figure 3). This implies
that the aziridine on the semiquinone radical
does not have a pK in this region. However, the
absorbances at 400 nm were found to decrease
in the pH range of 4.5-6.5. This decrease is prob¬
ably due to both the protonation the aziridine
and the - O*" on the semiquinone radical (ie. Q*~
in neutral protonating to QH" in acid). Most
semiquinone radicals have a pK of around 4.0 to
6.0 Unfortunately, due to the instability of 5
E09 in acid solutions,4-8 it was not possible to
accurately determine either the pK of the aziri¬
dine or of the semiquinone.
The semiquinone radicals were found to be in
equilibrium with the hydroquinone and parent
quinone. The equilibrium constant, K4 was 84 ± 12
at pH 9.0 and 8 ± 2 at pH 10.0. Similar equilibria
have been observed for several quinones includ¬
ing simple benzoquinones, naphthoquinones and
adriamycin.17'18'19 For simple quinones, the de- j
crease in the equilibrium constant in going from
neutral to alkaline pH is normally due to the in¬
volvement of protons in the equilibrium reaction
and the deprotonation of the resulting hydroqui¬
none in alkaline pH.17 Hence, although the equi- j
librium constant could not be accurately
measured at pH 7.4, there is no reason to suppose
that an equilibrium does not occur at this pH and
indeed it has been reported that when E09 is
reduced by DT-diaphorase, semiquinone e.s.r sig¬
nals can be detected.26
The semiquinone of E09 reacts with oxygen
(reaction 6) with a rate constant of 1.3 ± 0.15 x
108 M"1 s"1 and thus is expected to be removed in
well oxygenated cells. Similarly, the hydroqui¬
none of E09 also reacts relatively rapidly with
oxygen to form hydrogen peroxide (reaction 10).
The autoxidation of hydroquinones has been
extensively studied17'24 and is believed to be medi¬
ated by the semiquinone radicals involving reac¬
tions of the type:
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Q- +Q- + 2H^QH2 + Q (40
Q- + O2-+Q + CV" (6)
02" + 02- + 2H+->H202 + 02 (11)
CV" + Q"~ + 2FT -> Q + H202 (12)
Interestingly, the one-electron potentials for
duroquinone and E09 are similar12 and yet the
rate of autoxidation of durohydroquinone is sev¬
eral orders of magnitude slower.17 However, in
the case of duroquinone, the equilibrium is
strongly in favour of hydroquinone formation11
and hence the amount of available semiquinone
that can react with oxygen at any one time, is
expected to be much less than that of E09.
In a previous study, it was shown that DNA
strand breaks are formed whenDNA is incubated
with E09 and DT-diaphorase in the presence of
air.20 The extent of strand breaks was unaffected
by the presence of superoxide dismutase and so it
was proposed that the strand breaks were as a
consequence of DNA alkylation by E09.
Unfortunately, the effects of catalase or metal
chelators were not reported in this study. Hence,
an alternative explanationcould be that the strand
breaks were produced simply as a consequence of
the formation of hydrogen peroxide. It is signifi¬
cant that a recent study on the formation of E09-
DNA cross links produced by DT-diaphorase
under nitrogen reported that strand breaks were
not detected.4 These simple reactions could, at
least in part, explain the enhanced cytotoxicity of
E09 in cells under hypoxia.23 If it is assumed that
the toxicity in air is primarily due to hydrogen
peroxide and superoxide anions, then these prod¬
ucts are expected to be much less damaging than
the formation of DNA cross links and strand
breaks formed from the direct interactions of the
reduced form(s) of E09 with DNA.
However, it has recently been shown that al¬
though DT-diaphorase contributes to the cyto¬
toxicity under aerobic conditions, it appears to
protect cells under hypoxia.5 The conclusion from
this study would be that, under hypoxia, the
hydroquinone reactions are not damaging. It was
suggested that as a protonated aziridine is neces¬
sary for reactions with DNA bases, the pK of the
aziridine on the semiquinonemay bemuch higher
than that of the hydroquinone and hence at phys¬
iologically relevantpH the semiquinones could be
more reactive.However, the present studies show
(Figure 3) that the pK of the aziridine on the
semiquinonemust be less than about 5.5. Surpris¬
ingly, the pK of the aziridine on E09 has not been
reported but it is expected to be similar to that of
other aziridinylquinones which are 2.8 for mito¬
mycin C21 and typically between 2.5 and 4.0 for
diaziridinylbenzoquinones (Butler et al., unpub¬
lished). As the predicted order in the pK's of the
aziridines should be quinone<hydroquinone<
semiquinone, it is unlikely that the pK's of the
semiquinone and the hydroquinone will be suffi¬
ciently different to account for the difference in
reactivities. However, the semiquinones could be
more reactive than the hydroquinones towards
DNA alkylation due to other factors such as dif¬
ferent hydrogen bonding between theDNA bases
(which does, in some instances, favour the forma¬
tion of crosslinks as opposed to single al-
kylations),2223 or selective activation of the vinyl
group. Unfortunately, the structures of the toxic
DNA crosslinks produced from reduced E09 are
not known.
The present results clearly show that the semi¬
quinones and hydroquinones can be in equilib¬
rium although it is extensively in the direction
of hydroquinone formation at physiologically
relevant pH. Nonetheless, the DNA crosslinks
formed by the reduction of relatively high con¬
centrations of E09 with purified DT-diaphorase4
could be explained by a direct reaction of a more
reactive semiquinone which is produced from
the equilibrium in a similar manner as the hydro¬
quinone apparently reacts with oxygen. It is also
significant that in this study, the DNA cross-
linking from both the DT-diaphorase and the
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xanthine oxidase reductions was found to in¬
crease as the pH was changed from 5.5 to 7.0.
This is contrary to what would be expected from
the activation of the aziridines10,22 but it is con¬
sistentwith the equilibrium beingmore in favour
of semiquinone formation.
The question arises as to whether this equilib¬
rium will be of significance in cellular systems
under hypoxic conditions. The concentrations of
E09 necessary to kill cells are typically in the
nanomolar range.23,5 Hence although it may be
possible that the semiquinones could, in principle,
react together and formhydroquinones is unlikely
that the back reaction of the equilibrium will be
important at these very low concentrations of
drug. Thus, within cellular systems, the reduction
of E09 by DT-diaphorase should lead simply to
the formation of the hydroquinone. Within the
cell, the hydroquinone may be less reactive than
the semiquinone, as discussed above, or the
hydroquinone could be detoxified and excreted
following the formation of glucoronide-,
sulphate- or glutathione-adducts. Consequently,
hypoxic cells which have high levels of DT-
diaphorase could be protected against damage by
E095 by these mechanisms.
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INTRODUCTION
Mitomycin C (MMC) is a naturally occurring antibiotic that was
isolated in 1958 from the fermentation broth of Streptomyces
caespitosus. It was shown to exhibit a broad spectrum of anti-
tumour activity in preclinical animal screens and less toxicity
compared to other mitomycins, and was introduced into clinical
trials in Japan where anticancer activity was confirmed in
humans [1]. MMC, which remains an important component in
combination chemotherapy of breast, lung and prostate cancer,
is among the few drugs to possess even marginal activity
against colorectal cancer, and is probably the drug of choice for
intravesical administration in superficial bladder cancer [2].
A number of recently published studies have extended and
challenged many of our longstanding views on the molecular
pharmacology ofMMC, particularly in the areas of mechanism
of action, DNA adduct profiles, enzymology of metabolic acti¬
vation and drugmetabolism. Therefore, it was considered timely
to re-evaluate these areas and attempt to present a picture which
is both cohesive and consistent.
MECHANISM OF ACTION
In 1964, it was first proposed that MMC required
biotransformation, preferentially under anaerobic conditions,
before drug activation occurred resulting in crosslinking ofDNA
[3]. To this day, this mechanism, termed anaerobic bioreductive
alkylation [4], is generally accepted as holding true, even though
considerably more details are now available on the type of
metabolism, the chemical intermediates involved, the types of
DNA adducts formed and the sequence specificity of alkylation.
The first stage in activation of MMC is quinone
reduction,which can be catalysed by several different enzymes,
either through a one electron pathway producing a semiquinone
free radical intermediate or a two electron pathway producing a
hydroquinone intermediate (Figure 1). In the presence of oxy¬
gen, the semiquinone will enter into a redox cycle, which
although evolving reactive oxygen species, is generally accepted
as not being critical for antitumour activity (pathway 2, Figure
1) [5, 6]. Generation of alkylating moieties by two electron
reductases is unimpeded by molecular oxygen. After bioreduc-
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tion, the C9a O-methyl group leaves the mitosane nucleus as
methanol, a C9, 9a double bond forms producing the mitosene
nucleus followed by proton assisted aziridine ring opening to
generate an electrophilic carbon centre at CI which alkylates
DNA [4]. In this scheme, the key intermediate formed is a
quinone methide (QM) [7]. Once the QM bonds to DNA, this
promotes the carbamate group to leave yielding a C10 reactive
centre which acts as the second point of attachment to produce
DNA crosslinks [8, 9], While MMC possesses no DNA binding
activity, the QM is believed to bind non-covalently to DNA with
high affinity by non-specific intercalation through a mechanism
which is dependent on the ionisation of its 2-amino group and is
enhanced under acidic conditions [10]. Reversible non-covalent
binding can be viewed as a precursor event to irreversible
covalent bonding. The QM reaction scheme is the pathway of
MMC metabolic activation which is accepted by the majority of
workers but at least three different alternative reaction schemes
have been proposed [11-13].
It has been demonstrated recently by purely chemical means
that, rather than acting as an electrophile at neutral pH (resulting
in DNA bonding) (pathway 3, Figure 1) and a nucleophile at
acidic pH as originally hypothesised (pathway 1, Figure 1)
[7], the QM is predominantly nucleophilic in character at all
functional pHs between 5.5 and 8.5 [14]. This theory does
not challenge the concept of the QM, but explains why 2,7-
diaminomitosene (2,7-DM, the product of the QM acting as a
nucleophile) is the major metabolite of MMC seen in vivo (see
below). It also suggests that DNA bonding is precluded unless
the QM is in close proximity to a nucleophilic centre on DNA,
otherwise it will preferentially react with a solvent proton to
yield 2,7-DM. The electrophilic metabolites of MMC—1,2 cis
and 1,2 trans 1-hydroxy 2,7-diaminomitosene (cis and trans-
hydro)—are now proposed to be derived from a 7-aminoaziridin-
omitosene intermediate. This, in turn, is the oxidised form of
theMMC quinone-reduced intact aziridino product, leucoazirid-
inomitosene(LAZM)(Figure 1) [14]. Since7-aminoaziridinomi-
tosene is only likely to form under more alkaline conditions, this
explains why the cis- and trans-hydro metabolites are also only
observed at more alkaline pH [11,14],
Based on an extensive series of biological studies employing
the enzyme DT-diaphorase to activate MMC, two other key
1928
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Figure 1. Proposed pathways of metabolic activation of mitomycin C (MMC) after one or two electron quinone reduction. Pathways are
explained in more detail throughout the text.
intermediates have been proposed together with the QM as the
precursors to DNA covalent bonding (pathway 5, Figure 1)
[15]. These are the quinone-reduced intact aziridino products,
leucoMMC (fully reduced MMC) and LAZM (fully reduced
MMC minus the C9a O-methyl group), and their dependence
on proton-assisted aziridine ring opening to yield electrophilic
intermediates has been cited to explain the pH dependence of
MMC DNA interstrand crosslinks (ISC).
COVALENTMODIFICATION OF DNA
A variety of MMC DNA adducts have been reported. It has
been claimed that the major sites of covalent modification are at
0-6 guanine followed by N-6 adenine and then N-2 guanine
[16]. In a series of elegant studies, Tomasz's group has demon¬
strated that N-2 guanine is the preferred site ofmonoalkylation
(90% of all DNA bonding) after bioreduction and chemical
reduction, and identified the first bifunctional alkylation product
as the N-2 guanine/iV-2 guanine crosslinked adduct [9, 17]. The
second site of attachment on MMC was the C-10 position, as
originally hypothesised by Iyer and Szybalszi in 1964. Computer
models have indicated that this bisadduct fits snuggly into the
minor groove of DNA with minimal distortion to the structure
ofB-DNA, and have provided a rationale for the base specificity
of MMC alkylation for guanine [17]. Using molecular biology
techniques, an absolute requirement for guanine has been
confirmed, and a sequence selectivity of ISC for 5'-CpG repeats
has been demonstrated [18]. Studies by several independent
laboratories have confirmed N-2 guanine as the principal site of
covalent attachment to DNA [19, 20]. As well as ISC, MMC
forms a dGpdG intrastrand crosslinked adduct [21]. An orien¬
tation model has been proposed to explain the sequence selec¬
tivity of MMC crosslinks [22, 23]. The C-l mononfunctional
adduct complexed at N-2 guanine (which always forms first) can
only point in one direction where the C-10 carbamate group of
MMC is facing the 3' direction of the minor groove. Therefore,
only when a G is situated 3' of the monofunctional adduct in the
complementary strand of DNA can a crosslink possibly form.
This case is only satisfied with CG.CG or less frequently with
GG.GG.
After metabolic activation with DT-diaphorase, an N-7 guan¬
ine adduct appears to account for greater than 90% of all MMC
covalently bonded to DNA [24], and this probably reflects the
unique manner In which the enzyme metabolises MMC. At
pH 7.8, where predominately electrophilic intermediates are
evolved, enzyme inhibition ensues as a result of protein alky¬
lation and crosslinking [25]. At more acidic pH (5.8), nucleo-
philic intermediates are evolved resulting in the efficient forma¬
tion of 2,7-DM. This metabolite can then act as a substrate
for further bioreduction by DT-diaphorase, yielding the N-7
guanine monofunctional adduct complexed to C-10 of MMC.
Evidence in favour of this proposal was presented with the
finding that, when 2,7-DM was used as a substrate for DT-
diaphorase instead ofMMC, similar patterns ofDNA alkylations
to MMC were observed. Thus, DT-diaphorase-mediated DNA
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monoalkylation by MMC may have an absolute requirement for
2,7-DMmetabolite formation. Other enzymes involved inMMC
metabolic activation, such as cytochrome P450 reductase, xan¬
thine oxidase and xanthine dehydrogenase, are not inhibited at
physiological pH, although their activity can fall significantly
from pH 6.0 to 7.4 [26, 27]. The mechanism of DT-diaphorase
inhibition has been speculated to be due to the orientation of
MMC in the active site of the enzyme, bringing it in close
proximity to specific nucleophilic sites on the protein [15]. N-2
guanine alkylation and minor groove 5'-CG ISC can also be
detected after DT-diaphorase-mediated metabolism, but these
were believed to be derived from the leucoMMC and LAZM
intermediate forms ofMMC and were only minor products [24].
The chemical structure of all the major in vivo DNA adducts
formed in EMT6 mouse mammary tumour cells after exposure
to MMC has recently been reported [28]. The major species
detected under aerobic conditions were the N-2 guanine-iV-2
guanine crosslinked adduct, followed by the decarbamoyl N-2
guanine monofunctional adduct, then the dGpdG intrastrand
crosslink and finally the N-2 guanine monoadduct. These four
adducts correspond to the same species that are formed in vitro
after either chemical reduction or enzyme catalysed metabolism
[9, 17, 21, 29J. A fifth dG adduct, codenamed Y, was detected
but not identified chemically, and this product may represent
the N-7 guanine adduct produced by DT-diaphorase. Under
hypoxic conditions, levels of crosslinked adducts increased
significantly, along with adduct Y. Treatment with the DT-
diaphorase inhibitor, dicoumarol (DIC), resulted in elimination
of the N-2 monofunctional adduct and a significant reduction in
Y under hypoxic conditions, but produced large increases in
both the inter- and intrastrand crosslinks. These results add
weight to the view that the DNA modifications induced by DT-
diaphorase are principally monoalkylations, and suggest that
bifunctional alkylations are generated predominately under
hypoxia by one electron reductases, such as cytochrome P450
reductase, cytochrome b5 reductase and xanthine oxidase, all of
which have been shown to be present in this cell fine [30-32].
This conclusion, if true, has major significance since it is
generally recognised that crosslinks are more lethal to cells than
monofunctional adducts [28, 33, 34], In aerobic conditions,
DIC still eliminated the N-2 monofunctional adduct, reduced Y
but also reduced the number of crosslinks. Interestingly, DIC
enhanced the formation of a sixth DNA adduct, codenamed X,
particularly under hypoxia, and this has been attributed to the
action of xanthine dehydrogenase, which has been previously
isolated from EMT6 cells and shown to be stimulated 6-7-fold
by this agent [31].
ENZYMOLOGY OFMETABOLIC ACTIVATION
Several enzymes can catalyse the in vitro metabolic activation
ofMMC, and these include cytochrome P450 reductase [26, 29],
xanthine oxidase [26, 29] and cytochrome b5 reductase [30]
acting as one electron reductases; and DT-diaphorase [20] and
xanthine dehydrogenase [31] acting as two electron reductases.
Cytochromes P450 are believed not to transfer electrons directly
to MMC, but may facilitate quinone reduction at least
2-fold through drug binding [32]. This view has been recently
challenged where cytochromes P450 have been shown to reduce
MMC to a semiquinone free radical, which caused toxicity
to hepatocytes by alkylating reduced glutathione [35]. The
hierarchy of participation from each of these reductases to
metabolic activation of MMC in vivo has still to be established,
but it is emerging that under different physiological conditions
different enzymes may prevail [36], Cytochrome P450 reductase
is believed to predominate in artificially hypoxic cells [37, 38],
although there have been reports that reduced expression of
this enzyme leads to resistance only in normo-oxic cells [39],
Numerous studies with cancer cell lines support a major role
for DT-diaphorase in MMC metabolic activation in normally
oxygenated cancer cells but not in hypoxic cells [40-44]. How¬
ever, a recent study has shown that DT-diaphorase can reduce
MMC with equal facility under aerobic and anaerobic conditions
in HT-29 human colon cancer cells [45].
A new role has been suggested for DT-diaphorase in the
metabolic activation of MMC and its closely related analogue
indoloquinone, E09 [46, 47], namely, that DT-diaphorase pro¬
tects cells from the hypoxic cytotoxicity of these drugs. Accord¬
ing to this hypothesis, cell fines which express high levels of DT-
diaphorase are more resistant to MMC than cell lines which
express low levels of the enzyme, but only under hypoxic
conditions. Under normal oxidative conditions, the converse
applied where a direct correlation was observed between DT-
diaphorase expression and cytotoxicity, confirming many pre¬
vious studies which have also shown this to be the case [40-44].
A major cornerstone in the hypothesis was the finding that DIC
increased hypoxic cytotoxicity ofMMC and E09 preferentially
in cell fines rich in DT-diaphorase (5-10-fold increase versus a
I-3-fold). However, results generated using extremely high
concentrations (200 p.M) of DIC should be viewed with great
caution since this agent can also inhibit cytochrome b5 reductase
[15] and cytochrome P450 reductase [48], stimulate xanthine
dehydrogenase [26] and induce the formation of unique DNA
covalent adducts [28],
While it is unclear what the biochemical basis is behind these
results, similar observations have been made by other groups in
different cell fines [28, 32, 45], indicating that this is probably a
real phenomenon. Two valid propositions have been put forward
to explain their results: (i) that one electron reductases are more
effective at metabolising MMC than DT-diaphorase (but that
DT-diaphorase prevails under hypoxic conditions); and (ii) that
the semiquinone form of MMC (the product of one electron
reduction) is more toxic than the hydroquinone form of MMC
(the product of DT-diaphorase metabolism) under anaerobic
conditions [46]. The second explanation can be discounted
more easily since, under hypoxic conditions, due to rapid
disproportionation of the semiquinone free radical, the hydro¬
quinone form ofMMC is believed to act as a common intermedi¬
ate after both one and two electron reduction [11, 15]. The first
explanation is probably more valid since it can be supported by
an emerging body of results which indicate that DT-diaphorase
is less effective than one electron reductases in MMC metabolic
activation. Firstly, pH dependent alkylation of DT-diaphorase
results in enzyme inhibition at physiological pH, but this effect
is less pronounced with one electron reductases. Secondly,
DT-diaphorase produces predominately monofunctional N-7
guanine DNA adducts which are believed to be less cytotoxic
than the bifunctional crosslinks formed by one electron
reductases [28]. Thirdly, all the major enzymes involved in
MMC bioreduction exhibit very low affinity constants (Km) for
the drug, thus, neither one should show a preference for MMC
as a substrate. Xanthine oxidase and cytochrome P450 reductase
have a Km of 2 mM [26, 49], xanthine dehydrogenase a Km of
299 p.M [27] whilst DT-diaphorase also has a low Aim[50].
Therefore, the enzyme which is present in largest amount is
likely to carry out the majority ofMMC bioreduction regardless
of intrinsic catalytic activity, and the pattern of metabolic
Molecular Pharmacology of Mitomycin C 1931
activation produced will parallel the biochemical properties of
that particular enzyme.
Recent results from our laboratory lend support to the above
conclusion [51]. When MMC was incubated with whole homo-
genates of the mouse colon adenocarcinoma MAC 16, which is
rich in DT-diaphorase, the pattern of metabolism recorded was
characteristic of DT-diaphorase, that is no increase in activity
under hypoxic conditions and inhibition by DIC at a lower
concentration (10 p-M). However, when the tumour was sub¬
jected to subcellular fractionation, three fractions were isolated
with the ability to convert MMC into 2,7-DM (mitochondria,
microsomes and cytoplasm) and the fraction containing DT-
diaphorase exhibited the lowest intrinsic activity. In contrast,
the MAC 26 tumour, which is low in DT-diaphorase, but
contained the same highly active mitochondrial enzyme, pro¬
duced a pattern of metabolism consistent with one electron
reduction: stimulation of metabolism by hypoxia and higher
levels ofactivity under hypoxia compared to MAC 16 [51].
Many human tumours, such as liver, colon, breast and non
small cell lung cancer, are rich in DT-diaphorase, making this
enzyme a good candidate for the enzyme-directed approach to
cancer chemotherapy [52-54]. However, recent data with DT-
diaphorase and MMC suggest caution when applying that
approach to this drug and related compounds, such as E09. In
tumours that are high in DT-diaphorase, induction of hypoxia
will only increase antitumour activity by a smallmargin, if at all,
but this should be from a level which is much higher than in
tumours low in DT-diaphorase. Tumours that are low in DT-
diaphorase may be less responsive, but could become substan¬
tially more sensitive by the induction of hypoxia, if such
modulation was achievable in vivo. Thus, on balance, tumours
high in DT-diaphorase would appear to be optimal for treatment
with MMC. The one caveat to this conclusion is that it is based
on data generated in vitro with cell lines, and these studies do
not take into account the obvious biological and physiological
differences that exist in solid tumours and their cellular hetero¬
geneity. With this in mind, it has been demonstrated in a panel
of four human xenografts that an inverse relationship exits
in vivo between DT-diaphorase expression and antitumour
activity, and that DIC increased antitumour activity to a greater
extent in the tumours expressing the highest levels of DT-
diaphorase [53], These data parallel more closely the in vitro
scenario ofhypoxic cancer cells treated with MMC [46, 47],
DRUG METABOLISM
Despite overwhelming evidence for the major role of drug
metabolism in the mechanism of action of MMC and in its
clearance from the body, no previously published preclinical (or
clinical) pharmacokinetic study has reported detection ofMMC
metabolites in either plasma or tissues [55-58]. Recently, analyti¬
cal techniques have been published which can detect in vivo
MMC and its three primary bioreductive metabolites 2,7-DM,
cis- and trans-hydro in rodent transplantable tumour tissue (the
Sp 107 rat mammary carcinoma and MAC 16 and 26 murine
colon cancer) [59], Five MMC metabolites were detected in
Sp 107 10 min after drug administration, including the three
primary metabolites. These techniques have been applied to
characterise further MMC metabolism in vivo in tumour tissue
[36, 60]. In an initial study, metabolism was investigated in the
MAC 16 tumour which is rich in DT-diaphorase. One single
metabolite was detected, 2,7-DM, which was generated in a
burst ofactivity that extended over 30 min after drug instillation
[36]. The rapid clearance of 2,7-DM may reflect the fact that
this metabolite is only an intermediate in a complex chain of
metabolic events [8, 11]. In vitro, 2,7-DM only has a half life of
13 min when incubated with either cytochrome P450 reductase
ofxanthine oxidase [26]. Induction ofhypoxia by administration
of albumin microspheres resulted in a reduction in 2,7-DM
formation, confirming that DT-diaphorase protects MMC from
metabolic activation under anaerobic conditions [36]. In a
separate study, 2,7-DM was shown to have a half life of 30 min
after intratumoural (i.t.) injection of 1 mg MMC in the Sp 107
tumour and 5 min after i.t. injection of 100 p,g. In that study,
decarbamoyl 2,7-DM (DC 2,7-DM, a secondary metabolite)
was also detected [60]. This metabolite may reflect Afunctional
metabolic activation of MMC at CI and C10, whereas 2,7-DM
may reflect monofunctionalmetabolic activation [16, 17]. Levels
of DC 2,7-DM were 5-10-fold lower than 2,7-DM. The forma¬
tion of DC 2,7-DM was also much slower that 2,7-DM and its
half life was 130 min. These in vivo data parallel closely the
kinetics of DNA covalent bonding after treatment of cells with
MMC, or incubation of the drug with purified cytochrome P450
reductase and xanthine oxidase in a cell free system [49, 61].
DNA bonding occurred in a rapid burst of activity during
the first 6 min of drug incubation: by 20 min the levels of
monofunctional DNA adducts appeared to plateau and there¬
after there was a steady rise in the formation of crosslinks for a
further 70 min [49], The rapid appearance and disappearance of
the major metabolite (2,7-DM) may explain why all previous
preclinical pharmacokinetic studies have failed to detect this
product in either plasma or tissues.
In those in vivo studies, tumour levels of 2,7-DM correlated
better than MMC to antitumour activity [36], In vitro studies
have also identified a correlation between 2,7-DM levels and
cytotoxicity in human colon cancer cell lines [40]. Together,
these data may shed light on the nature of the ultimate cytotoxic
species after MMC treatment in view of the fact that generation
of 2,7-DM appears to be an obligatory step in N-7 monoalkyl-
ation of guanine [24].
CONCLUSIONS
Themolecular pharmacology ofMMC remains a very complex
subject. Over the past five years, a number of seminal papers
have expanded our understanding, clarified certain areas of
controversy and at the same time challenged some of our
longstanding opinions. The most significant development has
been in defining the role of the obligate two electron reductase
DT-diaphorase. While it was originally believed by some that
this enzyme did not accept MMC as a substrate, it has now
emerged that it occupies a unique and central role in the
molecular pharmacology of the drug. Since this enzyme is
expressed at very high levels in a number of human tumours,
this role clearly has clinical significance. If DT-diaphorase is
present at high levels, it will act as the main MMC metabolising
enzyme, resulting in metabolic activation both under aerobic
and anaerobic conditions. However, because the enzyme is not
as efficient as one electron reductases in activating the drug, the
enzyme effectively protects cells from the maximum degree of
drug-induced damage possible under hypoxic conditions. When
DT-diaphorase is present at lower levels, itmay still predominate
in aerobic cells because one electron reductases are effectively
inhibited by oxygen. Under anaerobic conditions, one electron
reductases will participate significantly and the drug may have
greatly increased activity. Ultimately, the pattern of MMC
metabolic activation, and hence its antitumour activity, will
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depend on the balance of enzyme activities present in a tumour
and on its oxidative state.
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